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Abstract 
Bladder cancer is the seventh most common cancer. Recurrence after surgical removal of 
tumours is common and nearly half of the patients present with muscle invasive disease or 
harbour occult distant metastases. In such cases effective systemic therapies aimed at 
eliminating micro-metastases may improve outcome.  
Most patients who initially respond to chemotherapy (methotrexate, vinblastine, 
doxorubicin, and cisplatin or gemcitabine and cisplatin or carboplatin) relapse within the 
first year and the median survival is about 12 months. Consequently, there is a need to find 
drug targets that enhance the effects of existing chemotherapy and/or reverse drug 
resistance. Drug resistance is believed to cause treatment failure in >90% of patients with 
metastatic cancer, and resistant micro-metastatic cells may also reduce the effectiveness of 
adjuvant chemotherapy.  
We used a kinome-based siRNA screen in T24 bladder cancer cells to try and identify novel 
druggable regulators of chemoresistance in bladder cancer cells. The screen has identified 
23 common kinases that sensitise and 2 that antagonise the cytotoxic effects of both 
cisplatin and paclitaxel in T24 cells upon knockdown. We have further identified 63 kinases 
that significantly alter the response of cells to cisplatin and 60 kinases that significantly 
change the viability response to paclitaxel. 
13 of the hits were validated across two additional cell line and further work was done to 
elucidate the role of RSK4 in cancer. RSK4 not only sensitises bladder cancer cells to cisplatin 
and paclitaxel but it also has a role in migration in invasion.  
RSK4 seems to have a regulatory role which governs cancer metabolism, drug resistance and 
motility. Further studies are needed to clarify this role and specific inhibitors of RSK4 need 
to be developed in order to explore its potential use as a therapeutic target in cancer.  
Keywords:  Bladder cancer, Drug resistance, RNA interference screen, Cisplatin, Paclitaxel. 
 
 5 
 
 
 
 
 
Acknowledgements 
 
 
I am thankful to my supervisors,  Prof. Michael J. Seckl & Dr. Olivier E. Pardo for 
their constant encouragement and  input in this work. Their patience and 
interest kept me going and helped me work throughout. My gratitude goes to Mr 
David Hrouda  and others in the department of urology at Imperial College NHS 
Trust who supported me during my time in the lab and provided me with clinical 
training.  I also want to thank Dr Ana Costa Pereira for her input and advice at 
various stages. Special thanks to Dr Rajat Roy who helped me at every step in the 
lab, patiently explained  the techniques to me and helped me troubleshoot 
problems.  I also wish to thank  Dr. Francesco A. Mauri, Diane Watling, Dr Anna 
Marie Tommasi and my colleagues in the lung group who helped and even 
contributed at various stages.  I also want to mention Samuel Kalu, who carried 
out an M.Res project under my supervision and also contributed to this study. I 
also want to thank my family including my mum and dad for all the support and 
motivation they provided. My wife deserves great credit for her understanding, 
patience and support all the time. Finally, I wish to give credit to the charities 
contributing to our lab and also the Imperial College NHS Healthcare Trust for 
their financial support. 
 
 
 
 
 6 
Contents 
List of Figures .............................................................  11 
List  of Tables .............................................................  14 
Abbreviations ............................................................. 15 
1. Introduction  ............................................................................   23 
1.1  Cancer   ..................................................................................   24 
1.1.1 Cancer Morbidity .........................................................................   24 
1.1.2 Cancer Mortality  .........................................................................   24 
1.1.3 Cancer Characteristics  ................................................................    26 
1.1.4 Normal Epithelium and Extracellular Matrix ...............................    27 
1.1.5 Malignant Transformation  ..........................................................   29 
1.1.6 Invasion and Metastasis  ..............................................................   31 
1.1.6.1  Development of New Blood Vessels (Neoangiogenesis)  .......   33 
1.1.6.2  Extension and Infiltration of Cancer Cells  ..............................  34 
1.1.6.3  Cancer Cell Motility and Migration  ........................................  35 
1.1.6.4  Release and Survival of Cancer Cells in Circulation  ................  36 
1.1.6.5  Extravasation of Cancer Cells at Distant Sites  ........................  36 
1.1.6.6  Homing and Colonisation of Cancer Cells at Metastatic Sites . 38 
1.1.7 Mitogen Activated Protein Kinase (MAPK) Signalling Pathway ...... 39 
1.1.8 Metabolic Pathway and cancer  ...................................................... 42 
1.1.8.1  The Glycolytic Pathway  ............................................................ 42 
1.1.8.2   Glycolytic Pathway Enzymes in Cancer  ................................... 44 
1.1.8.3  Warburg Effect in cancer  ........................................................  44 
1.2  Bladder Cancer  ..................................................................................... 47 
1.2.1 Anatomy and Histology of the Bladder  ........................................... 48 
1.2.2 Etiology and Risk Factors  ................................................................  49 
1.2.3 Pathology  ........................................................................................  53 
 7 
 
 
1.2.4 Treatment of Bladder Cancer  ..........................................................  57 
1.2.4.1  Treatment of Non-Muscle Invasive Bladder Cancer  .................  58 
1.2.4.2  Treatment of Muscle Invasive Bladder Cancer  .........................  59 
1.2.5 Chemotherapy in Bladder Cancer  ...................................................  60 
1.3  Chemotherapeutic Drug Resistance in Bladder Cancer ..............  64 
1.4  Kinases and Bladder Cancer  ..............................................................  66 
1.5  RNA interference and Kinome Screen  ............................................  66 
1.5.1 RNA Interference  ............................................................................   66 
1.5.2 Screening Kinases affecting Sensitivity to Chemotherapy  ...............  68 
1.6  Aims of the project ................................................................................  70 
2. Experimental Materials & Methods  .......................................................  71 
2.1 Materials  ..................................................................................................  72 
2.1.1 Reagents  ..........................................................................................  72 
2.2 Methods  ...................................................................................................  73 
2.2.1 Cell Culture  ....................................................................................... 73 
2.2.2 Protein Extraction for Western Blotting  ..........................................  74 
2.2.3 Cytoplasmic and nuclear protein Fractionation  ..............................   75 
2.2.4 Sodium dodecyl sulphate – Polyacrylamide gel Electrophoresis (SDS-
PAGE)  ................................................................................................  76 
2.2.5 Western Blotting  ..............................................................................  76 
2.2.6 RNA Interference (RNAi)  ..................................................................  77 
2.2.7 Drug Treatment  ................................................................................  79 
2.2.8 Crystal Violet Cell Viability Assay  ......................................................  80 
2.2.9 Reverse transcription (RT)  ................................................................  81 
2.2.10 SYBR green-based real time quantitative PCR (qPCR)  ......................  82 
2.2.11 Cell Migration Assay  .........................................................................  83 
2.2.12 Invasion Assay  ..................................................................................  83 
 
 8 
 
2.2.13 Zebrafish Metastatic Model  ..............................................................  84 
2.2.14 Immuno-histopathology  ....................................................................  85 
2.2.15 Statistical Analysis  ............................................................................   86 
2.2.16 NMR Spectroscopy & Analysis  .........................................................   86 
         2.2.16.1  Media Sample Collection  ......................................................   86 
         2.2.16.2  Methanol Quenching  ............................................................   86 
         2.2.16.3  Preparation of Culture Media  ...............................................   87 
         2.2.16.4  Preparation of Cell Extracts  ..................................................   87 
         2.2.16.5  NMR Data Acquisition & Processing  .....................................  87 
2.2.17   Bioluminescent Imaging  ..................................................................  88 
3. A High Throughput Kinome Screen Identifies Novel Regulators of 
Chemosensitivity in Bladder Cancer cell Line  ......................................  89 
  3.1  Screen Setup  ..............................................................................................  90 
              3.1.1  Determination of IC50 drug concentrations  .............................................  90 
              3.1.2  Controls  ...................................................................................................  91 
              3.1.3  Transfection Control  ................................................................................  93 
              3.1.4  Data Analysis  ...........................................................................................  94 
     3.2  The Kinome Library  ..................................................................................  97 
     3.3  Screening Method  ....................................................................................  97 
     3.4  Results  .........................................................................................................  99 
         3.4.1  Effect on Cell Viability  ..............................................................................  104 
           3.4.2  Drug Response Hits from the Primary Screen ..........................................  105 
           3.4.2.1  Common Hits  ..................................................................................  105 
           3.4.2.2  Cisplatin only Hits ............................................................................  107 
           3.4.2.3  Paclitaxel only Hits  .........................................................................  109 
    3.4.3  Validation of Hits from Primary Screen  ...................................................  111 
    3.4.4  Targets Included  ......................................................................................  111 
    3.4.5  Validation Results  ....................................................................................  112 
3.5  Discussion  ...................................................................................................  115 
 9 
 
 
4. RSK4 knockdown sensitises Cancer Cells to both Cisplatin & 
Paclitaxel.  ......................................................................................................   116 
  4.1  RSK4 sensitises cancer cells to Cisplatin and Paclitaxel  ...............  118 
  4.2  RSK4 knockdown decreases XIAP levels  ......................................  120 
  4.3  RSK4 knockdown leads to an increase in RSK1 levels  ..................  121 
  4.4  RSK1 knockdown increases Resistance to Chemotherapy  ........... 123 
  4.5  RSK4 knockdown leads to a decrease in RSK2 levels  ...................  125 
  4.6  RSK4 knockdown inhibits Migration and Invasion .......................  125 
  4.7  Discussion ....................................................................................  130 
5. Expression of RSK4 in bladder cancer and lung cancer tissue 
microarray (TMA)  ........................................................................................  132 
   5.1  Immunohistochemistry of Bladder cancer TMA  .........................  133 
   5.2  Optimisation of RSK4 antibody for Immunohistochemistry (IHC)  134 
   5.3  The Bladder cancer TMA  ............................................................. 134 
   5.4  IHC Results  ..................................................................................  135 
   5.5  RSK4 expression in Lung cancer TMA  .......................................... 138 
   5.6  Discussion  ....................................................................................  139 
6. Role of RSK4 in metastasis In Vivo  ................................................... 142 
   6.1  Zebrafish Experiments  ................................................................  143 
   6.2  Mouse Experiments  ....................................................................  144 
         6.2.1  Results  ...................................................................................................   145 
   6.3  Discussion ....................................................................................  152 
7. Metabolic effects of RSK4 in T24 & A549 cell lines .......................  153 
    7.1  NMR Data Acquisition & Analysis  ................................................................  154 
    7.2  Results  ......................................................................................................  154 
        7.2.1  Analysis of media samples from control and siRSK4 treated A549 & T24     
 10 
                   cells ......................................................................................................... 154 
          7.2.2  Changes in Metabolite Consumption/Production over a 48h period  ..  157 
          7.2.3  Metabolite Concentrations within A549 cell extracts after 48 hrs  .....  163 
    7.3   Discussion  .................................................................................  164 
8. Discussion  ..................................................................................  167 
    8.1  Relevance of the Screen  .......................................................................  169   
    8.2  RSK family of Kinases  .............................................................................  170 
        8.2.1  Structure of RSK4  ...................................................................................  170 
          8.2.2  Mechanism of Activation of RSKs  ..........................................................  172 
          8.2.3  RSK expression and Localisation ............................................................  173 
          8.2.4  Regulation of Cellular processes by RSKs ...............................................  174 
    8.3  RSK4 in Cancer  ...........................................................................  175 
    8.5   Conclusions & Future Work   .....................................................  183 
9. Bibliography  ...............................................................................  185 
10. Appendices  .................................................................................  216 
 
 
 
 
 
 
 
 
 
 
 
 
 
 11 
List of Figures 
 
1.   Global burden of cancer per 100,000 population and its distribution 
2.   European Age-Standardised Incidence Rates of bladder cancer  
3.   European Age-Standardised Mortality Rates for bladder cancer 
4.   Organisation of epithelium 
5.   Hallmarks of Cancer 
6.   Emerging Hallmarks of Cancer 
7.   The Metastatic Cascade 
8.    Intravasation of Cancer cells at distant sites 
9.    Schematic representation of the MAP Kinase pathway 
10.  Glycolytic or Embden Meyerhof Pathway 
11.  The effects of Oncogenes & Tumour suppressor genes on Metabolism 
12.  Anatomical relations of a normal Bladder 
13.  Hematoxylin and Eosin stained histological sections of normal human bladder 
14.  Molecular pathways of pathogenesis and progression in bladder cancer   
15.  Multistep Progression in Bladder Cancer 
16.  Stages of Tumour Invasion in Bladder Cancer  
17.  Role of Neoadjuvant Chemotherapy in Bladder cancer 
18.  Flowchart depicting Chemotherapy Regimes in Bladder Cancer 
19.  Mechanism of RNA interference 
20.  Representative view of selected wells of crystal violet stained 96 well plate 
21.  Difference in the intensity of staining assessed by absorption values at 595 nm 
22.  Response of T24 cells to the drugs cisplatin and paclitaxel.  
23.  Representative crystal violet stained l plate depicting the effect of IC50  
            concentrations of cisplatin and paclitaxel 
24.  Photomicrographs (10X) of T24 cells showing the effects of transfection 
25.  Graphs representing cell death when T24 cells are treated with 3.5µM cisplatin  
        following siRNA-mediated knockdown of various kinases. 
26.  Plate configuration of the Qiagen kinome library used in the screen. 
27.  Schematic depiction of the screening method followed 
28.  Results of the kinome screen 
 12 
29.  Kinases affecting viability compared to non targeting control. 
30.  Proportion of siRNAs from the kinome library that affected response of T24 cells  
        to cisplatin or paclitaxel.  
31.  Kinases having a significant effect on cell viability on subsequent treatment with  
        cisplatin  or paclitaxel. 
32.  Sensitivity indices of kinases having a significant effect on cell viability when  
        subsequently treated with cisplatin. 
33.  Sensitivity indices of kinases having a significant effect on cell viability when  
        subsequently treated with paclitaxel. 
34.  Results of the validation experiment 
35.  Role of RSK family members in cancer cell migration. 
36.  Sensitisation of T24 cells on knockdown with different oligonucleotides of RSK4. 
37.  Increased sensitivity of three different bladder cancer cell lines to Cisplatin &  
        Paclitaxel on down regulation of RSK4 
38.  Downregulation of RSK4 leads to decrease in the protein levels of XIAP. 
39.  Effect of RSK4 knockdown on the mRNA levels of XIAP. 
40.  Effect of RSK4 knockdown on the mRNA levels of RSK1. 
41.   mRNA levels of RSK4 and RSK1 in response to double knockdown of different  
         combinations of siRNAs. 
42.  Effect on sensitivity  of cancer cells to chemotherapy (cisplatin & paclitaxel) on  
        knockdown with pooled siRNA and individual oligonucleotides of RSK4 & RSK1 
43.  Effect of RSK4 knockdown on the mRNA levels of RSK2. 
44.  Effects of RSK1, RSK2, RSK4 and SP1 downregulation on cell migration in T24 cell  
        line. 
45.  Effects of RSK1, RSK2, RSK4 and SP1 downregulation on cell migration in A549 cell  
        line. 
46.  Effects of RSK4 downregulation on cell migration speed in EKVX & HOP62 cell  
        lines. 
47.  Downregulation of RSK4 inhibits T24, J82 and TCCSUP bladder cancer cell  
        invasiveness. 
48.  Optimisation of RSK4 antibody for immunohistochemistry done in A549 cells. 
49.  Results of immunohistochemical staining (IHC) of a bladder Tissue Microarray  
 13 
        (TMA)  
50.  Average values for the intensity of staining, percent positivity and  
        immunohistochemical score (IHS) of a bladder Tissue Microarray (TMA) 
51.  Distribution of the immunohistochemical score (IHS) when the transitional cell  
        carcinoma (TCC) cores are stratified on the basis of clinical stage of the patient. 
52.  Distribution of Immunohistochemical score (IHS) based on the histological grade  
        of the  transitional cell carcinoma (TCC). 
53.  RSK 4 immunohistochemistry in a lung cancer TMA. 
54.  Average score of RSK4 IHC staining across various lung cancer sub types. 
55.  Strength of RSK4 staining of tissue cores in three different lung cancer sub types. 
56.  Effects of downregulation of RSK4 on cell migration & invasion in zebrafish. 
57.  Serial Bioluminescent Imaging (ventral and dorsal) over 8 weeks. 
58.  Location of various metastatic lesions on BLI 'in vivo' and 'ex vivo' (upon  
        dissection). 
59.  CT imaging (surface rendering) assessment of bone metastatic lesions. 
60.  1H NMR spectrum of A549 cell media at 48 hours post transfection. 
61. 1H NMR spectrum of T24 cell media at 48 hours post transfection. 
62.  Change in metabolite concentration at 24 and 48 hour post transfection I. 
63.  Change in metabolite concentration at 24  and 48 hour post transfection II. 
64.  Hypothesised metabolic pathways that occur with the Warburg effect. 
65.  Metabolite concentrations obtained from A549 cell extracts at 48 hrs. 
66.  Structure of RSKs. 
67.  Mechanism of activation of RSKs. 
68 Crystal structure of various RSK inhibitors 
 
 
 
 
 
 
 
 
 
 
 14 
 
 
 
List of Tables 
 
1.    Signalling Pathways and Targets involved in different steps of the Metastatic  
       Cascade. 
2.    The 2004 WHO/ISUP Consensus Classification for Bladder cancer 
3.    TNM Classification for staging of Bladder Cancer 
4.    EAU guidelines for treatment of NMIBC 
5.    Mechanisms of Resistance to various Anticancer Drugs 
6.    siRNA Transfection Conditions 
7.    siRNA sequences used for Validation 
8.    Other siRNA Sequences used in the Project 
9.    Component volumes and concentration for preparation of mastermix for reverse  
        transcription  
10.  Cycling conditions for reverse transcription 
11.  Criteria followed in the data analysis to consider a hit as significant.  
12.  List of different bladder cell lines used in this project along with their  
        characteristics and differences. 
13.  Targets that were taken through the validation step  
14.  Summary of results of validation of hits from primary screen 
15.  Changes in metabolite concentrations for A549 cells over a 48 hour period. 
16.  Changes in metabolite concentrations for T24 cells over a 48 hour period. 
17.  Kinase families represented in our screen hit list. 
 
 
 
 
 
 
 
 15 
Abbreviations 
BC = ATP Binding Cassette 
ABESF = 4-(2-Aminoethyl)-benzenesulfonyl fluoride hydrochloride 
AKT= Serine Threonine Protein Kinase AkT  
AMF = Autocrine Motility Factor 
AMFR = Autocrine Motility Factor Receptor 
AMPK = AMP-activated Protein Kinase 
Angptl4 = Angiopoietin- like protein-4 
APS = Ammonium persulphate  
ARHGAP22= Rho GTPase activating protein 22 
ASCT2 =ASC-like Na+-dependent neutral amino acid transporter 2 
ATF-1 = Activating Transcription Factor-1 
BAD = BCL2-associated Agonist of Cell Death 
Bax= BCL2-associated X protein 
BCG = Bacillus Calmette-Guerin 
BCL2 = B-cell lymphoma protein-2 
BCL-XL  = BCL2 Like 1 (long) 
BI-DFS = Bladder Intact Disease free Survival 
BLI = Bioluminescent Imaging 
BMP = Bone Morphogenic Protein 
BRAF= v-Raf Murine Sarcoma Viral Oncogene homolog B1 
BSA = Bovine Serum Albumin  
BTK = Bruton Agammaglobulinemia Tyrosine Kinase 
BUB1B = Budding Uninhibited by Benzimidazoles - 1 beta 
Casp3= Caspase 3 
CCL2 = Chemokine (C-motif) Ligand 2 
cDNA = Complimentary DNA 
c-FOS = FBJ Murine Osteosarcoma Viral Oncogene Homolog 
CI = Confidence Interval 
CIS = Carcinoma in Situ 
cMOAT = Canalicular Multispecific Organic Anion Transporter 
 16 
COL4A3BP = Collagen Type IV alpha 3 binding protein  
COX 2= cyclooxygenase-2 
CPM = Cyclophosphamide 
CR = Complete Response 
CREB = cAMP Response Elements Binding Protein 
CT = Computed Tomography 
CTKD = C-terminal Kinase Domain 
CTNNB1 = Catenin (cadherin-associated protein), Beta 1 
DAPI = 4’,6-diamidino-2-phenylindole dihydrochloride 
DAPK1 = Death Associated Protein Kinase 1 
DHFR = Dihydrofolate reductase 
DMEM = Dulbecco's Modified Eagle Medium 
DMH2 = Dorsomorphin  
DMSO = Dimethyl Sulfoxide  
DNA = Deoxy Ribose nucleic Acid 
DNA A = Deoxy Ribose nucleic acid Alkylator 
DNAI = Deoxyribose nucleic acid inter/intracalator 
Dock3= Dedicator of cytokinesis 3 
DSA = 4,4-Dimethyl-4-silapentane-1-ammonium trifluoroacetate 
dsRBP = dsRNA Binding Domain 
dsRNA = double stranded Ribose Nucleic Acid 
DSS = Disease Specific Survival 
DTT = Dithiothreitol 
DUSP = Dual Specificity Protein Phosphatase 
ECM = Extracellular Matrix 
EDTA = Ethylene diamine Tetraacetic Acid EPHA2 = Ephrin type A Receptor 2 
EGF = Endothelial Growth Factor 
EGFR = Epidermal Growth Factor Receptor  
EPC = Endothelial Progenitor Cells 
ERBB2 = v-erb-b2 Erythroblastic Leukemia Viral Oncogene Homolog 2 
ERK = Extracellular Signal Regulated Kinase 
FCS = Fetal Calf Serum 
 17 
FGFR3 = Fibroblast Growth Factor Receptor type 3 
FAK = Focal Adhesion Kinase 
FGF = Fibroblast Growth Factor 
FH= fumarate hydratase 
FLIP= Flice Inhibitory Protein 
Fos= FBJ osteosarcoma oncogene 
FoxO = Forkhead Box O 
FRET = Forster resonance Energy Transfer 
Fyn= FYN oncogene related to SRC 
GAG = Glycosaminoglycan 
GALNT7= N-acetylgalactosaminyltransferase 7 
GAPDH= Glyceraldehyde 3-phosphate Dehydrogenase 
GC = Gemcitabine, Cisplatin 
GFP = Green Fluorescent Protein 
GFR = Glomerular Filtration Rate 
GLUT = Glucose Transporter 
GLS = Glutaminase 
GPC = Glycerophosphocholine 
GRB2 = Growth factor receptor-bound protein 2  
GS= Glutamine Synthetase 
GSH= Glutathione 
H3AsO4= Pentavalent arsenic compound 
HD MVAC = High dose intensity  MVAC 
HEPES = 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HETE = 12 Hydroxyeicosatetraenoic acid 
HGF = Hepatocyte Growth Factor  
HIF 1α = Hypoxia Inducible Factor 1α 
HK= Hexokinase 
HK2= Hexokinase 2 
HR = Hazards Ratio 
HRAS = Harvey Rat Sarcoma Viral Oncogene Homolog 
HRP = Horseradish Peroxidase  
 18 
ICAM-1 = Inter-cellular Adhesion Molecule 1 
IDH= Isocitrate dehydrogenase 
IGF = Insulin like Growth Factor 
IGFBP2= insulin-like growth factor binding protein 
IHC = Immunohistochemistry 
IHS = Immunohistochemical Score 
IL = Interleukin 
IMP-1 = Insulin-like Growth Factor II mRNA-Binding Protein 1 
ISUP = International Society of Urological Pathology  
JAK1= Janus kinase 1 
JUN = Jun proto-oncogene 
LDH=Lactate Dehydrogenase 
LDHA= Lactate Dehydrogenase A 
LKB1 = Serine Threonine Kinase 11 
MAPK = Mitogen Activated Protein Kinase 
MAPKK = Mitogen Activated Protein Kinase Kinase 
MCL1 = Myeloid Cell Leukemia sequence 1 (BCL2 related) 
MDR = Multi Drug Resistance 
MERTK= MER receptor tyrosine kinase 
MgCl2 = Magnesium Chloride 
MIBC = Muscle Invasive Bladder Cancer 
MKP = MAPK phosphatase 
MMP = Matrix Metalloproteinase 
MRI = Magnetic Resonance Imaging 
mRNA = Messenger RNA 
MRP1= Multidrug Resistance-associated Protein 1 
MSP = Macrophage Stimulating Protein 
MT = Metallothionein  
m-TOR = Mammalian Target of Rapamycin 
MVAC = Methotrexate, Vinblastine, Doxorubicin, and Cisplatin 
MYC = V-Myc Avian Myelocytomatosis Viral Oncogene Homolog 
NA = Numerical Aperture 
 19 
NAT = Normal Adjacent Tissue 
NCBI = National Centre for Biotechnology Information 
NCK = Non-catalytic (region of) Tyrosine Kinase Adaptor Protein 
NEDD9= Neural Precursor Cell Expressed, Developmentally Down-Regulated 9 
NFkB= Nuclear Factor kappa B 
NMIBC = Non-Muscle Invasive Bladder Cancer 
NNT = Number Needed to Treat 
NP-40 = Nonidet P-40 
NTKD = N-terminal Kinase Domain 
NUP = Nucleoporin 
OMM = Outer Mitochondrial Membrane 
OR = Overall Response 
OXPHOS= Oxidative Phosphorylation 
PBS = phosphate Buffered Saline 
PDGF = Platelet derived Growth Factor 
PDGFR = Platelet Derived Growth Factor Receptor (PDFGR) 
PDH=Pyruvate Dehydrogenase 
PDK1= pyruvate dehydrogenase kinase isoform 1  
PFA = Paraformaldehyde  
PFK= Phosphofructokinase 
PGC1β= peroxisome proliferator-activated receptor-γ, co-activator 1β 
PGI = Phosphoglucose Isomerase  
PGK= Phosphoglycerate Kinase 
PGM= Phosphoglycerate Mutase 
P-gp = P Glycoprotein 
PGSL-1 = P-selectin Glycoprotein Ligand 1 
PI3K= Phosphoinositide 3-kinase 
PITPNC1= phosphatidylinositol transfer protein, cytoplasmic 1 
PK= Pyruvate Kinase 
PLK1= Polo-like kinase 1 
PKM2 = Pyruvate Kinase M2 
PLCγ = Phospholipase C Gamma 
 20 
PMSF = Phenyl Methyl Sulfonyl Fluoride  
PS = Performance Score 
PVDF = Poly Vinylidene Difluoride 
qPCR = Quantitative Polymerase Chain Reaction 
RAPTOR = Regulatory Associated Protein of MTOR, complex 1 
RAS = Rat Sarcoma Viral Oncogene Homolog 
Rb = Retinoblastoma 
RHEB = RAS Homolog Enriched in Brain 
Rho A= ras homologue family member A 
Rho GAP= Rho GTPase activating protein 
Rho GEF= Rho guanine nucleotide exchange factor 
RIPA = Radio-Immunoprecipitation Assay 
RISC = RNA-induced Silencing Complex 
RNA = Ribose Nucleic Acid 
ROCK= Rho kinase 
RPMI-1640 =  Rosewell Park Memorial Institute - 1640 
RPS6KA1 or RSK1= p90 ribosomal protein S6 kinase 1 
RPS6KA2 or RSK3= p90 ribosomal protein S6 kinase 2 
RPS6KA3 or RSK2= p90 ribosomal protein S6 kinase 3 
RPS6KA6 or RSK4= p90 ribosomal protein S6 kinase 6 
RT = Reverse Transcription 
RTK = Receptor Tyrosine Kinase 
S100A4 = S100 calcium binding protein A4 
S100A8 = S100 calcium binding protein A8 
S6K2= S6 kinase-related Kinase 2 
SAA3= serum amyloid A 3 
SCO2= SCO2 cytochrome c oxidase assembly protein 
SDF-1 = Stromal Cell-derived Factor 1 
SDH= Succinate Dehydrogenase 
SDS-PAGE=Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis 
SEER = Surveillance, Epidemiology and End results 
SEM = Standard Error of the Mean 
 21 
SHC1 = SHC (Src homology 2 domain containing transforming protein 1  
SHP1 = Protein Tyrosine Phosphatase, non-receptor type 6 
SHP2 = Protein Tyrosine Phosphatase, non-receptor type 11 
siRNA = Small Interference RNA 
SLP76 = SH2 domain containing leukocyte protein of 76kDa 
SP1 = Specificity Protein 1 
SO = Superoxide 
SOS3 = Son of Sevenless 
SRC = v-src avian sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog 
STAT = Signal Transducer and Activator of Transcription 
TBS-T = Tris based saline with Tween 
TCA =  Tricarboxylic Acid 
TCC = Transitional Cell Cancer 
TEMED = N,N,N,N-tetrametiletilenodiamine 
TGFβ = Transforming Growth Factor β 
TIGAR= tumour protein p53-induced glycolysis and apoptosis regulator  
TMA = tissue Microarray 
TNF α = Tumour Necrosis Factor α 
Topo IIi= Topisomerase II inhibitor TP53= Tumor Protein p53 
TPI= Triosephosphate Isomerase 
TPoI = Tubulin Polymerisation Inhibitor 
TR = Total Repetition Time 
TRAIL = TNF-related apoptosis-inducing ligand 
TSC2 = Tuberous Sclerosis Complex 2 
TSF = Tumour Soluble Factor 
TSP = Trimethylsilyl Propionate 
TSP-1 = Thrombospondin 1 
TURBT = Transurethral Resection of Bladder Tumor 
UTR = Untranslated Region 
VASP = Vasodilator Stimulated Phosphoprotein 
VCAM-1 = Vascular Cell Adhesion Molecule 1 
VDAC = Voltage Dependent Anion Channels 
 22 
70VEGF = Vascular Endothelial Growth Factor 
VEGFR = Vascular Endothelial Growth Factor Receptor  
VHL= von Hippel-Lindau tumour suppressor 
VPF = Vascular Permeability Factor 
WAVE2= WASP (Wiskott-Aldrich syndrome protein) family verprolin  
                  homologous    protein 2 
WHO =  World Health Organisation 
XIAP = X-linked inhibitor of apoptosis protein  
 
 
 
 
 
 
 23 
 
Chapter 1 
 
 
 
 Introduction 
 
     
 24 
1.1 Cancer 
1.1.1 Cancer Morbidity 
Overall about 12.7 million people a year are diagnosed with cancer worldwide. Out of 
these, 6.7 million are male and 6.0 million are female. Taking the current trends in 
cancer incidence into account, the burden of disease due to cancer (Figure 1) is 
predicted to be about 22.2 million per year by the year 2030 [1].  
 
 
Figure 1: Global burden of cancer per 100,000 population and its distribution across the 
globe [GLOBOCAN 2008] 
1.1.2 Cancer Mortality 
After cardiovascular diseases, cancer is the most common non-communicable cause of 
death globally. It accounts for an estimated 7.6 million deaths a year worldwide and 
this number is predicted to rise to about 13 million by year 2030 [2].  About 4.3 million 
men and 3.3 million women globally die of cancer every year and the risk of dying from 
cancer before age 75 is 13.4 and 9.1 percent for these groups, respectively [1]. There 
are considerable variations in the cancer incidence and associated mortality across 
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genetic and ethnic groups, geographical locations [1] and socioeconomic groups [3]. 
While the proportion of deaths due to cancer is only 5% in Africa compared to about 
23% in North America [4], this could be due to lack of facilities to diagnose and 
maintain a cancer registry.  In fact cancer incidence and mortality rates in low and 
middle income countries has been increasing over time and cancer is emerging as a 
major public health challenge as the population is aging and cancer risk factors like 
smoking, obesity and inactivity are on the rise [5].  
In UK, a total of 324,579 persons were diagnosed with cancer in year 2010 and around 
159,178 deaths in year 2011 were due to cancer. Although cancer incidence is higher 
in males than females (Figure 2), the mortality rates due to the same in UK are almost 
equivalent (Figure 3). The incidence rates of cancer have increased by about 5% in the 
last decade (2000-2009) [6] but the mortality rates during the same period have fallen 
by about 12% [6]. By 2030, the incidence of cancer in men is expected to rise by more 
than 50 per cent to over 236,000 whereas an increase by 37 per cent to over 200,500 
is forecast in women. The age standardised mortality rates in both men and women is 
predicted to fall by about 17% by the year 2030 [7] . 
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Figure 2:  European Age-Standardised Incidence Rates of bladder cancer per 100,000 
Population, by Sex, Great Britain 1975-2010 [7]. 
However, there would be an increase in the overall number of cancer deaths (30% in 
men and 15% in women) merely due to the sheer increase in the number of people 
diagnosed with the disease  [8].   
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Figure 3:  European Age-Standardised Mortality Rates for bladder cancer per 100,000 
Population, , by Sex, Great Britain 1971-2009. [8] 
1.1.3 Cancer characteristics 
Cancer is a term synonymous with malignant tumours or malignant neoplasms. Based 
on the degree of differentiation, malignant neoplasms range from well-differentiated 
cancers to undifferentiated. This lack of differentiation, also called ‘anaplasia’, is a 
hallmark of malignant transformation and manifests in the form of cellular and nuclear 
pleomorphism (variation in size and shape), hyperchromatic nuclei and nucleoli (dark 
staining), increased nuclear to cytoplasmic ratio, large nucleoli, abnormal DNA copy 
number (aneuploidy) and increased mitotic spindles. The cells lose their polarity and 
they grow in an anarchic and chaotic manner.  
Neoplasms arising in the mesenchymal tissue are called ‘sarcomas’ whereas the ones 
that arise in epithelia are called ‘carcinomas’. More than 85% of cancers are 
carcinomas that arise from epithelial linings of tissues and organs. Hence an 
understanding of the anatomical, physiological and pathological biology of the 
epithelium and its microenvironment is essential for in-depth comprehension of the 
complex pathological that are carcinomas. 
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1.1.4 Normal Epithelium and Extracellular Matrix 
The normal epithelium is constituted by a regular arrangement of epithelial cells and 
lines the outer surface of the body and the inner surface of the body cavities and 
viscera in the form of single or multiple layered sheets. Depending upon the location 
and structure, the epithelial tissue serves functions like protection, selective 
permeability, secretion, absorption, transport and sensory perception. These 
individual units have a strong apical-basolateral polarity – the apical surface which 
faces the lumen, the lateral surface which is adherent to the adjacent cells and the 
basal layer facing the extracellular matrix (basal lamina and vascular supply).  
The epithelial cells are anchored to each other and to the extracellular matrix through 
various interactions like tight junctions (zonula occludens), desmosomes (macula 
adherens), adherens junction (zonula aherens) and gap junctions (Figure 4). In 
addition to providing structural support, these interactions regulate several properties 
that are important for the epithelium to fulfil its functions. For instance, tight 
junctions provide the epithelium with impermeability; adherens junctions bind 
epithelial cells together; desmosomes provide structural support; and gap junctions 
allow cell-to-cell transport of small molecules [9].  
Epithelial cells rest upon the semi-permeable basal lamina. The basal lamina lies 
parallel to the basal epithelial cell membrane and is normally about 100-150nm in 
thickness. Adjacent to the basal lamina another layer of connective tissue is seen and 
the two together are referred as the basement membrane. This layer provides 
support, adhesion and selective permeability and influences epithelial organisation 
and survival. It consists of a mixture of non-fibrillar amorphous collagen (mostly type 
IV), laminin, heparan sulphate, proteoglycans, and other glycoproteins [10]. 
In addition the epithelial cells are supported by a stroma and, depending upon the 
organ, a layer of muscle or bone. The basement membrane and stroma together are 
referred as the extracellular matrix (ECM). The components of the basement 
membrane are 
a. Matrix Fibers: Matrix fibers include collagen, elastins and fibrilins and provide 
structural support to the epithelium. There are over 20 variants of collagen but the 
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most common form is the Type I. Type I, II, III and IV have been extensively studied. 
Type I, II and III have a fibrillar structure and make up 90% of the body collagen 
whereas Type IV lacks distinct fibrils and is a constituent of the basal laminae. Fibers 
composed of fibrillin and elastin confer elastic properties to the epithelium.  
b. Matrix Macromolecules : These include proteoglycans and adhesive glycoproteins. 
Previously referred to as ‘ground substance’, they have an amorphous, gel like 
appearance and consist of polysaccharides and proteoglycans associated with 
significant amount of water due to their high negative charge. The primary function of 
this matrix is to provide nutrients and mechanical support.  
 
 
Figure 4: Organisation of an epithelium A) Hematoxylin and Eosin stained transitional cell 
epithelium of the bladder with underlying basement membrane and B) Electronic 
micrograph of the epithelium depicting various types of interactions. Figure adapted from 
Atlas of functional Histology. Mosby Elsevier [11]. 
Proteoglycans are predominantly made by fibroblasts (chondroblasts and osteoblasts 
in cartilage and bone, respectively) and are carbohydrate rich glycosaminoglycans 
(GAGs) complexed to a protein core. GAGs are sulphated polymers of amino sugars 
and include chondroitin sulphate, keratin sulphate, dermatan sulfate and heparin 
sulphate. Many GAGs can link together (e.g. by attaching to hyaluron) and form highly 
negative charged proteoglycan aggregates that have high affinity for water and thus 
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are gel-like in consistency and along with collagen resist compressive deformation. 
Adhesive glycoproteins include fibronectin, integrin and laminin [11]. 
In addition to providing a supportive role to the epithelium, the ECM acts as a 
reservoir for growth factors and thus influences epithelial cell proliferation [12]. Also, 
during the metastatic process, it constitutes a mechanical barrier to invasion of deeper 
tissues but at the same time also acts as a substratum allowing malignant cells to 
adhere and migrate. 
1.1.5 Malignant transformation 
The transformation of a cell to a malignant phenotype is a step-wise process that 
generally occurs over an extended period of time and results in aberrations in the 
regulatory pathways that govern normal cell proliferation and homeostasis. The steps 
followed during this process are sometimes designated as (a) Initiation, (b) Promotion 
and (c) Progression and can be brought about by intrinsic (genetic abnormalities, 
mutations and hormones) or extrinsic (environmental, radiation, chemicals, 
occupational, dietary) factors.  While these factors will impact differently on the cell, 
carcinogenesis will ultimately occur as a result of non-lethal genetic damage 
(mutations, balanced translocations, gene amplification, epigenetic changes) which 
brings about an alteration in regulatory proto-oncogenes, tumour suppressors and 
genes involved in DNA repair [13].  These alterations bring about physiological 
changes that have been referred to as the ‘hallmarks of cancer [14]. These are listed 
below and depicted in figure 5. 
i) Self-sufficiency in growth signals 
ii) Evasion from growth suppressors 
iii) Resistance to programmed cell death (apoptosis) 
iv) Limitless replicative potential 
v) Sustained angiogenesis 
vi) Invasion and Metastasis 
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Genetic evolution and selection of malignant tumours bring about changes in the 
cancer cells such that they become more aggressive (e.g. increased invasive 
properties) and less responsive to therapy over time.   
 
 
Figure 5: The figure depicts the classical 'hallmarks of cancer' that are known to play a role 
in carcinogenesis. Figure adapted from The hallmarks of cancer. Cell 2000; 100(1):57-70  
[14].  
 
There is growing evidence that in cancer cells there is ‘Reprogramming of energy 
metabolism’ so as to support the increased energy demands and active ‘Evasion from 
Immune Destruction’. The two characteristics have been referred to as the ‘emerging 
hallmarks’ of cancer (Figure 6) [15].  
The acquisition of these hallmarks is enabled by the development of successive 
mutations leading to genomic instability and promotion of tumour progression by 
inflammatory (immune) cells in the tumour microenvironment [16].  
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Figure 6: The figure depicts the emerging 'hallmarks of cancer' that have recently been 
shown to contribute to tumour progression. Figure adapted from Hallmarks of Cancer: The 
Next Generation. Cell March 2011; 144(5):646-674 [15]. 
 
1.1.6 Invasion & Metastasis 
‘Malignant invasion’ is the spread of cancer cells into the adjacent healthy tissues and 
organs i.e. beyond the layer of tissue in which it originated. ‘Metastasis’ on the other 
hand refers to the spread of cancer cells from the primary tumour site to other distant 
sites in the body. Tumours spread from the primary site to other sites either by 1) 
‘Extension’ in continuity beyond the organ or tissue of origin, 2) ‘Dissemination’ 
beyond the tissue of origin to non-continuous adjacent structures and 3) ‘Distant    
spread' by the haematogenous or lymphatic route or via the coelomic cavities (e.g. the 
pleural and peritoneal spaces).  
Normally the ECM acts as a physical barrier to the spread of cancer cells. However, 
this protection is limited as the disease progresses, cancer cells rely on complex 
interactions with ECM in order to invade and metastasise. The pathogenesis of 
invasion and metastasis involves the following steps: 
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Figure 7: This diagram shows the various steps in the metastatic cascade starting from the 
selection of clones capable of migration and metastasis and ending with full colonisation at 
a distant site. Figure adapted from [17]. 
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a) Development of new blood vessels (neo-angiogenesis)  
b) Extension and infiltration of cancer cells into host tissue with penetration of 
small blood vessels and lymphatics. 
c) Intravasation and release of individual cancer cells or tumour emboli into the 
lumen of penetrated vessels. 
d) Promoted survival of cancer cells in circulation. 
e) Trapping of cancer cells in capillary beds of distant organs. 
f) Extravasation of tumour cells from the capillary vessels. 
g) Homing and subsequent growth of tumour cells at the distant site. 
Figure 7 below depicts the various steps in the metastatic cascade. 
 
1.1.6.1 Development of new blood vessels (Neoangiogenesis) 
The physiological blood supply of the host tissue can only sustain cancerous 
growths to a point (1-2 cm in diameter) before the demand for nutrients and waste 
removal exceed available resources. At this point, new blood vessels sprout from 
pre-existing vasculature to meet this increased demand. These newly generated 
blood vessels suffer from disorganised structures that make them leaky and dilated 
promoting tumour cell invasion and metastasis.  
Neovascularisation is normally controlled by a balance between angiogenic and 
anti-angiogenic factors. However, in cancers, angiogenic factors are increased and 
anti-angiogenic factors inhibited. Pro-angiogenic factors include the vascular 
endothelial growth factors (VEGFs), fibroblast growth factors (FGFs), transforming 
growth factor β (TGFβ), platelet derived growth factor (PDGF), tumour necrosis 
factor α (TNFα) and Interleukins  4 & 8 (IL-4 & IL-8).  The expression of pro-
angiogenic factors is increased in response to the hypoxia which manifests within 
the tumours when these outgrow their blood supply. Indeed, hypoxia causes 
activation of the hypoxia inducible factor 1α (HIF 1α) that binds to the hypoxia 
response elements present in the genes of various cytokines including VEGF, PDGF, 
endothelin, insulin like growth factor II (IGF II) and endothelial growth factor (EGF) 
[18].  
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The main anti-angiogenic factor is thrombospondin 1 (TSP-1). TSP-1 has a complex 
role in the regulation of angiogenesis and this plays a crucial role in tumour growth 
and progression [19]. In the context of urothelial cancer, TSP-1 expression was 
higher in normal bladder compared to bladder cancer tissue and lower levels of 
TSP-1 expression correlates with malignant aggressiveness [20]. In fact, an 
activating transcription factor-1 (ATF-1) mediated hepatocyte growth factor (HGF) 
induces downregulation of TSP-1 expression and in thyroid cancer this has been 
shown to promote invasion [21]. 
1.1.6.2 Extension and infiltration of cancer cells  
An interaction of the tumour cells with the ECM is vital for the process of invasion 
and metastasis. In order to gain access to the circulation, the tumour cells have to 
breach the basement membrane and pass through the interstitial tissue.  As a first 
step in this process, the tumour cells need to loose contact with each other. As 
explained earlier, cell-to-cell contacts in normal cells are maintained by E-cadherin. 
However, following mutation of the E-cadherin gene, activation of β-catenin or 
inappropriate expression of E-cadherin suppressing transcription factors such as 
SNAIL or TWIST, the function of E-cadherin is impaired in almost all epithelial 
cancers [22]. In addition to this, the ECM needs to be remodelled to enable 
infiltration of the tumour cells. This is facilitated by the secretion of proteolytic 
enzymes by tumour or stromal cells, leading to the degradation of the basement 
membrane and interstitial matrix. Such proteolytic enzymes include matrix 
metalloproteinases (MMPs) [23] and cathepsins [24]. 
Cancer cell  migration is a complex process involving interaction of various 
signalling pathways that ultimately converge onto the actin cytoskeleton to initiate 
movement. Growth factors can modulate the process directly or indirectly [25]. 
The dynamic cytoskeletal changes during migration are brought about by cell-
matrix interactions, actin-myosin contractions and contact disassembly mediated 
by GTPases such as Rho family, cdc42 and Rac as well as integrins and proteases 
[26]  
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1.1.6.3 Cancer cell motility & migration 
Cancer cells either migrate as individual cells or collectively [27]. Single cell 
invasion can either be mesenchymal [28] or  amoeboid [29]. Mesenchymal 
migration shows loss of epithelial cell polarity as a result of epithelial to 
mesenchymal transition (EMT) and is characterised by elongated cells displaying 
filopodia protrusions at the leading edge that generate adhesive contact with the 
surrounding matrix [30].  In contrast, during amoeboid migration, cells appear 
rounded and the movement is mediated by actin protrusions called blebs that 
generate propulsive force [31].  
Amoeboid motility is seen in cells with diffuse actin cytoskeleton and is 
accomplished as a result of short lived and less adhesive cell matrix interactions 
almost independent of integrins and focal contact interactions or proteolytic 
activities. This form of cell migration is RhoA/ROCK-mediated with active actin-
myosin contractility enabling cells to squeeze through gaps at a high speed [32]. A 
characteristic feature of cancer cells demonstrating amoeboid movement is F-actin 
rich pseudopodia and these direct the cancer cells towards blood vessels during 
chemotaxis [33]. Very often cancer cells switch between these two types of 
movements and this is regulated by changes in tissue microenvironment [34].  
Some cancer cells migrate collectively in the form of sheets, strands or clusters. In 
this collective form of migration, cell-cell adhesions are maintained and adhesion 
molecules expressed. These sheets or clusters of cells also form protrusions, apply 
pericellular proteolysis and use actin-myosin contraction for cell movement, 
however, the tails are not retracted but mechanical forces on the adjacent cells are 
exerted[35].  Such dissemination is crucial for spread of tumour cells through the 
lymphatics and circulation as the cohort of cells has a higher capacity to survive 
and resist anchorage independent cell death (Anoikis) [36].  Very often in cell 
cultures, leader cells with a highly polarised morphology and formation of 
lamellopodia have been demonstrated and these cells prepare the migratory  
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tracks and drag their adjacent cells along [37].  All the types of cancer cell motility 
are a result of formation of F-actin rich protrusions that are employed by the cells 
to adhere to their surroundings. Such  protrusions are named on the basis of their 
shape at the leading edge and thus can be pseudopodia (round), filopodia (needle 
shape), lamellopodia (flat) or lobopodia (cylindrical) [38].  
1.1.6.4 Release & Survival of cancer cells in circulation 
The integrin mediated adhesive interaction and secretion of proteolytic enzymes 
play a role in intravasation of cancer cells into the blood stream or lymphatics as 
well and thus aid metastasis. An inherent leakiness of the tumour vasculature 
coupled with microvessel density facilitates this process [39] and it is estimated 
that a total of 3-4 million cells per gram of tumour enter the blood stream [40]. 
However, the majority of these cells do not possess metastatic potential and fail to 
survive as they lack acquired genetic features to help them escape anoikis, 
immune surveillance and mechanical or shear stress in the circulation. 
Malignancies tend to induce a hypercoagulable state and this may provide a 
survival advantage to tumour cells in circulation as platelets shield them from 
immune destruction and shear stress in the bloodstream [41].  Platelets also 
promote adhesion of tumour cells to the endothelium and secrete factors like TGF 
β1 that induce EMT and thus play an important role in metastasis [42].  
1.1.6.5 Extravasation of cancer cells at distant sites 
From the circulation tumour cells extravasate into distant tissues, as a result of 
cytokine mediated interaction between the tumour cells and the endothelium. 
Cancer cells adhere to the luminal vascular membrane and roll over it to identify a 
convenient site for traversing the endothelial monolayer and entering into the 
interstitial space of the target organ [43]. This process is quite similar to leucocyte 
adhesion to the capillary endothelium and is brought about by low affinity 
interactions between glycoproteins such as P-selectin glycoprotein ligand 1 (PGSL-
1) and the corresponding transmembrane receptors for called selectins. A more 
stable adhesion between the cell adhesion molecules (CAMs) like the inter-cellular  
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adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1)  
follows [44]. These interactions may be the reason for organ tropisms of 
metastasis from primary tumours as endothelial cells from different location 
exhibit distinct adhesive properties. For example study of various prostate cancer 
cell lines have shown preferential adhesion to endothelial cells of bone marrow 
compared to lung in which corresponds to the pattern of metastases in prostate 
cancer [45].  
 
 
Figure 8: This diagram shows the interaction of cancer cells with endothelial cells leading 
to secretion of various tumour soluble factors (TSFs) that affect membrane permeability 
to promote extravasation and hence metastasis. VEGF = Vascular endothelial growth 
factor or vascular permeability factor (VPF); Angpt4= Angiopoietin- like protein-4; EGF= 
endothelial growth factor; HGF=  hepatocyte growth factor or scatter factor (SF); SDF-1= 
stromal cell-derived factor 1; 12(S) HETE= 12 Hydroxyeicosatetraenoic acid and CCL2= 
chemokine (C-motif) ligand 2. Figure adapted from [47]. 
As a normal intact endothelium represents a barrier to cancer cell extravasation, 
an increase in permeability of the vascular endothelium is essential for 
extravasation. This occurs as a result of the release of vasoactive compounds on  
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contact of cancer cells to the endothelium [46]. Tumour cells have been shown to  
secrete various vasoactive factors including Vascular endothelial growth factor 
(VEGF), Angiopoietin- like protein-4 (Angptl4), endothelial growth factor (EGF), 
hepatocyte growth factor (HGF), stromal cell-derived factor 1 (SDF-1), Fibrinogen, 
12(S) Hydroxyeicosatetraenoic acid (HETE), and a variety of pro-inflammatory 
cytokines and chemokines and these contribute in the transformation of an 
impermeable endothelial monolayer into a permeable one (Figure 8) [47].  
1.1.6.6 Homing and colonisation of cancer cells at metastatic sites 
As mentioned earlier, metastasis is quite an inefficient process and part of it is 
down to difficulty in initiation of growth in a secondary organ. Cancer cells may be 
shed into circulation and they may succeed in travelling to a distant site but then 
may fail to thrive or remain dormant [48]. Genetic and epigenetic changes in the 
cancer cells as well as a conducive host microenvironment play an essential role in 
how successfully   cancer cells will develop into secondary tumours [49]. Tumour 
host interactions within the parenchyma of target organs determine the 
subsequent success of metastatic colonisation and growth of microscopic 
metastasis into macroscopic lesions. Integrins, again, have a role to play and 
promote ‘outside-in’ cell signalling that mediates proliferation. This can be 
achieved either directly talking to signalling proteins like focal adhesion kinase 
(FAK) or indirectly by a cross talk with other signalling pathways (Table 1) [50].  
Other cell surface receptors like CD44 also aid in post-extravasation survival. 
Furthermore, proteases like MMPs activate growth factors including VEGF, TGF-β, 
bone morphogenic proteins (BMPs) and these contribute towards cancer cell 
survival in host tissues. In addition, cancer cells interact with both resident cells 
and the immune cells which have both supportive and inhibitory effects [51].   
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Table 1: Summary of the various signalling pathways and targets involved in different 
steps of the metastatic cascade. PI3K= Phosphoinositide 3-kinase ; Rho A= ras 
homologue family member A; ROCK= Rho kinase; Rho GEF= Rho guanine nucleotide 
exchange factor; Rho GAP= Rho GTPase activating protein; Dock3= Dedicator of 
cytokinesis 3; NEDD9= Neural Precursor Cell Expressed, Developmentally Down-
Regulated 9; WAVE2= WASP (Wiskott-Aldrich syndrome protein) family verprolin 
homologous protein 2; ARHGAP22= Rho GTPase activating protein 22; PDK1= pyruvate 
dehydrogenase kinase, isozyme 1; JAK1= Janus kinase 1; IGFBP2= insulin-like growth 
factor binding protein; PITPNC1= phosphatidylinositol transfer protein, cytoplasmic 1; 
MERTK= MER receptor tyrosine kinase; GALNT7= N-acetylgalactosaminyltransferase 7; 
TGF β= Transforming growth factor; MMP= matrix metalloprotease; NFkB= nuclear 
factor kappa B; Fos= FBJ osteosarcoma oncogene; VEGF= vascular endothelial growth 
factor ; VEGFR= vascular endothelial growth factor receptor; TNF α= Tumour necrosis 
factor α; COX 2= cyclooxygenase-2;  S100A8= S100 calcium binding protein A8; SAA3= 
serum amyloid A 3; S100A4= S100 calcium binding protein A4. Table adapted from[52]. 
 
1.1.7   Mitogen Activated Protein Kinase(MAPK) Signalling Pathway 
The MAPK signalling pathway plays an important role in cell migration, proliferation, 
differentiation, survival and metabolism [53]. It is highly conserved from yeast to 
mammals and the activation of the pathway can be brought about by a wide range of 
stimuli including various receptor tyrosine kinases and serine/threonine kinases.  
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MAPK signaling occurs downstream of receptor tyrosine kinases (RTKs) such as 
epidermal growth factor receptor (EGFR), platelet derived growth factor receptor 
(PDFGR), vascular endothelial growth factor receptor (VEGFR) and transmits growth 
factor signals from the cell membrane to the nucleus. The binding of ligands (e.g. EGF, 
VEGF, PDGF etc) leads to dimerisation and activation of RTKs [54]. This brings about an 
allosteric rearrangement of the receptors leading to auto- and trans- phosphorylation 
of the tyrosine residues within their cytoplasmic tail [55].  These phosphotyrosine 
residues serve as docking sites for src homology-2 (SH-2) domain-containing proteins 
including adaptor proteins (NCK, GRB2), scaffolds (SLP76, SHC), kinases (BTK, SRC, FPS), 
phosphatases (SHP1/2), phospholipases (e.g. PLCγ) and transcription factors (e.g. 
STAT) [56]. These molecules then propagate the signal to downstream effectors 
(Figure 9).  
For instance, after binding to RTKs, GRB2 recruits Son of sevenless (SOS) via its SH3 
domain and activates the small Rho GTPase p21 RAS (RAS) by promoting the exchange 
of  the GDP bound to Ras (GDP-Ras inactive) for a GTP (GTP-Ras active) [57] [58]. 
Active Ras then binds the N-terminal part of p74 RAF (RAF) [59] and promotes its 
activation and this in turn phosphorylates and activates mitogen activated protein 
kinase kinases (MAPKKs) dual-specificity protein kinases 1 and 2 (MEK1/2) [60]. MEK, 
in turn, activates p42 and p44 mitogen activated protein kinase (p42/44MAPK) also 
known as extracellular signal regulated kinases 1 and 2 (Erk1/2), respectively.  
Activated ERKs can phosphorylate more than a hundred different substrates and thus 
generate a wide range of biological outcomes [61]. ERK substrates include various 
plasma membrane proteins, cytosolic proteins, cytoskeletal proteins, nuclear 
substrates and transcription factors [62].  
The MEK/ERK pathway is the best studied of the MAPK pathways. ERK, in absence of 
growth signals is mainly cytoplasmic associated with MEK or other scaffold or 
regulatory proteins. However, in the presence of growth signals, ERK is 
phosphorylated by MEK and this leads to translocation of ERK to the nucleus. 
Interestingly, the components of the nuclear pore complex e.g. nucleoporins (NUPs) 
are substrates of ERK [64] and thus in a way ERK regulates its own nuclear transport. 
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ERK dimers are required for phosphorylation and mainly present in the cytoplasm 
whereas monomeric ERK is nuclear and associates with and phosphorylates 
 
 
Figure 9: Schematic representation of the MAP Kinase pathway activated by a receptor 
tyrosine kinase (RTK). The negative controls are indicated in red lines. DUSP: dual specificity 
protein phosphatase; GRB2: growth factor receptor-bound protein 2; MKP: MAPK 
phosphatase; SHC: SRC homology 2 domain containing transforming protein 1; SOS: son of 
sevenless, RSK= p90 ribosomal protein S6 kinase; src= v-src sarcoma viral oncogene 
homolog; Fyn= FYN oncogene related to SRC. Figure adapted from [63]. 
transcription factors [65].  It is pertinent to mention that many of the effects of ERK 
are brought about by the p90 ribosomal protein S6 kinase family members. 
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1.1.8  Metabolic Pathway and Cancer 
As mentioned earlier, one of the emerging hallmarks of cancer is reprogramming of 
energy metabolism. Metabolic alterations due to changes in mitochondria, redox 
regulation and bioenergetics play a key role in the proliferation, survival and response 
to therapy. Therefore, a better understanding of the metabolism of cancer cells could 
not only advance our understanding of the neoplastic process but may also help in the 
development of new therapeutic strategies and enhance selectivity by targeting the 
unique metabolic processes of a particular cancer type [66].  
1.1.8.1 The Glycolytic Pathway 
Glycolyis also known as the Embden Meyerhof pathway is a series of metabolic 
steps leading to the conversion of one molecule of glucose into two molecules of 
pyruvate and two molecules of ATP. The first phase of this pathway is energy 
consuming and utilises two molecules of ATP to convert one molecule glucose into 
one molecule of fructose 1,6 bisphosphonate.  The second phase is initiated by 
aldolase converting fructose 1, 6 bisphosphonate into two molecules of 
dihydroxyacetone phosphate which is an isomer of glyceraldehyde 3 phosphate. 
Each molecule of glyceraldehyde 3 phosphate gets converted to pyruvate and in 
the process two molecules of ATP are generated. The pyruvate is then used up in 
the TCA cycle under aerobic conditions for further generation of energy in the form 
of ATP. Alternatively it may get converted to lactate in anaerobic conditions. The 
complete glycolytic pathway is depicted in figure 10. 
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Figure 10: The glycolytic pathway also known as the Embden Meyerhof pathway. The 
pathway channels glucose molecules into generation of energy-rich ATP molecules that 
fuel cellular metabolism. H3AsO4= Pentavalent arsenic compound; HK= hexokinase; PGI= 
phosphoglucose isomerase; PFK= phosphofructokinase; TPI= triosephosphate isomerase; 
GAPDH= glyceraldehyde 3-phosphate dehydrogenase; PGK= phosphoglycerate kinase; 
PGM= phosphoglycerate mutase; PK= pyruvate kinase; PDH=pyruvate dehydrogenase; 
LDH=lactate dehydrogenase. Figure adapted from [67]. 
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   1.1.8.2    Glycolytic pathway enzymes in cancer 
Many of the enzymes in the glycolytic pathway have diverse roles and some of 
them act as regulatory proteins for transcription [68], apoptosis [69] and cell 
motility [70]. Hexokinase, which catalyses the first rate limiting step of glycolysis, 
has been known to be overexpressed in many cancer types [71] to increase the 
glycolytic rates that can fuel the metabolic needs of cancer cells [72].  Co-
expression studies have revealed the presence of functional p53 response 
elements on hexokinase, thus playing a regulatory role in many tumour cell types 
[73]. Hexokinase also interacts with voltage dependent anion channels (VDAC) 
which lie in the outer mitochondrial membrane (OMM) and play a crucial role in 
apoptosis and its regulation by the members of Bcl2 family [74]. Indeed, BAD, a 
pro-apoptotic Bcl2 family member that induces apoptosis by inhibiting anti- 
apoptotic protein Bcl-Xl, is known to be part of the mitochondrial complex with 
which VDACs interact.  
Phosphoglucose isomerase (PGI), also known as the autocrine motility factor 
(AMF),  has been established to have a dual function as catalytic enzyme in 
gluconeogenesis-glycolytic pathway and as an extracellular cytokine. It interacts 
with its receptor (AMFR) located in the endoplasmic reticulum and functions as an 
E3 ubiquitin ligase [75]. AMF/AMFR interaction has been shown to promote cancer 
cell migration in vitro and also increase chances of metastasis in vitro [76]. It also 
enhances angiogenesis and overexpression of AMF in various cancers has been 
associated with a poor prognosis [77].  
A recent proteome analysis has shown that aldolase, enolase and 
phosphoglycerate mutase are overexpressed in lung squamous cell carcinoma [78].  
One of the isoenzymes of pyruvate kinase (PK) called PK isoenzyme type M2 is in 
particular expressed by the tumour cells and is thought to improve the ability of 
tumour cells to survive in conditions of hypoxia and low nutrition [79.  
1.1.8.3   Warburg Effect in Cancer 
In the first quarter of the twentieth century, an observation was made by Warburg 
that tumour cells metabolize more glucose to lactate than normal cells even in the 
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presence of sufficient oxygen [80]. In other words, cancer cells process glucose by 
lactic acid fermentation and circumvent the passage of pyruvate through the citric 
acid (TCA) cycle. Subsequent work in this area established that this is true not only 
for solid tumours but also for haematological malignancies [81]. This represents a 
shift to a ‘primitive metabolic pattern’ as this increase in glycolytic activity was 
similar to that seen in early embryonal cells [82]. Lactate production, which in 
normal cells is inhibited in the presence of oxygen (Pasteur Effect), tends to be two 
orders of magnitude higher in cancer cells even in aerobic conditions. Warburg 
postulated that disturbance of respiration was the fundamental reason for 
increase in aerobic glycolysis and concluded that ‘The origin of cancer lies in the 
anaerobic metabolic component of normal growing cells, which is more resistant to 
damage than is the respiratory component. Damage to the organism favours this 
anaerobic component and, therefore, engenders cancer’ [83].  
Whereas normal cells produce most of their ATP through the mitochondrial 
oxidative phosphorylation in aerobic conditions via the TCA cycle, cancer cells 
generate more than half of their ATP through glycolysis [84]. The postulated 
explanation for this include mitochondrial defects as a result of mitochondrial DNA 
mutations, relative hypoxia considering the oxygen demands, oncogenic signals 
like Ras, Bcr-Abl etc and abnormal expression of certain enzymes including 
hexokinase [67]. 
The links between the Warburg effect and cancer are multifaceted as tumour 
suppressor genes and oncogenes play an important role in the regulation of 
metabolic enzymes and various molecules involved in glucose homeostasis (Figure 
11) [85].  An increase in the uptake of glucose by cancer cells is crucial for the 
Warburg effect to occur and this is made possible by an increase in the amount of 
glucose transporter (GLUT) proteins downstream of activated Ras, MYC and src 
oncogenes [86].  LDHA, a key enzyme in lactate production is a Myc responsive 
gene and Myc-mediated induction of LDHA is important for an increase in aerobic 
glycolysis and lactate production [87].  Myc also promotes alternative splicing of 
the pyruvate kinase M2 (PKM2), an isoform which is universally expressed in 
cancers and promotes aerobic glycolysis [88].  
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Figure 11: The effects of oncogenes and tumour suppressors on metabolism.  Myc= v-
myc avian myelocytomatosis viral oncogene homolog; HIF-1= hypoxia-inducible factor 1; 
p53= tumor protein p53; AkT= serine threonine protein kinase AkT; GLS= glutaminase; 
GS= glutamine synthetase; ASCT2 =ASC-like Na+-dependent neutral amino acid 
transporter 2; FH= fumarate hydratase; GLUT= glucose transporter; GSH= glutathione; 
HK2= hexokinase 2; IDH= isocitrate dehydrogenase; LDHA= lactate dehydrogenase A; 
NF-κB= nuclear factor-κB; OXPHOS= oxidative phosphorylation; PDK1= pyruvate 
dehydrogenase kinase isoform 1; PGAM2= phosphoglycerate mutase 2; PGC1β= 
peroxisome proliferator-activated receptor-γ, co-activator 1β; PKM2= pyruvate kinase 
M2; SDH= succinate dehydrogenase; TIGAR= tumour protein p53-induced glycolysis and 
apoptosis regulator; SCO2= SCO2 cytochrome c oxidase assembly protein; VHL= von 
Hippel-Lindau tumour suppressor [89]. 
AKT, a serine threonine kinase, causes a 2-3 fold increase in total cellular ATP 
content and this is partly due to an increase in AKT mediated increase in glycolysis. 
This is mediated by expression and membrane translocation of glucose 
transporters and effects on the expression, activity and facilitation of 
mitochondrial interaction of hexokinase [90]. AKT also phosphorylates and thereby 
activates an important rate controlling glycolytic enzyme called 
phosphofructokinase 2 (PFK2) and reverses the suppression of glycolytic activity by 
the transcription factor FoxO [91].  
The tumour suppressor gene p53 controls the transcriptional regulation of 
glycolytic enzymes so that glycolysis is suppressed and mitochondrial respiration 
promoted. The suppression of glycolysis is brought about by inhibition of 
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phosphoglycerate mutase 2 (PGAM2) and activation of tumour protein 53 induced 
glycolysis and apoptosis regulator (TIGAR) [92]. p53 also transactivates gutaminase 
2 (GLS2) which leads to an increase in glutathione production which mops up 
reactive oxygen species such as H₂O₂ & O²¯ [93]. The oncogene β-catenin (CTNNB1) 
increases the expression of glutamine synthetase (GS) which produces glutamine 
and this makes the cancer cells independent of extracellular glutamine for use in 
mitochondrial respiration. Glutamine synthetase (GS) expression has been shown 
to reflect a more favourable clinical outcome in hepatocellular cancer [94]. 
    
1.2  Bladder Cancer 
Bladder cancer is the seventh most common cancer in the UK with 10,324 new cases 
diagnosed in 2010 and 5081 deaths from this disease in 2011 [95]. Bladder cancer is 
2.5 times more common in men than in women. However, female sex is an adverse 
prognostic factor for recurrence, progression and cancer related survival in patients 
with MIBC undergoing BCG therapy for bladder cancer (HR: 3.53; p = 0.004) [96]. 
Women also fare worse than men after radical cystectomy for MIBC in terms of cancer 
specific mortality (HR: 1.35; p = 0.048) [97].  It is the fourth most common cancer in 
men after prostate, lung and colorectal cancers [98].  Even though bladder cancer can 
occur at any age, it generally is a disease of middle age. The mean age of diagnosis is 
69 years in males and 71 years in females [99]. The incidence of bladder cancer and 
related mortality increases with age in both men and women. Bladder cancer is more 
common in whites than in African Americans (22 per 100,000 compared to 13 per 
100,000); however as per Surveillance, Epidemiology and End results data, the latter 
tend to have a worse prognosis with a 5-years survival rate of only 66% compared to 
81% in white patients (SEER 1996-2004) [98].  Being married, when taken into account 
independently of other risk factors, has been seen to lead to a favourable survival 
outcome [100].  
More than 90% of bladder cancers are transitional cell carcinomas and in the following 
text the term ‘bladder cancer’ will refer to ‘transitional cell carcinoma of the bladder’ 
unless specified otherwise.  
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1.2.1    Anatomy and histology of the bladder 
So as to understand the pathologic aspects of bladder cancer, a brief account of 
important anatomical and histological features of the bladder is essential. The 
bladder is a pelvic organ with its posterior surface or the base lying in a posterior 
and inferior position separated from the anterior wall of the rectum by soft tissue 
and seminal vesicles in men (Figure 12A). In women the cervix and proximal 
portions of the vagina are interposed between the base of the bladder and the 
rectum (Figure 12B). These relationships are important because it explains why 
these are the organs most commonly involved by contiguous spread of primary 
bladder cancers. 
 
 
Figure 12: Median sagittal section showing the anatomical relations of a normal bladder 
in a (A) Male pelvis and (B) Female pelvis. Figure adapted from[277] 
Histologically, the bladder wall is composed of four layers namely, from inside 
out， ‘tunica mucosa’, ‘tela submucosa’, ‘tunica muscularis’ and ‘tunica serosa’, 
(Figure 13).  The innermost ‘tunica mucosa’ is a thin pale-rose coloured transitional 
epithelium of three to seven layers and is separated from the submucosa by the 
basement membrane. The ‘tela submucosa’ also known as ‘lamina propria’ 
consists of areolar tissue with a thin band of smooth muscle fibres that is variable 
in its extent. The ‘tunica muscularis’ also called ‘muscularis propria’ consists of a 
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complex of interlacing smooth muscle bands. These are arranged in three layers – 
inner longitudinal, middle circular and outer longitudinal. The outermost ‘tunica 
serosa’ is derived from the peritoneum and is reflected onto the abdominal and 
pelvic walls.  
 
Figure 13: Hematoxylin and Eosin stained histological sections of normal human 
bladder (A) Shows the layers of the bladder wall and (B) a higher magnification view of 
the transitional cell epithelial layer (tunica mucosa). 1 = tunica mucosa or transitional 
epithelium; 1A = superficial layer, 1B = basal layer, 1C = basement layer; 2 = tela 
submucosa; 3 = inner longitudinal layer of tunica muscularis; 4 = middle circular layer of 
tunica muscularis; 5 = outer longitudinal layer of tunica muscularis; 6 = tunica serosa.  
1.2.2      Etiology & Risk factors 
The etiological risk factors that predispose to development of bladder cancer are 
classified into ‘external or environmental exposures’ and ‘inherited genetic 
predispositions’. Acquired carcinogen exposure is the key step in bladder cancer 
pathogenesis and primary prevention approaches for avoidance of such exposure 
can be most effective in reducing the disease specific mortality. 
The ‘environmental or extrinsic factors’ recognised to have a causal relationship 
with bladder cancer include cigarette smoking, occupational exposure to 
chemicals, analgesic abuse, ingestion of arsenic, dietary factors, infections 
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(bacterial, parasitic, fungal or viral), chronic irritation secondary to bladder calculi 
and receiving genotoxic chemotherapeutic agents.  
Smoking, as a factor, is the most important as it has a huge epidemiological impact 
due to widespread consumption all over the world (20% of adults in United States 
& Europe). Historically, smoking patterns have reflected the incidence of bladder 
cancer as well. Until the middle of twentieth century it was mainly men who 
smoked but females took up smoking in the latter part while smoking rates in men 
declined such that currently the prevalence of smoking is almost similar in both 
sexes. Reflecting a latency period of about 30 years it is noticeable that the 
incidence of bladder cancer is dropping in men and rising in women.  
Smoking tobacco increases the risk of bladder cancer four times (HR: 4.1; 95% CI, 
3.7–4.5) [101] [102]. The pathophysiological link to bladder cancer is the presence 
of aromatic amines, such as β-naphthylamine, and polycyclic aromatic 
hydrocarbons in tobacco smoke. These carcinogens are excreted in urine and 
hence can affect any part of the urinary tract. In people who quit smoking this risk 
is lower but the risk reduction to baseline takes about 20 years (HR: 2.22; 95% CI, 
2.03–2.44) [103] [102]. The degree of risk, however, depends on the number of 
cigarettes, the duration of smoking and the degree of inhalation (inhalation into 
the chest increases risk compared with inhalation into the mouth only) [104]. The 
risk also depends on the type of tobacco smoked i.e. ‘black’ or ‘blonde’. Because 
‘black tobacco’ contains a higher concentration of N-nitrosamine and 2-
napthylamine, the risk of bladder cancer is higher [105].  
Even passive exposure to tobacco smoke during childhood and adulthood has been 
found to increase the risk of urothelial cancer (HR: 3.08; 95% CI, 1.16–8.22) [106]. 
Quitting smoking has been found to be an independent prognostic factor 
associated with prolonged disease-specific and overall survival in patients treated 
with radical cystectomy for bladder cancer [107]. In smokers diagnosed with 
bladder cancer, failure to quit smoking predicts a more ominous outcome even in 
those who have non-invasive cancers initially [108]. 
Occupational or environmental exposure to chemicals which can act as 
carcinogens for bladder cancer include aromatic amines like aniline dyes, 2-
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naphthylamine, 4-aminobiphenyl, 4-nitrobiphenyl, 4-4-diaminobiphenyl 
(benzidine), and 2-amino-1-naphthol [109], combustion gases, soot from coal and 
chlorinated aliphatic hydrocarbons [110] and certain aldehydes such as acrolein 
used in chemical dyes and in the rubber and textile industries [111]. Therefore 
occupations associated with a higher risk of bladder cancer include painters, metal 
workers, autoworkers, dyers, leather workers, beauticians, etc. Artificial 
sweeteners previously believed to be a risk factor, have been absolved of a major 
role in the aetiology of bladder cancer [101].  
Pelvic irradiation also increases the risk of bladder cancer. In women treated with 
radiotherapy for ovarian or cervical cancer, the risk of bladder cancer increased 2-4 
times over a ten year period, when compared to those who had surgery only [112]. 
Radiotherapy for prostate cancer also increases the age standardised incidence 
rate of bladder cancer (HR: 1.70; 95%CI, 1.57–1.86) [113]. Among 
chemotherapeutic agents, cyclophosphamide has been shown to increase the risk 
of developing bladder cancer nine-fold. The latent period of developing bladder 
cancer in such cases is short and these tumours are often highly aggressive and 
muscle invasive at diagnosis [114]. Acrolein, a metabolite of cyclophosphamide 
which also causes hemorrhagic cystitis, is implicated in bladder cancer as well and 
the uroprotectant mesna may reduce this risk [115].  Long term administration of 
Pioglitazone, a thiazolidinedione used as an anti-diabetic agent has also been seen 
to increase the risk of bladder cancer (HR:1.4; 95% CI, 1.03–2.0) [116]. 
Some chronic medical conditions can either directly or indirectly increase the 
chances of urothelial tumourigenesis. These conditions include chronic urinary 
retention and upper tract dilatation, chronic irritation of the urothelium and 
chronic schistosomal infection (Schistosomiasis caused by schistosoma 
hematobium and enedemic in northern Africa). Schistosomiasis, however, causes 
‘squamous cell cancer’ of bladder rather than the ‘transitional’ type. A higher risk 
of urothelial cancer has also been seen in people with diabetes mellitus who are on 
oral hypoglycaemics for a long duration (HR: 2.2; 95% CI, 1.3–3.8) [117].  
Dietary factors like total fluid intake, alcohol, coffee, chlorination in water, 
ingestion of meat and vitamin supplements, though initially thought to have a role, 
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have been shown to not influence development or prevention of bladder cancer. 
On the other hand, dietary arsenic exposure more than doubles the lifetime 
mortality risk from bladder cancer [118]. 
There is no strong evidence for the role of hereditary factors in bladder cancer 
[119]. However inherited enzyme polymorphisms that activate or inactivate 
potential carcinogens can modulate the response to equal exposures to these 
compounds and the subsequent development of bladder cancer. For example, 
rates of acetylation of 4-aminobiphenyl which is found in several industrial 
chemicals and cigarette smoke can determine the susceptibility of a person to this 
malignancy. Acetylation detoxifies this potential carcinogen and hence slow 
acetylators accumulate this compound, predisposing them to the development of 
the disease [120]. 
 
Figure 14: Pictorial illustration of the two main molecular pathways of pathogenesis and 
progression in bladder cancer. Figure adapted from [124]. 
 
Genetic factors have an important role in the pathogenesis of bladder cancer 
although different mechanisms might be involved (Figure 14). The induction of the 
RAS oncogene has been found to be associated with bladder cancer and in some 
 
 53 
studies correlates with a higher histological grade [121]. Another known 
mechanism is the inactivation of tumour suppressor genes. The TP53 gene that 
normally inhibits cell cycle progression, promotes DNA repair, directs abnormal 
cells towards apoptosis and inhibits angiogenesis is frequently altered in bladder 
cancer [122]. Most TP53 mutations are missense substitutions but some of them 
can be frame shift insertions and deletions or other infrequent alterations [123].  
Reduced or altered expression and/or function of retinoblastoma (Rb) gene and its 
regulators p15, p16, p21 and p27 results in unregulated transition of the cell from 
G1 to S phase, thus driving cellular proliferation [125]. The third genetic 
mechanism playing a role in bladder cancer is the amplification or overexpression 
of genes encoding for growth factors or their receptors. Two such genes important 
in the development and progression of bladder cancer are the epidermal growth 
factor receptor (EGFR) or ERBB1 [126] and ERBB2 [127].  
1.2.3 Pathology 
Bladder cancer like other cancers is a multistep process progressing through 
various degrees of dysplasia to varying grades of anaplasia and depth of 
penetration as illustrated in figure 15. It is well established that more than 90% of  
 
Figure 15: Schematic diagram illustrating the multistep progression through various 
degrees of differentiation in bladder cancer. CIS= carcinoma in situ. Figure adapted 
from [129] . 
all malignant bladder tumors are transitional cell carcinomas. After consensus in a 
conference of the pathologists of World Health Organisation (WHO) and 
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International Society of Urological Pathology (ISUP), a classification system was 
adopted (Table 2) to remove the discrepancies and differences prevalent earlier 
[128]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Histological types of transitional carcinoma of bladder as per the WHO/ISUP  
consensus classification. Table adapted from [128]. 
 
In addition to this classification, pathologists use a grading system based on the 
degree of anaplasia in the cells. This system is based on the 1973 WHO 
classification and, based on tissue architecture, the lesions can be Grade I (well 
differentiated tumour), Grade II (moderately differentiated tumour) and Grade III 
(poorly differentiated tumour). There is usually a strong correlation between the 
tumour grade and stage with most grade I and II tumours being non-muscle 
invasive and most Grade III tumours muscle invasive.  
 
Table 2.   The 2004 WHO/ISUP Consensus Classification 
 
Normal 
    Normal 
 
Hyperplasia 
    Flat Hyperplasia 
    Papillary Hyperplasia 
 
Flat Lesions with Atypia 
    Reactive / Inflammatory Atypia 
    Atypia of unknown significance 
    Dysplasia (low grade intraurothelial neoplasia) 
    Carcinoma in situ ( high  grade intraurothelial   
    neoplasia) 
 
Papillary Neoplasms 
     Papilloma 
     Inverted papilloma 
     Papillary neoplasm of low malignant potential 
     Papillary carcinoma, low grade 
     Papillary carcinoma, high grade 
 
Invasive Neoplasms 
       Lamina propria invasion 
      Muscularis propria (detrusor) invasion 
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Figure 16: (A) Diagram showing stages of tumour invasion in bladder cancer with (B) 
corresponding layers in a normal bladder. Also seen are photomicrographs of (C) CIS (D) 
superficial Ta tumour, (E) mucle invasive T1 tumour and (F) muscle invasive T2 tumour at 
higher magnification. Figure adapted from [130]. 
Transitional cell carcinomas have two basic morphologic expressions: papillary 
lesions accounting for 70% to 80% of these tumours and a flat lesion accounting for 
the other 20% to 30%. The diagnosis is based on cystoscopy, cytology, 
transurethral resection of bladder tumour (TURBT), imaging studies, and 
histopathologic findings. As of now, no urinary molecular makers provide a 
diagnostic accuracy as good as a combination of cystoscopy and urine cytology.  
 56 
TNM Classification of Malignant Bladder Tumours 
Tx Primary tumour cannot  be assessed 
T0 No evidence of primary tumour 
Ta Papillary, epithelium confined 
Tis Flat, carcinoma in situ 
T1 Lamina  propria invasion 
T2a Superficial muscularis propria invasion (inner half) 
T2b Deep muscularis propria invasion (outer half) 
T3a Microscopic extension into perivesical fat 
T3b Macroscopic extension into perivesical fat 
T4a Cancer invading pelvic viscera (prostate, vaginal wall, rectum, uterus etc) 
T4b Cancer extending to pelvic side walls, abdominal walls or bony pelvis 
 
Nx Node status unknown 
N0 No histologic pelvic node metastasis 
N1 Single positive node <2cm in diameter below common iliacs 
N2 Single positive node 2-5cm in diameter or multiple positive nodes < 5cm 
N3 Positive nodes >5cm in diameter 
  
Mx Distant metastasis status unknown 
M0 No distant metastasis 
M1 Distant metastasis present 
Table 3: TNM Classification for Staging of Bladder Cancer (TNM Classification of 
Malignant Tumours, 7th edition, 2009). 
Depending on the depth of penetration of the tumour cells into the bladder wall 
(Figure 16), bladder cancer can be superficial or non-muscle invasive (Tis, Ta, T1) 
and infiltrative or muscle invasive (T2, T3, T4). This is based on the staging system 
by TNM classification as shown in Table 3 (TNM Classification of Malignant 
Tumours, 7th edition, 2009). Carcinoma in situ (CIS) is a high grade carcinoma 
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confined to the urothelium and has a flat velvety, non-papillary appearance. It can 
be focal or diffuse and often not visible at all and may need special procedures like 
blue light cystoscopy for higher diagnostic accuracy [131] [132].  In the context of 
presentation, CIS can either be primary (no previous or concurrent papillary 
tumours, no previous CIS), secondary CIS (previous history of papillary tumours but 
no CIS), recurrent CIS (repeat occurrence of isolated CIS) and concurrent CIS (in the 
presence of papillary tumours in bladder). 
1.2.4 Treatment of Bladder Cancer  
At presentation, about 75-85% of bladder tumours are superficial or non-muscle 
invasive bladder cancers (NMIBC) whereas the rest are infiltrative or muscle 
invasive bladder cancers (MIBC) [133].  Among NIMBC, approximately 70% are pTa, 
20% are pT1 and 10% are pTis [134]. Around 10-15% of superficial tumours 
progress to become invasive during the course of the disease [135].  The low grade 
Ta lesions have a recurrence rate of 50-70% but a low rate (5%) of progression. 
However, high grade T1 or Tis lesions have a recurrence rate of 80% and a 50 % 
progression rate. In addition to the tumour grade and TNM category, prognosis for 
NMIBC is also correlated with the tumour size, multiplicity, papillary or sessile 
morphology, prior recurrence rate and concomitant carcinoma in situ (CIS)[136]. 
CIS lesions though non-invasive are high-grade and have a 40-80% risk of 
progression to MIBC if left untreated [137]. Almost all of MIBCs are high grade 
[138] at the time of diagnosis.  
In bladder cancer, surgical removal of the primary tumour represents the best 
chance of cure. However, tumour recurrence is common [124] and nearly half of 
the patients presenting with muscle invasive disease or progressing to this state 
from non-muscle invasive cancer harbour occult distant metastases [139]. 
Consequently, the five-year survival rate which is >90% for localised bladder cancer 
falls to about 45% in cases with regional spread and is only 6-8% in metastatic 
bladder cancer [98]. This cancer, like other malignancies, follows the general 
concept of multi-step carcinogenesis in which progressive genetic and epigenetic 
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changes enable progression from non-invasive disease through to malignant 
change involving invasion and metastasis [140][141]. 
1.2.4.1 Treatment of Non-Muscle Invasive Bladder Cancer 
Complete endoscopic removal also known as transurethral resection (TUR) of is the 
standard initial treatment for bladder tumours. It not only removes macroscopic 
tumour burden but also provides tissue for pathological grading by the 
histopathologist. This provides information about risk stratification and further 
treatment is directed accordingly (Table 4).   
Treatment recommendations in NMIBC based on risk 
stratification 
Low risk Primary, solitary, Ta, G1, 
<3cm, no CIS 
TURBT + One immediate 
instillation of chemotherapy 
+ Follow up cystoscopies 
Intermediate 
risk 
All categories between low 
risk and high risk 
TURBT + Relook TURBT in 
6-8 weeks + One 
immediate instillation of 
chemotherapy followed by 
further instillations for a 
maximum of one year or 
one full year of BCG + 
Follow up cystoscopies 
High risk Any of the following 
- T1 tumours 
- G3 tumours 
- CIS 
- Multiple and recurrent 
and large (>3cm) Ta, G1 
TURBT + Relook TURBT in 6-8 
weeks + Intravesical full dose 
BCG instillation for 1-3 years 
+ Follow up cystoscopies or 
radical cystectomy (in highest 
risk tumours) 
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& G2 tumours 
Highest risk - T1G3 associated with 
concurrent bladder CIS, 
multiple and/or large 
T1G3, TIG3 with CIS in 
prostatic urethra and 
micro papillary variant 
of TCC.  
- BCG refractory cases 
Radical cystectomy should be 
considered /recommended 
Table 4: The above table lists the EAU guidelines for the treatment recommendations for 
NMIBC based on risk stratification. TURBT = Transurethral resection of bladder tumour; 
Chemotherapy = either Mitomycin C or Epirubicin or Doxorubicin; BCG= Bacillus Camille 
Guerin. Table adapted from [133]. 
 
1.2.4.2 Treatment of Muscle Invasive Bladder Cancer  
For cases where the initial histological analysis after TURBT indicates a muscle 
invasive disease,  a Computed Tomography (CT) scan of the chest, abdomen and 
pelvis including an excretory phase urography is performed for the purpose of 
staging in order to decide optimal further management [142]. Magnetic 
Resonance Imaging (MRI), because of its time consuming nature, is used for 
staging only if CT is contraindicated either because of contrast administration or 
radiation dose. The overall accuracy of the two modalities for detection and 
staging of bladder cancer is similar [143],  although the CT has lower sensitivity 
(89% versus 100%) but a higher specificity (95% versus 73%). A new method of 
staging transitional cell bladder cancer using supermagnetic iron oxide 
nanoparticles (ferumoxtran-10 enhanced) reaches a sensitivity of 96% and a 
specificity of 95% for detection of lymph node metastasis as small as 2mm, in the 
limited studies conducted so far [144]. 
Radical cystectomy with urinary diversion is recommended in T2-T4a, N0M0 
disease and should be performed within 3 months of diagnosis for favourable 
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outcome [145]. Radical cystectomy involves complete removal of bladder & 
adjacent organs [146] and pelvic lymph node dissection is an important part of 
the procedure [147] It not only aids staging but also improves the outcome. The 
recurrence free and overall survival in men and women treated with radical 
cystectomy has been estimated to be between 66-68% and 58-66% respectively 
at 5 years and between 60-73% and 43-49% respectively at 10 years. This 
outcome is far superior than that obtained with any other bladder sparing 
modality [148] even in elderly patients [149], although at the cost of increased 
post-operative morbidity [150].  In patients with multiple comorbidities, a  
validated Charlson score is often used to decide whether to adopt radical surgery 
or a bladder sparing modality as a management plan [151]. External beam 
radiotherapy (EBRT) is recommended as a therapeutic option only when the 
patient is unfit for surgery or bladder sparing multimodality treatment [152].  
Bladder sparing multimodality treatment involves a combination of TURBT, 
radiotherapy and chemotherapy and demands a close multidisciplinary approach 
and patient compliance. This treatment is usually reserved for a small subset of 
well informed, well selected patients who are highly motivated and for whom 
cystectomy is not an option [133].  Some of the studies have suggested 10 year 
outcomes similar to Radical cystectomy with multimodality treatment [153].  In 
fact, as a guide for clinicians to provide individual estimates of complete 
response (CR), disease specific survival (DSS) , and bladder intact disease free 
survival (BI-DFS), prognostic nomograms have been developed [154]. 
In T4b disease, radical cystectomy can only be offered as a palliative treatment 
and is usually done for relief of intractable symptoms like pain, bleeding, lower 
urinary tract symptoms and fistula formation, where other measures have failed. 
Chemotherapy is the main modality of treatment in advanced and metastatic 
bladder cancer.   
 1.2.5     Chemotherapy in Bladder Cancer   
It is thought that the stage-dependent survival reduction in advanced bladder 
cancer is due to the presence of micro metastases at the time of surgery. While 
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more extensive lymph node dissection may have both prognostic and therapeutic 
significance, effective systemic therapies aimed at eliminating micrometastases 
may improve outcome. Perioperative chemotherapy can be administered before 
(neoadjuvant) or after (adjuvant) cystectomy to eradicate subclinical disease and to 
improve survival.  
 
Figure 17: Hazard ratio plot for overall survival from different trials comparing 
Neoadjuvant chemotherapy (NeoCT) + Radical cystectomy to control (Radical cystectomy 
alone). Each trial is represented by a square, the centre of which gives the hazard ratio 
for that trial. The size of the square is proportional to the information in that trial. Ends 
of horizontal bars denote the 99% confidence interval (CI) and inner bars mark the 95% 
CI.  The black diamond gives the overall hazard ratio for the combined results of all trials; 
the shaded diamonds denote the hazard ratios for the trial groups; the centre denotes 
the hazard ratio, the extremities the 95% CI. The top three trials used single agent 
neoadjuvant chemotherapy whereas the rest used combination chemotherapy. Figure 
taken from [155] 
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Neoadjuvant chemotherapy potentially allows down staging of inoperable lesions 
and treatment of micrometastases. Neoadjuvant chemotherapy leads to an 
improvement in overall survival (5%) and bladder cancer specific survival (14%) at 5 
years (Figure 17), with a relatively low number needed to treat (NNT) estimated at 
20 [155]. The downside is that it can delay surgical treatment especially if the 
patient develops significant toxicity to it.  
Chemotherapy in the adjuvant setting offers a similar modest 9% improvement in 
overall survival at 5 years [155]. There is a growing body of evidence that supports 
the idea that chemotherapy be integrated with surgical management of MIBC for 
better patient outcomes [156].  
In the treatment of metastatic bladder cancer, consensus has been reached that 
cisplatin based combination chemotherapy is more effective than single-agent 
chemotherapy [157]. The traditional reference standard regimen consists of 
Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (MVAC) but more recently 
this has been replaced by a combination of Gemcitabine and Cisplatin or 
Carboplatin which is better tolerated [158]. In terms of response both regimens are 
equivalent with an overall response (OR) rate of about 40% - 60% and complete 
response (CR) rate of about 15% - 20%, although long term disease free survival is 
rare. Taxanes have been used in trials on patients with advanced bladder cancer 
with response rates ranging from 25-80% in combination chemotherapy regimens 
[159] [160]. Other clinical trials with a combination of Paclitaxel and Gemcitabine 
[161]; Cisplatin and Docetaxel [162]; Cisplatin and Paclitaxel [163]; Gemcitabine, 
Paclitaxel and Cisplatin [164]; Paclitaxel, Carboplatin and Gemcitabine [165] have 
all led to response rates better than those seen with any single agent. Cisplatin 
based combination chemotherapy has been found to be more effective than 
carboplatin based chemotherapy. However, carboplatin based combination 
chemotherapy is used as a first line treatment for patients ineligible to have 
cisplatin (Figure 18). These include patients with abnormal renal function, poor 
performance score (PS) and poor prognostic score [166].  
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Figure 18: A flowchart depicting chemotherapy regimes adopted in the management of 
bladder cancer based on patient characteristics. GFR = Glomerular filtration rate; MVAC = 
Methotrexate, Vinblastine, Doxorubicin, and Cisplatin; GC = Gemcitabine, Cisplation; HD 
MVAC = High dose intensity  MVAC. Figure adapted from European Urology guidelines for 
Muscle Invasive & Metastatic Bladder cancer. 
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                1.3   Chemotherapeutic Drug Resistance in Bladder Cancer 
The overall response rates to standard cisplatin based combination regimen (MVAC) 
have varied between 40% and 70%, with complete response (CR) in 15%–25% and 
median survivals up to 16 months [157][160][167]. Most responding patients relapse 
within the first year and the median survival is about 12 months [168]. The newer 
cisplatin-gemcitabine combination does not show added benefit in terms of overall 
survival, time to disease progression, or response rate [169] but is better tolerated. 
Those patients who relapse following cisplatin based primary chemotherapy or who 
failed to respond initially can still benefit from further treatment with taxanes such as 
paclitaxel. However, overall only 30% will respond and the benefit is short lived so 
overall survival remains poor. Consequently, there is a need to find new drug targets 
that could enhance the effects of existing chemotherapy and/or reverse drug 
resistance in bladder cancer. 
Chemotherapeutic drug resistance can either be intrinsic or acquired during treatment 
due to microevolutionary pressure on tumor cells. A frustrating property of such 
resistance is that the tumours not only become resistant to the drugs originally used to 
treat them, but also to  mechanistically unrelated compounds preventing these to be 
successfully used as follow-on therapies [170]. This resistance is known to occur at 
many levels, including changes in drug uptake or efflux, drug breakdown, alterations in 
drug targets, changes in signaling pathways triggered by drug-induced damage, and 
attenuation of the apoptotic response. 
Drug resistance, whether intrinsic or acquired, is believed to cause treatment failure in 
over 90% of patients with metastatic cancer, and resistant micrometastatic tumour 
cells may also reduce the effectiveness of chemotherapy in the adjuvant setting [171]. 
Recent research has provided us with a better understanding of the mechanisms 
underlying drug resistance in cancer chemotherapy. This has identified various ATP 
binding cassette (ABC) transporters like P glycoprotein (P-gp), multidrug resistance-
associated protein (MRP1) and canalicular multispecific organic anion transporter 
(cMOAT or MRP2) to play a role in multi-drug resistance (MDR) [172]. Both P-gp and 
MRP1 function as drug efflux pumps that actively transport drugs from the inside of  
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cells to the outside and interfere with the intracellular accumulation of drugs 
necessary for cancer cell killing (Table 5). 
 
Table 5: Mechanisms of resistance to various anticancer drugs, including those 
for bladder cancer [172]. 
 
The expression of P-gp is encoded by the MDR 1 gene and overexpression can lead to 
resistance to structurally and functionally unrelated anticancer drugs [173]. P-gp is 
located on the plasma membrane of the resistant cells and can bind and transport the 
anticancer drugs in an ATP-dependent manner from inside the cell to the extracellular 
space, thereby preventing the compounds from exerting their toxic effects [174]. The 
levels of MDR1 mRNA correlates with clinical drug resistance and various stimuli such 
as anticancer drugs, DNA damaging agents, heat shock, ultraviolet irradiation and 
serum starvation, upregulate the activity of the MDR1 promoter. Similar up-regulation 
is observed following p53 mutation or activation of the RAS oncogene. The human 
cMOAT is found overexpressed in many cisplatin resistant cancer cell lines [175] and 
transfection of its anti-sense increased the sensitivity of the resulting cells to cisplatin, 
vincristine, doxorubicin and other drugs [176].  
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However, selective inhibitors of the above targets have failed in multiple phase II and 
III clinical trials across various cancer types indicating that there must be other 
prevailing unidentified drug resistance mechanisms [177].  
1.4 Kinases and Bladder Cancer 
Protein kinases comprise more than 520 regulators of intracellular signal transduction 
pathways [178]. Many protein kinases have been found to play a role either upstream 
or downstream of known oncogenes or tumour suppressor genes [179] and any 
alterations in the protein kinase genes can impact on cellular processes like cell 
differentiation, motility, division and apoptosis [14].  
In bladder cancer an alteration in expression or a mutation in various kinases such as 
epidermal growth factor receptor (EGFR), v-erb-b2 erythroblastic leukemia viral 
oncogene homolog 2 (ERBB2), fibroblast growth factor receptor type 3 (FGFR3) and 
platelet derived growth factor receptor beta (PDGFR β) have been shown and targeted 
therapies towards these proteins are at various stages of development [180]. Another 
kinase Ephrin type A receptor 2 (EPHA2) has been found to be over expressed in 
bladder cancer and its level of expression correlates with tumour grade [181]. 
PIM 1, a serine-threonine kinase, plays a role in bladder cancer initiation and 
progression and its knockdown sensitises bladder cancer cell lines to docetaxel and 
doxorubicin [182]. VEGFR and EGFR inhibition in bladder cancer cells lines by 
vandetanib sensitised the cells to cisplatin treatment [183]. However, the role of 
kinases in bladder cancer chemoresistance has not previously been systematically 
studied.   
1.5   RNA interference and Kinome screen 
1.5.1   RNA Interference  
Initially described in plants and fungi, RNA interference was later found to be 
conserved in various animals including higher mammals. It can be explained as a 
post-transcriptional gene expression downregulation as a result of mRNA 
degradation by the formation of double stranded RNA (dsRNA) [184]. RNA 
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interference as a gene silencing technique in molecular medicine has developed as 
a crucial tool and helped unravel the role of specific proteins in various biological 
phenomenon. It also enabled the identification of many novel therapeutic targets 
for the treatment of various disease including cancer.  
RNA interference involves the targeted degradation of specific mRNAs using 
complementary sequences leading to the formation of dsRNAs. In the cytoplasm, 
the dsRNAs are cleaved by an RNAse III enzyme called DICER [185]. The dsRNA 
binding domain (dsRBP), on the human Dicer which is a 1922 amino acid (~200kDa) 
long, recognises the long dsRNA and with the aid of RNA helicase hydrolyses ATP 
culminating into unwinding of the RNA duplex and their cleavage into 21-25 base 
pair RNA fragments called small interfering RNA (siRNA) [186]. Following DICER 
induced cleavage of the siRNA, the guide strand is recognised by the multiprotein 
RNA-induced silencing complex (RISC) catalytic component, an endoribonuclease called 
Argonaute 2 [187]. Argonaute 2 slices the passenger strand while keeping the guide 
strand to further associate and slice complementary mRNA. The RISC complex is 
recycled for further round of slicing of the target mRNA, thus regulating the expression 
of corresponding proteins [188].  
In the lab RNA interference is brought about by a variety of tools. Among these are 
the small interference (siRNAs), short hairpin RNAs (shRNAs) and the micro RNAs 
(miRNAs). siRNAs are 20-25 nucleotide long duplexes  consisting of a sense and an 
antisense strand with phosphate group at the 5’ end and a phosphate group, 
hydroxyl group & two nucleotide overhangs at the 3’ end. These siRNAs unwind 
due to helicase activity of RISC and the antisense strand attaches to the RISC and 
targets the specific mRNA (Figure 19) [189].  However this silencing is transient. 
shRNAs, on the other hand, have prolonged silencing effect and are 50-100 base 
pair single strand RNA molecules. The complimentary regions are spaced such that 
they fold back on themselves with the help of a hairpin loop. Again the Dicer 
converts it to siRNAs leaving the rest of the mechanism conserved [190]. miRNAs 
inhibit translation mainly by binding to the 3’UTR region (or even the 5’UTR region) 
of the target mRNA. However, they have also been reported to bind partially 
complementary mRNAs and, in some cases, even activate gene expression [191].  
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Figure 19: The mechanism of RNA interference. Gene expression starts with the 
transcription of the gene sequence into a messenger RNA (mRNA) by an RNA polymerase 
in the nucleus. In the cytoplasm the mRNA is translated by the ribosomal machinery into 
a protein. With RNA interference, the presence of a complementary RNA sequence in the 
cytoplasm leads to the formation of a double stranded RNA (dsRNA). This is cleaved by 
the Dicer complex into small interfering RNAs of 21 to 25 base pairs (bp). Alternatively 
synthetic siRNA duplex can be introduced into the cell using transfection. The RNA-
induced silencing complex (RISC) and its catalytic subunit, Argonaute 2 (Ago2) load the 
siRNA duplex, slice the passenger strand and use the guide strand to further recognise 
and slice complementary mRNAs before being recycled. Figure adapted from 
http://www.gene-quantification.de/rnai.html. 
 
1.5.2   Screening kinases affecting sensitivity to chemotherapy 
The aim of this project is to get a better understanding of the molecular 
mechanisms of resistance to chemotherapeutic drugs in smoking related cancers in 
general and bladder cancer in particular. This would help identify new druggable 
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targets which reverse the chemoresistance and sensitise bladder tumour cells to 
the chemotherapeutic drugs cisplatin or paclitaxel. This may lead to the 
development of new agents capable of improving patients’ response and 
prolonging their survival. Moreover, the addition of such agents to existing 
chemotherapeutic regimens would potentially lead to a reduction in the 
therapeutic dose of anti-neoplastic drugs and thus decrease their toxicity profile.  
RNA interference as a means of downregulating the expression of specific genes 
has expanded to the extent that siRNA libraries targeting the entire genome or 
kinome have been designed. The approach has been successfully adopted in many 
focussed or genome wide screening studies [192]. The use of this methodology can 
systematically work out the effect of single-gene silencing on a cellular process of 
interest. No such screen has been performed for determination of novel targets 
that can potentially affect the sensitivity of bladder cancer to chemotherapy. 
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1.6   Aims of the Project 
Our laboratory has previously carried out a kinome-wide short interfering RNA 
(siRNA) library screen and successfully identified multiple kinases enhancing and 
reducing the sensitivity of A549 non-small cell lung cancer cells to cisplatin or 
paclitaxel chemotherapy [193]. Thus, here we will repeat this approach in the 
frequently used T24 bladder cancer cell line which will eventually reveal common 
and distinct targets between these two smoking-related cancers.  
This project will identify novel druggable regulators of chemoresistance in bladder 
cancer cells by: 
(1) Performing a kinome-based siRNA screen in T24 bladder cancer cells. 
(2) Validating hits from the primary screen using 
(a) Deconvolution of the initial siRNA pools 
(b) Alternate siRNA sequences 
(c) Use of additional bladder cancer cell lines 
(3) Analysing the expression of a subset of validated hits in tissue micro-arrays 
from primary and metastatic bladder tumours as well as normal bladder 
tissue 
(4) Elucidating the mechanisms of action of some promising targets.  
(5) Effect of the selected hit(s) on migration and invasion. 
(6) Identify areas of future research and collaborations in order to translate the 
findings of this project into a clinically relevant output. 
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Experimental 
Materials & 
Methods 
 
 
 72 
2.1   Materials 
2.1.1   Reagents  
Ammonium persulphate (APS), bovine serum albumin (BSA), carbenicillin, cis-
Diammineplatinum(II) dichloride (Cisplatin), Dulbecco's modified eagle medium 
(DMEM), 4’,6-diamidino-2-phenylindole dihydrochloride (DAPI), dithiothreitol 
(DTT), ethylenediaminetetraacetic acid (EDTA) and EDTA 0.02% (w/v), 
formaldehyde 37% (w/v), L-glutamine solution, glycine, 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), magnesium chloride (MgCl2), merbarone, 2-
β-mercaptoethanol, neomycin (G418), Nonidet P-40 (NP-40), N,N,N,N-
tetrametiletilenodiamine (TEMED), paraformaldehyde (PFA), penicillin-
streptomycin solution, phenylmethylsulfonyl fluoride (PMSF), proteinase K, 
saponin, sodium acetate (CH3COONa), sodium azide (NaN3), sodium chloride 
(NaCl), sodium deoxycholate (C24H39O4Na), sodium orthovanadate (Na3VO4), 
Triton X-100, trypsin 10X solution [2.5% (w/v)],  were all purchased from Sigma-
Aldrich (Steinheim, Germany). 
Aprotinin and leupeptin were purchased from Calbiochem (Darmstadt, Germany). 
Protein quantification assay and bromophenol blue were bought from Bio-Rad 
(Munich, Germany). A 30% solution of acrylamide and bis-acrylamide (37.5:1 ratio) 
was purchased from National Diagnostics (Hull, UK). Polyvinylidene difluoride 
(PVDF), nitrocellulose membranes and ImmobilonTM western chemiluminescence 
horseradish peroxidase (HRP) substrate were purchased from Millipore (Bedford, 
USA). Milk was from Fluka BioChemika (Buchs, Switzerland). Enhanced 
chemiluminescence (ECLTM) western blotting detection reagents were acquired 
from GE Healthcare (Buckinghamshire, UK). QIAshredderTM columns, RNeasy® Mini 
kit and Allstars siRNA negative control were purchased from QIAGEN (Hilden, 
Germany). High capacity cDNA reverse transcription kit and the Power SYBR® Green 
PCR master mix were purchased from Applied Biosystems (Warrington, UK). 
Ethanol, methanol, potassium chloride (KCl) and tris(hydroxymethyl) 
aminomethane (Tris-base) were purchased from BDH Chemicals (Poole, UK). 
Complete mini EDTA-free protease inhibitor cocktail tablets and glycogen were 
 73 
obtained from Roche diagnostics (Indianapolis, USA). Phosphate buffered saline 
(PBS) tablets were from Oxoid limited (Hampshire, England). Agarose, glycerol, 
hydrochloric acid (HCl), potassium hydroxide(KOH) and sodium dodecyl sulphate 
(SDS) was purchased from Fisher Scientific (Loughborough, UK). DNA ladders were 
obtained from New England Biolabs (Hertfordshire, UK) whereas Page Ruler™ plus 
prestained protein molecular weight 
Protein markers were ordered from Fermentas (Thermofisher, USA). Crystal violet 
was obtained from GURR (High Wycombe Bucks, UK). X-Ray films were purchased 
from Fujifilm (Minato-ku, Japan). Type I rat tail Collagen were obtained from BD 
Bioscience (Erembodegem, Belgium). RNAiMax transfection reagent was obtained 
from Invitrogen (Oregon, USA).  
A small interfering RNA (siRNA) library (Human Kinase siRNA Set V2.0) targeting 
(with four separate oligonucleotides per gene) the kinome was obtained from 
Qiagen (Hilden, Germany).  For validation and other purposes, we bought siRNA 
SMART pools and deconvoluted single sequences from Dharmacon (Lafayette, CO, 
USA).  
2.2      Methods 
  2.2.1 Cell Culture  
All cell culture experiments are carried out in level 2 bio-safety hoods. Cells 
passaged less than twenty times are used for the experiments. The adherent 
human transitional cancer cell lines T24, J82 and TCCSUP were purchased from the 
ATCC-LGC Standards Partnership (VA, USA). The cells are propagated in sterile T-
150 flasks (Corning) and cultured in 50 ml of RPMI-1640 (Rosewell Park Memorial 
Institute - 1640) medium (Sigma-Aldrich) supplemented with 10% fetal calf serum, 
100 units/ml penicillin and 100 μg/ml streptomycin, 2 mM L-glutamine (PSG, Sigma 
Aldrich) in a humidified atmosphere at 37o C, 5% CO2. Human lung adenocarcinoma 
A549 cells were obtained from Cancer Research UK/London Research Institute cell 
services (London, UK) and grown in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with fetal calf serum, glutamine & penicillin/streptomycin as above 
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and grown in an incubator at 37o C, 10% CO2.  The cells are maintained at sub-
confluent densities and sub-cultured (1 in 10 dilution) twice a week, following 
trypsinisation with 0.5mg/ml solution of trypsin in 0.2 mg/ml 
ethylenediaminetetraacetic acid (EDTA) in Dulbecco’s Phosphate Buffered Saline 
(Gibco). 
2.2.2   Protein Extraction for Western Blotting  
The lysis buffer used for protein extraction is the radio-immunoprecipitation assay 
(RIPA) buffer (1% Trition X 100; 1% sodium deoxycholate; 0.1% SDS; 0.15 M sodium 
chloride and 0.01 M sodium phosphate pH 7.2). This lysis buffer was supplemented 
by a cocktail of protease inhibitors (Roche Diagnostics). Although the exact 
composition of this cocktail is not disclosed, it contains 4-(2-Aminoethyl)-
benzenesulfonyl fluoride hydrochloride (AEBSF), aprotinin (a trypsin inhibitor), 
leupeptin (a lysosomal protease inhibitor) and pepstatin (an aspartyl protease 
inhibitor). The buffer was further supplemented with phosphatase inhibitors, 10 
mM sodium fluoride (NaF) (serine/threonine phosphatase inhibitor), 1 mM sodium 
orthovanadate (Na₃VO₄) (a tyrosine phosphatase inhibitor) and 
phenylmethylsulfonyl fluoride (PMSF) (protease inhibitor).  
The cells are seeded into a six well plate (Corning) at a density of 2 X 10⁵ cells per 
ml of antibiotic free medium per well and left in the incubator. 24 h later, 
transfection with a particular siRNA is carried out and the plates replaced in the 
incubator. Forty-eight hours post transfection, the cells are placed on ice, the 
medium aspirated and the cells washed twice with 1 ml of cold phosphate buffered 
saline (PBS). Next the cells are lysed and cellular proteins extracted by directly 
adding the supplemented radio-immunoprecipitation assay (RIPA) buffer as 
described above.  The cells are then scraped off and left to lyse in 1.5 ml eppendorf 
tubes for 10 min on ice before the lysate is clarified in a centrifuge for 15 minutes 
at 4o C and >10,000g. The supernatant is retrieved carefully and protein 
quantification performed using the Bradford method [194]. Equal protein amounts 
from each sample are then collected, mixed with the appropriate amount of 4x 
Laemmli buffer and boiled on a heat block for 5 min. These are then either 
immediately run on a SDS-polyacrylamide gel or stored at -20oC for later analysis. 
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2.2.3   Cytoplasmic and nuclear protein fractionation 
Protein fractionation of the cytoplasmic and nuclear compartments was also 
performed. Briefly, the cells were plated (5 x 10⁶ cells in a 10 cm dish) and on the 
following day transfected with the siRNA. 48 h later, the cells were suspended in 
cytosolic fractionation buffer [10 mM HEPES pH 7.6, 3 mM MgCl2, 40 mM KCl, 2 
mM DTT, 5% (v/v) glycerol, 1% (v/v) Triton X-100, 2 mM NaF, 0.1 mM Na3VO4, 1 
μg/ml leupeptin, 10 μg/ml aprotinin and 1 mM PMSF] and ‘swelled’ on ice for a 
maximum of 10 min. The crude cytosolic fraction was separated from the nuclear 
pellet by centrifugation at 600 xg for 5 minutes at 4 °C. The supernatant 
corresponding to the cytosolic fraction was further pre-cleared by centrifugation at 
16,200 xg for 10 min at 4 °C. The nuclear pellet was resuspended and washed by 
centrifugation at 600 xg for 5 minutes at 4 °C in fractionation washing buffer (10 
mM HEPES pH 7.6, 1.5 mM MgCl2, 10 mM KCl, 1 mM DTT, 2 mM NaF, 0.1 mM 
Na3VO4, 1 μg/ml leupeptin, 10 μg/ml aprotinin and 1 mM PMSF). Following this 
step, the nuclear pellet was resuspended in nuclear fractionation extraction buffer 
[20 mM HEPES pH 7.6, 1.5 mM MgCl2, 420 mM NaCl, 1 mM DTT, 25% (v/v) glycerol, 
2 mM NaF, 0.2 mM EDTA, 0.1 mM Na3VO4]. The nuclear fraction was obtained 
upon sonication for 30 min (high power 30 s pulses at 30 s interval) in ice-cold 
water, using a Bioruptor sonicator. Pre-clearance of this fraction was done by 
centrifugation for 10 min at 17,000 xg at 4 °C. 
Protein quantification of whole cell extracts prepared with RIPA lysis buffer or 
obtained by cytoplasmic and nuclear fractionation was performed by 
spectrophotometry using either a spectrophotometer DU® series 500 (Beckman 
Instruments, Fullerton, USA) or a plate reader Sunrise-Basic (Tecan, Grodig, 
Austria). BioRad protein assay, based on the colorimetric method of Bradford for 
quantification of solubilised proteins, uses the Coomassie Brilliant Blue G-250 dye 
in acidic conditions and was performed according to the manufacturer’s 
instructions. Upon protein binding there is an absorbance shift of the dye from 465 
to 595 nm, which allows for protein concentration to be calculated by interpolating 
the absorbance values of the samples read at 595 nm in a BSA standard curve. 
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2.2.4 Sodium dodecyl sulphate – Polyacrylamide gel electrophoresis (SDS-
PAGE) 
Gels are made with a 4% acrylamide stacking gel [4% acrylamide, 0.125 M Tris pH 
6.8, 0.1% SDS, 0.075% ammonium persulphate (APS) and 0.083% 
tetramethylethylenediamine (TEMED)] and a 7.5%-15% (depending on the 
molecular weight of the protein of interest) resolving gel [7.5 -15% acrylamide, 
0.375 M Tris pH 8.8, 0.1% SDS, 0.06% APS, 0.07% TEMED] as per the Laemmli 
method [195]. Protein samples are boiled at 95o C for 5 min and pelleted by 
centrifugation at >10,000g for 1 minute before being loaded on the lanes in the gel 
and electrophoresed to separate the proteins or being stored at -20oC . 
Electrophoresis was performed using a Tris-glycine running buffer [2.5mM Tris, 
0.2M glycine and 0.1%SDS] at 20mA per gel using the SE400 Sturdier Vertical 
Electrophoresis Unit (Hoefer, Holliston, MA, USA) for the large gels and the Mini-
Protean BioRad gel electrophoresis for the smaller gels (BioRad, Munich, Germany). 
2.2.5  Western blotting  
Following SDS-PAGE, the iBlot™ dry blot system (Invitrogen, USA) is used to transfer 
proteins from the gel onto a nitrocellulose or polyvinylidene fluoride (PVDF) 
membrane (Invitrogen). The membrane is then blocked at room temperature for 1 
h in Tris based saline with Tween (TBS-T) containing 5% dry skimmed milk. The 
membranes are washed three to four times for 15 min each and the relevant 
antibody diluted in 5% BSA in TBS-T is then added and the membrane incubated for 
at least 2 hrs at room temperature or overnight at 4 o C. After washing them four to 
five times for 15 min each in TBS-T, the membranes are incubated in the relevant 
secondary antibody (conjugated with HRP) diluted in 5% BSA in TBS-T for at least 1 
h. The blots are again washed three to five times, each for 15 min, and subject to 
enhanced chemiluminescence (ECL) reagent according to manufacturer’s 
instructions (Amersham, GE Healthcare). ECL signals are recorded in the dark room 
by placing the treated membrane against a photographic film (Fujifilm) in an X-ray 
cassette.      
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2.2.6   RNA Interference (RNAi)  
Using the forward transfection technique, the cells are seeded in antibiotic free 
culture medium and incubated at 37⁰ C at the corresponding CO₂ concentration for 
each particular cell line for 24 hours prior to transfection. The transfection 
conditions for each assay are summarised in Table 6 below.   
 
Cell Line 
 
 
 
Cell density 
 
 
 
Plate 
Format 
 
 
Assay 
 
 
 
Lipofectamine 
RNAiMax™ / well (μl) 
 
 
T24 
 
 
1 X 10³ cells 
 
 
96 wells 
 
 
Migration 
 
 
0.1 
 
 
TCC-SUP 
 
 
1.25 X 10³ cells 
 
 
96 wells 
 
 
Migration 
 
 
0.1 
 
 
J82 
 
 
1.25 X 10³ cells 
 
 
96 wells 
 
 
Migration 
 
 
0.1 
 
 
A549 
 
 
1 X 10³ cells 
 
 
96 wells 
 
 
Migration 
 
 
0.1 
 
 
T24 
 
 
2 X 10³ cells 
 
 
96 wells 
 
 
Cell Viability Assay 
 
 
0.1 
 
 
TCC-SUP 
 
 
3 X 10³ cells 
 
 
96 wells 
 
 
Cell Viability Assay 
 
 
0.1 
 
 
J82 
 
 
3 X 10³ cells 
 
 
96 wells 
 
 
Cell Viability Assay 
 
 
0.1 
 
 
A549 
 
 
2 X 10³ cells 
 
 
96 wells 
 
 
Cell Viability Assay 
 
 
0.1 
 
 
T24 
 
1.5 X 10⁵ cells 6 wells RT-PCR 3.0 
 
TCC-SUP 
 
2 X 10⁵ cells 
 
6 wells 
 
RT-PCR 3.0 
 
J82 
 
2 X 10⁵ cells 6 wells RT-PCR 3.0 
 
A549 
 
1.5 X 10⁵ cells 6 wells RT-PCR 3.0 
 
T24 
 
1.5 X 10⁵ cells 6 wells SDS-PAGE 3.0 
 
TCC-SUP 
 
2 X 10⁵ cells 6 wells SDS-PAGE 3.0 
 
J82 
 
2 X 10⁵ cells 6 wells SDS-PAGE 3.0 
Table 6: siRNA transfection conditions. RT-PCR=Reverse transcriptase – Polymerase chain 
reaction; SDS-PAGE=Sodium dodecyl sulphate polyacrylamide gel electrophoresis. 
Just before transfection, the cells are washed with fresh antibiotic free culture 
medium. Transfection at siRNA concentration of 25 nM is carried out according to  
 
 78 
 
the manufacturer’s instructions in Opti-Mem medium (Gibco) using Lipofectamine 
RNAiMax (Invitrogen) as the transfection reagent. In short, the mixture of siRNA 
and transfection reagent is incubated for 20 min at room temperature and then 
added to appropriate wells. To allow target downregulation the cells are incubated 
at 5% CO2 / 37 
oC for 48 h before being treated with either cisplatin or paclitaxel.  
 
Target Gene (Alternate name) Ref Seq ID Dharmacon sequence numbers 
ADK NM_001123 02, 03, 04, 05 
BMPR1A (ALK3) NM_004329 03, 07, 08, 24 
BMPR1B (ALK6) NM_001203 01, 03, 04, 05 
CDKL3 NM_016508 01, 02, 03, 04 
CKMT1 NM_020990 01, 02, 04, 17 
EEF2K NM_013302 01, 02, 03, 04 
EPHB6 NM_004445 05, 06, 07, 08 
GIT2 NM_139201 01, 02, 03, 04 
GNE NM_005476 01, 02, 03, 04 
IRAK1 NM_001569 01, 03, 04, 07 
IRAK2 NM_001570 01, 03, 04, 17 
ITK NM_005546 09, 11, 12, 25 
ITPK1 NM_014216 01, 02, 03, 04 
ITPKA NM_002220 04, 05, 06, 20 
ITPKB NM_002221 05, 06, 07, 09 
MAP3K5 NM_005923 01, 03, 04, 09 
MAP4K4 (HGK) NM_145686 05, 06, 08, 09 
MAPK10 (JNK3) NM_138980 01, 02, 03, 04 
PDLIM5 NM_006457 13, 14, 15, 16 
PIP5K1C NM_012398 01, 02, 03, 04 
PRKAR2A NM_004157 01, 02, 03, 04 
PRKAR2B NM_002736 01, 02, 03, 04 
PRKCB1 NM_002738 06, 09, 10, 12 
PRKCL2 (PKN2) NM_006256 03, 09, 10, 11 
RPS6KA6 (RSK4) NM_014496 01, 02, 03, 04 
RPS6KC1 NM_012424 01, 02, 05, 18 
SNF1LK2 (SIK2) NM_015191 05, 09, 10, 23 
STK22B (TSSK2) NM_053006 01, 02, 03, 05 
TNNI3K (CARK) NM_015978 03, 05, 06, 07 
ULK4 NM_017886 02, 03, 04, 05 
UMP-CMPK (CMPK) NM_016308 01, 02, 03, 04 
 
Table 7: siRNA (in alphabetical order) sequence numbers used for the validation of the 
chemosensitivity screen. Ref Seq ID = National Center for Biotechnology Information 
(NCBI) reference number for each transcript targeted. 
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Controls used included untransfected cells and cells transfected with a non-
targeting siRNA pool. The screen was done using Qiagen kinome siRNA library 
comprising of four oligonucleotides for each target. Further validation of hits 
generated from the screen was done using the smart pool siRNA from Dharmacon 
(Lafayette, CO, USA). A list of sequence numbers used for validation of the screen is 
provided in Table 7. 
Similar information about various other siRNAs used for other experiments in the 
project are listed in Table 8. 
Target Gene (Alternate name) Ref Seq ID Dharmacon sequence numbers 
RPS6KA1 (RSK1) NM_002953 06, 07, 08, 12 
RPS6KA3 (RSK2) NM_004586 01, 02, 03, 04 
RPS6KA2 (RSK3) NM_021135 01, 02, 03, 04 
Caspase 8 NM_033358 01, 02, 07, 25 
BUB1B NM_001211 01, 02, 04, 05 
COL4A3BP NM_031361 01, 02, 03, 04 
FLIP (c-FLAR) NM_003879 04, 16, 17, 18 
PLK1 NM_005030 05, 06, 07, 08 
SP1 NM_138473 01, 02, 03, 04 
 Table 8: Other siRNA (no order) sequence numbers in the project. Ref Seq ID = National 
Center for Biotechnology Information (NCBI) reference number for each transcript 
targeted. 
 
2.2.7   Drug Treatment 
Following transfection and after allowing 48 hours incubation for target down-
regulation, the culture medium is aspirated and cells washed with complete 
medium. Medium containing either cisplatin or paclitaxel (Sigma-Aldrich) at their 
IC50 is added to the respective ‘drug treated’ plates or respective wells. All the 
plates are then placed in the incubator for 48 hours to allow the drugs to exert 
their effects before viability is analysed. 
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2.2.8    Crystal Violet Cell Viability Assay 
After incubation with the relevant factors, variations in cell number are determined 
by the crystal violet assay. The medium is removed and the wells washed gently 
with PBS to remove the dead cells. 
 
 
Figure 20: Representative view of selected wells from a 96 well plate fixed and stained 
for 20 min with 0.5% (w/v) crystal violet prepared in 25% Methanol. 
The cells are fixed and stained for 20 min with 0.5% (w/v) crystal violet prepared in 
a 25% (v/v) methanol solution. Once fixed the plates are washed in water and left 
to dry completely (Figure 20). The crystal violet precipitate is then solubilised using 
a 10% (v/v) solution of acetic acid and the absorbance measured using a 
spectrophotometer at 595 nm. Differences in the intensity of the detected staining 
correlates with changes in cell numbers as demonstrated in Figure 21.  
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Figure 21: Difference in the intensity of staining as assessed by absorption reading 
values at 595 nm (lower panel) correlates with changes in the cell number as 
demonstrated by crystal violet staining (upper panel). These results are representative 
of experiments performed at least in triplicate. UT= untreated; NT= no transfection; 
MT= mock transfection; Luc= luciferase; BRaf= v-Raf murine sarcoma viral oncogene 
homolog B1; S6K2= S6 kinase-related kinase 2; FLIP= flice inhibitory protein; Bax= 
BCL2-associated X protein; PLK1= polo-like kinase 1; Casp3= caspase 3. 
Mean and standard error of the mean (SEM) of independent experiments were 
calculated. Statistical analysis was performed using a two-tailed Student’s t-test to 
determine the statistical significance of the differences observed. A p-value below 
0.05 was considered significant.  
 
2.2.9   Reverse transcription (RT)  
 
The efficiency of downregulation following siRNA transfection and the changes in 
the expression of other genes was assessed by measuring the mRNA levels by RT-
PCR.  RNA was extracted using the Qiagen RNAeasy kit according to the 
manufacturer’s protocol. Total RNA concentration was measured using a NanoDrop 
ND1000 spectrophotometer (Labtech international, East Sussex, UK).  
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Reverse transcription was carried out using the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, USA). RT-PCRs were carried out using the 
Fast SYBR® Green Master Mix PCR kit (Applied Biosystems, USA). A 2X mastermix is 
prepared on ice using the kit components at the following volume per reaction 
(Table 9). 
 
Component 
Volume per reaction (Multiplied by the number of 
reactions needed to obtain the desired volume of the 
mastermix) (μl) 
10X RT buffer 2.0 
25XdNTP Mix (100mM) 0.8 
10X Random Primers 2.0 
Multiscribe™ Reverse Transcriptase 1.0 
RNAse inhibitor 1.0 
Nuclease free water 3.2 
Total per reaction 10.0 
 
Table 9: Component volumes and concentration for preparation of mastermix for reverse 
transcription 
For each reaction, 10μl of the 2X mastermix is added to 10μl of RNA sample in a 
reaction tube. The tube is then centrifuged briefly and then loaded onto the 
thermal cycler to perform reverse transcription under the cycling conditions 
depicted in Table 10. 
 Step 1 Step 2 Step 3 Step 4 
Temperature (
o C) 25 37 85 4 
Time 10 minutes 120 minutes 5 minutes ∞ 
 
Table 10: Cycling conditions for reverse transcription 
 
2.2.10   SYBR green-based real time quantitative-PCR (qPCR) 
cDNA samples obtained by reverse transcription of RNA was analysed by qPCR. In 
brief, cDNA samples were diluted 1:20 and a cDNA standard was prepared by 
pooling equal amounts of each diluted sample. Four sequential 1:4 dilutions were 
made from this cDNA standard to obtain a standard curve (1, 1/4, 1/16, 1/64, 
1/256). This standard curve was used for checking primers efficiency, monitoring 
that the amplification was in the linear range and obtaining quantification values. 
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A volume of 5 μl of cDNA was used as template in a RT-qPCR reaction of 25 μl total 
volume, containing 12.5 μl of a 2X Power SYBR Green master mix, 1.25 μl of each 
forward and reverse primers and 5 μl of water. Amplification was carried in a 
7900HT Fast Real-Time PCR system (Applied Biosystems, Warrington, UK), with an 
initial activation step at 95 °C for 10 minutes and 40 cycles consisting of 15 seconds 
at 95 °C, followed by 1 minute at 60 °C. All reactions were carried out in triplicates 
and a non-template control (blank) was included. Two housekeeping genes (GAPDH 
& RNA28s) were used as reference genes to normalise gene expression of cDNA 
samples and data analysis was performed to determine the mRNA levels of several 
genes using the qbase PLUS 2.1 Academic Premium software (Biogazelle, 
Zwijnaarde, Belgium). 
2.2.11    Cell migration assay  
Random migration speed was measured as previously reported [196]. The cells 
were seeded in a 96 well-plates and incubated overnight at 37⁰ C and appropriate 
CO₂ concentration prior to siRNA transfection with the relevant RNAi. 48h later, 
time-lapse imaging was performed over 18 h (1 image every 10 min) using a 
motorised-staged environment-controlled Nikon microscope with the Metamorph 
imaging software (Molecular Devices). Each condition was performed in triplicate 
with two fields acquired for each replicate. Forty two cells per conditions were 
subsequently tracked using the Metamorph tracking module. Tracks were analysed 
using a previously published Mathematica notebook [196] (Wolfram Research). A 
one way ANOVA statistical test was used to assess the statistical significance of the 
results obtained with cells transfected with scrambled sequences used as 
reference.  
2.2.12   Invasion assay  
Cells were plated in 96 well-plates and incubated overnight at 37⁰ C at appropriate 
CO₂ concentration prior to RNAi transfection. 24h following RNAi transfection, the 
plate is allowed to equilibrate for ten minutes in the hood, the medium removed 
and 100 μl of freshly prepared type I rat tail collagen (final concentration 3mg/mL) 
in 1x final concentration DMEM supplemented with 1% FCS laid over the cells. The 
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plates are incubated for 4h at 37⁰ C, 10% CO2 to allow for the matrix to polymerise 
and then 25μl of DMEM/1% FCS added on the gel prior to incubation for 18h at 37⁰ 
C, 10% CO2. Next day, 25μl of DMEM/1% FCS supplemented with epidermal growth 
factor (EGF) at 1μg/mL) is added to the wells to stimulate invasion. Cells are then 
allowed to invade upward through the matrix for 48h. The plates are then fixed and 
stained by adding 150μL of 4% (w/v) PFA containing Sytox Green 1:1000 to each 
well and leaving the plate at 4⁰ C for 2 hours. The plate can then be either washed 
or just sealed and stored at 4⁰ C until acquisition. Each condition was performed in 
triplicate. 
The plates are acquired using a spinning disc confocal system (Molecular Devices) 
with a mixed gas laser. Nine fields of view per well are acquired for a total stack of 
350 μm at 7 μm increments. The laser focussed with a z offset of -30 μm below the 
bottom layer of cells so as to ensure that all layers were captured.  A 10x lens with 
a 0.5 numerical aperture (NA) and 488nm illumination was used to acquire images. 
The image stacks were analysed using a Mathematica notebook (Wolfram 
Research) programmed by Dr Alastair Nicol (Light Microscopy Department, CRUK, 
London, UK) to determine the extent of cell invasion. Results of nine stacks per well 
in triplicates were pooled before performing a one way ANOVA statistical analysis 
with scramble transfected cells as a reference.  
     2.2.13   Zebrafish Metastatic Model  
Zebrafish embryos at 4 h post-fertilisation (hpf) were microinjected under 
stereomicroscopic observation with Histone 2B-GFP expressing A549 cells into the 
cell mass using a 12 μm gauge borosilicate pipettes mounted on a Narishige 
microinjector. The embryos were then imaged under anaesthetic by widefield 
fluorescent microscopy at 48 hpf and the presence of A549 cells in 3 different 
compartments (head, middle and tail) recorded. H2B-GFP expression had no effect 
on baseline motility or invasiveness of A549 cells (data not shown). This work was 
performed in collaboration with the laboratory of Prof. Maggy Dalman (Division of 
Cell and Molecular Biology, Department of Life Sciences, Faculty of Natural 
Sciences, Imperial College London, London, UK) and involved Dr. Olivier Pardo, 
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Harriet Taylor, Alice Shia and Prof. Jonathan R Lamb. My participation to this work 
was marginal.  
2.2.14  Immuno-histopathology 
  
A syngeneic primary tumour tissue microarray (TMA) was compiled from 
cystectomy specimens of reports performed at the Imperial College Healthcare 
NHS Trust. (Ethics Reference: R12059). All slides from these cases were reviewed 
to confirm histotype as well as metastatic distribution and evaluate tissue quality. 
Immunostaining for pan-cytokeratin MNF116 and Vimentin were performed to 
evaluate the suitability of the tissue for immunohistochemical studies. 
Subsequently, 50 cases were considered suitable to be included in the TMA.  
The available data related to these cases including metastatic distribution were 
recorded. Three 1mm cores were obtained from the most representative and 
better preserved areas of the primary tumours and their metastases and re-
embedded in microarray blocks. Antigen retrieval was carried out using a 
modification on a previously published method [197]. Briefly, the sections were 
rehydrated in graded alcohols, heated in a microwave oven at 900W for 20 min in 
Citrate buffer at pH6 and cooled at room temperature before immunostaining. 
Endogenous peroxidase activity was suppressed by incubation with a 3% solution 
of H2O2 for 5 min. The primary antibodies were used at the following 
concentrations RSK1 (Santa Cruz, sc-231) 1/1200, RSK2 (Sigma, HPA003221) 1/300, 
RSK4 (Sigma, HPA002852) 1/100. The TMAs were incubated with the antibodies for 
1 h at room temperature and then processed using the Polymer-HRP Kit 
(BioGenex) with Diaminobenzidine development and Mayer’s Haematoxylin 
counterstaining. External positive controls were used according to the antibodies’ 
datasheets. Negative controls included omitting the primary antibody, competition 
with the peptide used to raise the primary antibody and staining of paraffin-
embedded A549 cells treated with a non-targeting scramble sequences or a 
relevant (RSK1, 2 or 4) siRNA. A semi quantitative immunohistochemical score (IHS) 
was used as previously described [198]. including assessment of both the 
percentage of positive cells and the intensity of staining. For the intensity, a score 
of 0 to 3, corresponding to negative, weak, moderate and strong positivity, was 
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recorded. The range of possible scores was thus 0 to 300. Each core was scored 
individually with three cores evaluated from each tumour/metastasis and the 
mean of the 3 readings calculated. If one core was uninformative the score applied 
was the mean of the remaining two cores. Two observers, blinded to all the clinical 
data, scored all cases and results were found to be consistent.  
TMAs for syngeneic primary bladder cancer and surrounding normal tissue were 
purchased from US Biomax Inc. and treated as described above. This work was 
performed in collaboration with Dr. Francesco A. Mauri (Histopathology, Imperial 
College London, Hammersmith Campus, London, UK). 
2.2.15   Statistical analysis 
Mean and standard deviation (SD) and/or standard error of the mean (SEM) of 
either three independent experiments or duplicates/triplicates of one 
representative experiment were calculated. A two-tail Student’s t-test was 
performed for statistical comparison of different conditions and p values superior 
to 0.05 were considered non-significant (ns) , while those inferior to 0.05 were 
considered statistically significant (*, p<0.05; **, p<0.01; ***, p<0.001 -; ****, 
p<0.0001). 
2.2.16   NMR Spectroscopy & Analysis 
2.2.16.1  Media Sample Collection  
1ml samples of conditioned culture medium were taken from each dish at the 
time of transfection, 24 h and 48 h after transfection. The samples were 
immediately frozen and stored at -40⁰ C for later analysis.  
2.2.16.2  Methanol quenching 
Media was removed from the dishes and the cells were repeatedly washed with 
cold (4⁰ C) phosphate buffered saline (PBS) to remove any traces of media. Cells 
were then lysed and quenched by adding cold (4⁰ C) methanol (on ice) and the 
cellular material detached from the plate using a cell scraper. The suspensions 
were dried down using a rotary speed-vacuum and stored at -40⁰ C. 
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2.2.16.3   Preparation of cell culture media  
NMR samples were made from 550 µL media and 50 µL heavy water (D₂O) 
containing 11.61 mM 4,4-Dimethyl-4-silapentane-1-ammonium trifluoroacetate 
(DSA) (final sample DSA concentration being 0.97 mM). Sample were then 
transferred to clean 5 mm NMR tubes and analysed by 1H-NMR with the known 
concentration of DSA used as an internal quantification standard. 
2.2.16.4  Preparation of cell extracts  
Methanol quenched samples are removed from the freezer and thawed on ice. 
While on ice CHCl3/MeOH 2:1 solution is added to each sample and then the 
samples vortexed to obtain an emulsion. The samples are kept in ice and after the 
addition of water (H2O), they are vortexed again and centrifuged at 14000 rpm 
for 10 minutes to separate the  ‘aqueous’ layer comprising hydrophilic 
metabolites. This extract is then carefully pipetted into a fresh tube.  The 
extraction step is repeated on the original sample and the extraction samples are 
pooled together in an eppendorf. These tubes are then placed in a fume cupboard 
overnight. Thereafter the samples are freeze-dried to sublimate any remaining 
water in the sample. The aqueous extracts are reconstituted in fully deuterated 
phosphate buffer consisting of 100 µM Trimethylsilyl propionate (TSP) and 
centrifuged at 14000 rpm for 5 minutes. 550 µL of the samples are added to the 
NMR tubes which are capped and labelled. 
2.2.16.5  NMR data acquisition and processing 
The 1H spectra are acquired at 300 K on a Bruker spectrometer (600MHz 1H 
frequency). The 1H spectra for the media samples are acquired using a total 
repetition time (TR) of 256 s and a 90° flip, the TR used for the cell extracts is 512 
s. The data is analysed using Topsin (Bruker). Metabolites are assigned to their 
corresponding peaks with Chenomix NMR suite 7.5 software. The metabolite peak 
areas for each media or cell extract spectrum are compared against each other 
using MATLAB software.  
Absolute sample concentrations are determined using the area under the curve 
for selected metabolite peaks normalised to DSA or TSP concentrations and 
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adjusted for the proton number associated with the peak of interest. Metabolite 
consumption and production rates were calculated by obtaining the picomolar 
difference for metabolites at a specific time point and dividing by the number of 
remaining viable cells in the culture. 
2.2.17     Bioluminescent Imaging 
Freshly prepared stock solution of Luciferin in sterile PBS was made at a 
concentration of 15mg/ml. After filtering it through a 0.2μm filter, luciferin 
10μL/g of body weight was injected intra peritoneally (i.p.) with a 25 gauge needle 
(150mg/kg) [213]. 15 minutes later the mice were imaged in the IVIS Spectrum 
chamber and dorsal and ventral BLI acquired. In vivo BLI was carried out on a 
weekly basis for 8 weeks and ex vivo BLI was carried out at the end of 8 weeks. 
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Chapter 3 
  
 
A HIGH THROUGHPUT 
KINOME SCREEN 
IDENTIFIES NOVEL 
REGULATORS OF 
CHEMOSENSITIVITY IN 
BLADDER CANCER CELL 
LINE 
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   Introduction 
Locally advanced and metastatic muscle invasive bladder cancer is associated with 
high morbidity and mortality risk. As chemotherapy is one of the mainstays of 
treatment in this group and can improve outcomes, development of drug resistance 
and toxicity of current chemotherapeutic agents is a major problem faced by clinicians 
during the course of the disease. An agent that has a potential to overcome the above 
problems can make more people suitable for chemotherapy in adjuvant and neo-
adjuvant settings in bladder cancer. Any such agent would most likely have a 
regulatory role in the cellular processes. 
Kinases regulate a vast array of cellular processes like cell differentiation, motility, 
division and apoptosis.  Hence we decided to focus on the kinases and utilise the 
kinome library for a screen to determine agents that alter the sensitivity to 
chemotherapeutic agents like cisplatin and paclitaxel. The secondary aim was to 
understand the role of any hit(s) so generated in other cellular processes like invasion, 
metastasis and anoikis. 
RNA transfection is a powerful tool that is relatively simple, relatively robust, quick and 
easy to master.   For such a large screen it serves ideally to systematically filter and 
generate targets of interest. We developed a kinome-based siRNA screen for studying 
changes in sensitivity to chemotherapeutic agents in cancer cells. The optimisation, 
results and validation of this screen are presented in this chapter. The screen was  
carried out in T24 bladder cancer cell line and two additional bladder cancer cell lines 
were utilised for the validation. 
 
3.1   Screen setup 
3.1.1   Determination of the IC50 drug concentrations 
In order to identify proteins acting as drug sensitisers and resistance mediators, we 
used the IC50 concentrations of the drugs cisplatin or paclitaxel so as to maximise 
the chance of detecting bi-directional cellular response to these  
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Figure 22: Response of T24 cells to the drugs cisplatin and paclitaxel. Line graph plots 
of the cell numbers normalised to untreated control (UT) as a function of drug 
concentration. T24 cells were plated in 96-well plates and incubated for 48 h with the 
relevant drug at the indicated concentrations. Crystal violet staining was then 
performed and absorbance reading performed at 595nm. Data points shown are 
average of triplicates. Error bars are SEM. Results shown are representative of 
experiments performed at least in triplicates. UT= untreated; DMSO= dimethyl 
sulfoxide control; μM= micromolar; nM= nanomolar. 
compounds. The drugs were freshly prepared in DMSO and addition of DMSO 
alone to the cell culture medium was used as a control. The respective IC50 
concentrations for cisplatin and paclitaxel, on repeated experiments, were 
determined to be 3.5μM and 40nM (Figure 22). 
3.1.2   Controls 
In addition to no transfection (NT) control we also included (a) non-targeting siRNA 
sequences (Luciferase) for assessing toxicity due to the transfection process alone,  
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(b) two sensitising siRNAs (positive) and (c) two antagonising (negative) controls in 
each experimental plate. These controls enabled us to determine sensitising or 
antagonising nature of the test siRNA. The siRNAs directed against FLIP (Flice 
Inhibitory protein) and COL4A3BP (Collagen Type IV alpha 3 binding protein) were 
selected as positive (sensitising) controls as they consistently sensitised the T24 
cells to cisplatin and paclitaxel treatment in the setup experiments (Figure 9). On 
the other hand the siRNAs directed against Caspase 8 and BUB1B (Budding 
Uninhibited by Benzimidazoles - 1 beta) were chosen to serve as negative 
(antagonising) controls as they consistently induced resistance to cisplatin and 
paclitaxel treatment in T24 cells in the setup experiments (Figure 23).  
FLIP plays a key role in regulation of various cell death pathways including 
apoptotic signalling pathway and is expressed aberrantly in various cancer types 
[199]. FLIP  is anti-apoptotic and  an important resistance factor that inhibits tumor 
necrosis factor α (TNF-α) & TNF-related apoptosis-inducing ligand (TRAIL)-induced 
apoptosis or apoptosis induced by cytotoxic agents in malignant cells [200]. This 
explains the sensitisation of bladder cancer cells to cisplatin and paclitaxel on 
downregulation of FLIP. COL4A3BP or CERT is a ceramide transport protein that 
has been shown to sensitise cancer cells to multiple chemotherapeutic agents and 
it is overexpressed in drug resistant cell lines [193]. 
BUB1B is a mitotic spindle checkpoint regulator, the knockdown of which 
antagonises the response of cancer cell lines to paclitaxel [193]. High expression of 
BUB1B protects against cancer by correcting mitotic checkpoint errors [201] and 
mutations of BUB1B have been shown to predispose to gastrointestinal cancers 
[202]. Caspase 8 is a critical initiator of extrinsic apoptotic pathway and a loss of 
caspase 8 promotes chemoresistance [203]. Similarly, upregulation of caspase 8 
sensitises cisplatin resistant ovarian carcinoma cells to TRAIL induced apoptosis 
[204]. 
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Figure 23: Representative crystal violet stained wells of a 96 well plate depicting the 
effect of IC50 concentrations of (A) Cisplatin and (B) Paclitaxel treatment on viability 
of T24 cells transfected with the non-targeting siRNA (siLuc); positive (sensitising) 
controls Flice inhibitory protein (siFLIP) and Collagen Type IV alpha binding protein 
(siCOL4A3BP); negative (antagonising) controls Caspase 8 (siCasp8) and Budding 
uninhibited by benzimidazoles 1 beta (BUB1B). No transfection (NT) and mock 
transfection (MT) controls are included. 
 
3.1.3   Transfection Control 
So as to assess the transfection efficiency throughout the screen, transfection of a 
pool of oligonucleotides directed against PLK1 (Polo like Kinase1), a kinase known 
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to regulate the exit from mitosis [205] were used. PLK1 RNAi transfection led to 
severe cell death visible under the microscope and hence served as a useful aid to 
ensure efficient transfection (Figure 24). 
 
 
Figure 24: Photomicrographs (10X) of T24 cells showing the effects of transfection 
with control siRNAs alone or in combination of either cisplatin 3.5μM (upper panel) 
or paclitaxel 40nM in a 96 well plate format. FLIP= flice inhibitory protein; PLK1= 
polo like kinase 1. Note the effect on viability of the T24 cells by PLK1 transfection. 
 
3.1.4  Data Analysis 
While cells die upon addition of the drug, some siRNAs increase or decrease this by 
targeting proteins important for the sensitivity of cells to chemotherapeutic 
agents. By comparing the cell death obtained upon combining the drug and siRNA 
treatment with that observed for each condition separately, we assessed whether  
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Figure 25: Graphs representing A) Cell death (fold of luciferase control) when T24 cells 
are treated with 3.5µM cisplatin following siRNA-mediated knockdown of various 
kinases. The green line represents cell death equivalent to that of luciferase control, B) a 
plot of the index of sensitivity or antagonism calculated as a difference of observed from 
expected cell death (explained in the text below).  NT= no transfection; MT= mock 
transfection; Luc= luciferase; BRaf= v-Raf murine sarcoma viral oncogene homolog B1; 
S6K2= S6 kinase-related kinase 2; FLIP= flice inhibitory protein; Bax= BCL2-associated X 
protein; PLK1= polo-like kinase. The bars are average of at least three replicates. 
Statistical test: Students T-Test. * = p< 0.05; ** = p< 0.01; *** = p< 0.001, n.s = not 
significant. 
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downregulation of individual kinases is antagonistic or synergistic with drug 
treatment [193], as illustrated in Figure 25. 
 In order to perform this analysis the individual effects of drug treatment and 
siRNAs on viability will be taken into account. The viability effect of siRNA without 
drug compared to luciferase siRNA control is designated as Rc/Cc (where Rc is the 
viability effect of the selected siRNA and Cc is the viability effect of luciferase siRNA 
both without drug). The effect of the drugs on viability of non-target control 
transfected cells is designated as Cd/Cc (where Cd is the viability effect of 
luciferase siRNA in combination with the drug). This enables us to calculate the 
expected combined effect (ECE) of siRNA and drug on cell viability: Rc/Cc*Cd/Cc. 
The observed combined effects (OCE) of drug and siRNA on cell viability compared 
to untreated luciferase control transfected cells is designated as Rd/Cc (where Rd 
is the viability effect of selected siRNA in combination with the drug). Hence an 
index of antagonism or sensitivity (SI) for each siRNA can be calculated by 
subtracting the OCE of drug and siRNA (Rd/Cc) from the ECE on cell viability i.e. SI = 
(Rc/Cc*Cd/Cc) - (Rd/Cc). For the SI to usefully predict antagonism or sensitivity, 
additional criteria (sensitivity ratio) Rd/Cd > 1.05 for antagonistic siRNAs and Rd/Cd 
< 0.95 for sensitizing siRNAs will be employed for hit selection as previously 
described [193].  
 
Criterion Sensitising Antagonizing 
Sensitivity Ratio < 0.95 > 1.05 
Sensitivity Index > 0.1 < -0.15 
Standard Error of Sensitivity ratio < 0.85 > 1.15 
         
Table 11: Criteria followed in the data analysis to consider a hit as significant.  
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3.2    The Kinome Library 
We performed the screen using the Qiagen Human Kinase siRNA Set V2.0 with 
four separate oligonucleotides per gene. All oligonucleotides are fully annealed 
and suspended at a concentration of 10 μM in 25 μl of 1X annealing buffer (30 
mM HEPES [pH 7.4], 100 mM Potassium Acetate, 2 mM Magnesium Acetate) per 
well. The siRNA oligonucleotides for each target gene are on separate plates (A, 
B, C, D).  
The siRNA set was stored in a -80 OC freezer and plates were thawed completely 
and centrifuged briefly before use. The kinome library plates are configured in a 
way that wells in columns 1 and 12 (except G12 and H12) are empty on every 
plate. The wells G12 and H12 contain the negative siRNA and siRNA against GFP 
respectively and can serve as mock controls. The rest of the wells (columns 2 to 
11) contain the oligonucleotide sequences of the kinome library (Figure 26).  
 
 
Figure 26: Plate configuration of the Qiagen kinome library used in the screen. 
3.3   Screening Method 
The library targets 691 kinases equating to 2764 oligonucleotides. We analysed 
the 4 oligonucleotides for each target separately. We conducted the screen as 
depicted in Figure 27 in 96 well plates while not using the border wells to avoid 
‘edge effects’. A separate incubator was dedicated for the screen to prevent 
interference due to other users opening/closing the incubator’s door. The wells  
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Figure 27: Schematic depiction of the screening method followed. T24 cells were 
transfected using individual siRNAs from the kinome library plate in a way that siRNAs in 
wells A2 to A10 of the library plate were in wells B3 to B11 of the experimental plate 1 
(EP1). Similarly siRNAs in wells B2 to B10, C2 to C10, D2 to D10, E2 to E10 and F2 to F10 
were in the wells C3 to C11, D3 to D11, E3 to E11, F3 to F11 and G3 to G11 of EP1 
respectively. siRNAs in wells G2 to G10 and H2 to H10 of library plate were in wells B3 to 
B11 and C3 to C11 of the experimental plate 2 (EP2). siRNAs of wells of column 11 (A 11 
to H11) of library plate were in the wells of row D (D3 to D10) respectively of EP2. Wells 
B2 to H2 of both EP1 and EP2 were reserved for the controls. The rest of the wells in EP2 
were untreated. For three conditions there were two plates each per library plate and 
each experiment was done in triplicate. Hence the experiment involved 18 plates per 
library plate which means a total of 648 experimental plates. 
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in the column 2 (B2 to H2) were reserved for the controls. To assess the effect of 
siRNA knockdown alone, a ‘non drug treated’ plates were used. All the 
experiments were done in triplicate and an average of the three used for data 
analysis. 
    
3.4    Results 
The full results for the screen are shown in Figure 28.  
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Figure 28: Results of the kinome screen carried out to identify novel targets that have an 
effect on the sensitivity of bladder cancer cells to chemotherapy (cisplatin & paclitaxel). 
the screen was carried out in T24 bladder cancer cell line. The figure shows the sensitivity 
indices for four individual siRNA oligonucleotides (1,2,3 &4) targeting each protein 
(arranged in alphabetical order) in the kinome library. All the sensitivity indices are color 
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coded as indicated with different shades of green denoting varying degrees of sensitisation 
while various shades of red denote degrees of antagonism upon knockdown of the targets. 
Hits were selected only if ≥2 of the four oligonucleotides showed similar and significant 
results. These results are based on the average calculated from plates in triplicate. The full 
names for all genes in the kinome library are defined in the description of the library in the 
appendix. the method of calculation of sensitivity index has been described earlier. 
 
3.4.1   Effect on cell viability 
As expected, in the screening experiment knockdown of some of the siRNAs on  
 
   siRNA Rc/Cc    siRNA Rc/Cc    siRNA Rc/Cc    siRNA Rc/Cc    siRNA Rc/Cc
STK25 TK2 KIAA1804 SH3KBP1 STK4
AKAP7 FUK SNRK UMP-CMP MAP2K4
PLK1 AKAP9 RIPK4 MST4 RPS6KB2
LOC392265 AATK TRAD IPKH2 RPS6KA3
AURKB CDC4BPA GSK3A LATS2 MAPK6
NEK8 CDK5R2 CKMT1 CARKL PRKAB2
ERK8 CDC2L1 MAP3K8 SNF1LK2 PDK4
DCAMKL2 GAK CSNK1E MAPKBP1 MAP3K10
LOC39097 HK1 CSNK2A1 AKAP10 MAK
MGC40579 MAP2K1 LOC161635 AKAP11 DCK
HIPK1 MAP4K2 BMP2K STK17B ATR
CIB3 MAP2K3 CLK4 IRAK3 CDKN1A
SORCS3 TTK RBKS CHEK2 CDKN2C
PTK9L MAPKAPK3 PANK3 SYK CSNK1A1
PLK4 TYROBP NJMU-R1 MAPKAPK5
TNK2 PIK3R3 PINK1 CDC2L5
MAPKAPK2 MKNK1 WNK3 PRKRA
ERN2 MAPK2K1IP1 PANK3 CDKL2
PIP5K2B RIOK3 TP53RK PRKD1
PIK3R3 PD1K1L P14K2B SKP1A
0.65 - 0.75 1.05 - 1.15
0.55 - 0.64 1.16 - 1.25
0.45 - 0.54 1.26 - 1.35
< 0.44  > 1.35
                   
Figure 29: Shown are kinases the silencing of which affected viability compared to the non-
targeting control. Rc/Cc values are represented using a color-coding (varying shades of 
green for decreased and various shades of red for increased cell viability). The values are 
an average of four individual oligonucleotides per siRNA. These values are based on an 
average calculated from the plates in triplicate. The full names of all genes are defined in 
the description of the library in the appendix. The method of calculation of sensitivity index 
has been described earlier. 
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their own led to a decrease (Rc/CC <1) whereas others led to an increase (Rc/CC  
>1) in cell viability. Figure 29 shows the kinases, the knockdown of which 
significantly influenced cell viability. Those coded in green caused cell death upon 
knockdown while those in pink had the opposite effect. The lower the Rc/Cc value, 
the higher the cell death upon knockdown and the higher the Rc/Cc value, the  
higher the cell number upon knockdown of the kinase considered.                  
 
3.4.2  Drug response hits from the primary screen 
Silencing of 83 kinases sensitised T24 cells to cisplatin treatment and silencing of 
80 kinases had the same effect on treatment with paclitaxel.  
 
 
Figure 30: The proportion of siRNAs from the kinome library that affected response of 
T24 cells to cisplatin or paclitaxel.  
 
3.4.2.1  Common Hits 
             After analysis of the screening data we found that silencing of a total of 25   
targets affected cell viability significantly in both the cisplatin as well as the  
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Figure 31 : Shown are the kinases the silencing of which had a significant effect on the cell 
viability on subsequent treatment with cisplatin  or paclitaxel. Sensitivity indices of four 
different oligonucleotides (1,2,3 & 4) of a particular kinase are represented in a color 
coded format such that the different shades of green denote varying degrees of 
sensitisation and various shades of red denote different degrees of antagonism. An siRNA 
was included as a hit only if ≥2 of the four oligonucleotides showed similar and significant 
results. These results are based on the average calculated from plates in triplicate. The full 
names of all genes in the kinome library are shown in the description of the library in the 
appendix. the method of calculation of sensitivity index has been described earlier. 
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paclitaxel treated conditions. 23 of these targets sensitised the cells to these 
drugs while 2 were antagonising (Figure 31). 
 
3.4.2.2  Cisplatin only hits 
             The screen revealed a total of 63 kinases which had a significant effect on the 
viability of T24 cells when treated with cisplatin. The knockdown of 60 of these 
sensitised the cells whereas silencing 3 of them antagonised to cisplatin 
treatment (Figure 32).               
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Figure 32 : Shown are sensitivity indices of kinases the silencing of which had a 
significant effect on cell viability when subsequently treated with cisplatin. Sensitivity 
indices of four different oligonucleotides (1,2,3 & 4) of a particular kinase are 
represented in a color coded format such that the different shades of green denote 
varying degrees of sensitisation and various shades of red denote different degrees of 
antagonism. An siRNA was included as a hit only if ≥2 of the four oligonucleotides 
showed similar and significant results. These results are based on the average 
calculated from plates in triplicate. The full names of all genes in the kinome library 
are shown in the description of the library in the appendix. the method of calculation 
of sensitivity index has been described earlier. 
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3.4.2.3  Paclitaxel only hits 
          The screen narrowed down 60 kinases which had a significant effect on the 
viability of T24 cells when treated with cisplatin. The knockdown of 57 of   
these sensitised the cells whereas silencing 3 of them antagonised to paclitaxel 
treatment (Figure 33).    
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Figure 33 : Shown are sensitivity indices of kinases the silencing of which had a 
significant effect on cell viability when subsequently treated with paclitaxel. Sensitivity 
indices of four different oligonucleotides (1,2,3 & 4) of a particular kinase are 
represented in a color coded format such that the different shades of green denote 
varying degrees of sensitisation and various shades of red denote different degrees of 
antagonism. An siRNA was included as a hit only if ≥2 of the four oligonucleotides 
showed similar and significant results. These results are based on the average 
calculated from plates in triplicate. The full names of all genes in the kinome library 
are shown in the description of the library in the appendix. the method of calculation 
of sensitivity index has been described earlier.  
 
 111 
 3.4.3   Validation of hits from the primary screen 
As siRNA screens have inherent false positives and false negatives rates, various 
steps were taken to validate the results from the screen [206]. Part of this issue was 
already addressed in our screen as we collected, separately, data from four 
individual sequences. However, to eliminate the possibility of provider’s linked bias, 
four alternative siRNA sequences per target were purchased from another provider 
(Dharmacon) and were tested using the same assay. For each target, these four 
oligonucleotides were pooled and the pools used for the validation experiments 
[207].  
The hits from the primary screen were also tested on 2 additional bladder cancer cell 
lines (J82 and TCC-SUP) so as to generalise the relevance of our findings in T24 cells. 
Phenotypic and genetic characteristics for the three transitional bladder carcinoma 
cell lines are listed in the Table 12 below. 
 
 
Table 12: List of different bladder cell lines used in this project along with their 
characteristics and differences. 
 
3.4.4   Targets Included 
The targets included for validation experiments comprised all the hits which upon 
knockdown affected the response of bladder cancer cells to both cisplatin & 
paclitaxel. As only two genes antagonised the effects of both cisplatin and paclitaxel 
in the screening experiment, we decided to include some of the hits which on 
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knockdown antagonised the effect of either of these chemotherapeutic agents. The 
complete list of selected targets is provided in Table 13. 
 
    Screen Result                       Hits for Validation 
 
Common Sensitising Hits                   ADK, BMPR1A, BMPR1B, CDKL3, CKMT1,   
                                                                 EEF2K, EPHB6, GIT2, GNE, MAP3K5, MAPK10,  
                                                                 MAP4K4, PDLIM5,  PIP5K1C, PKN2, PRKAR2A, 
                                                                 PRKAR2B, PRKCB1, RPS6KA6, RPS6KC1,  
                                                                 SNF1LK2,  STK22B, TNNI3K, UMP-CMPK, ULK4 
Common Antagonising Hits               IRAK2, ITK 
Other Antagonising Hits                     IRAK1, ITPKA, ITPKB, ITPK1 
Table 13: Targets that were selected for validation to narrow down the search for relevant 
hits that affect sensitivity of bladder cancer cells to chemotherapy (Cisplatin and paclitaxel). 
The targets are listed in alphabetical order. The full names of the genes are listed in the 
description of the kinome library. 
 
3.4.5   Validation Results 
The validation experiments were done under the same conditions as the screening 
experiment. The same set of positive (FLIP & COL4A3BP), negative (Caspase 8 &  
 
 
Table 14: Summary of results of validation of hits from primary screen across three different 
bladder cancer cell lines. 
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BUB1B) and transfection efficiency (PLK1) controls were used. Similar protocol and 
siRNA concentrations were used. Table 14 shows that 20 out of the 31 hits (almost 
65%) from the primary screen validated in the primary cell line (T24) used in the 
screening experiment, for both cisplatin and paclitaxel. Across the cell lines 16 of the 
31 hits (almost 52%) validated in at least two cell lines (T24 & TCCSUP or T24 & J82) 
for both the chemotherapeutic agents. Only 13 of the total hits (42%) reproduced 
the results of the primary screen across all the three cell lines (T24, TCCSUP & J82) 
and for both therapeutic drugs. The summary of the results is shown in Table 14. 
The complete validation results are shown in the Figure 34. 
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Figure 34: The table above shows the results of the validation experiment wherein the 
‘✔’denotes that results were comparable to those of the primary screen and a ‘ X’ denotes 
that the validation did not reproduce results from the screen.  These experiments were 
carried out in three different cell lines (T24, TCCSUP & J82) and as in the primary screen the 
change in sensitivity to cisplatin and paclitaxel in response to knockdown of the indicated 
target genes was tested. 
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3.5     Discussion 
 
A better understanding of molecular mechanisms regulating various cellular 
processes would help in improving outcomes of  various cancer types. Kinases play 
an important role in different cellular processes and  alteration in the way they 
express or function have been implicated in development of different types of 
cancer. Not very much is known about the role of kinases in bladder cancer. We 
employed a screen using small interference RNA technique to identify kinases 
affecting the response of cancer cells to chemotherapy. 
Using a 96 well plate format and crystal violet cell viability assay we identified 
kinases that affected the viability of T24 cancer cells to cisplatin and paclitaxel or 
both. 83 kinases influenced T24 bladder cancer cell sensitivity to cisplatin whereas 
80 kinases altered the sensitivity to paclitaxel in the same cell line. Of these 25 
kinases affected sensitivity to both cisplatin and paclitaxel. These common hits 
were selected for further validation experiments which were carried out in two 
additional bladder cancer cell lines (TCC-SUP & J82). This effectively improved the 
robustness of the hits and narrowed the search further.  
13 of these 25 hits reproduced the effect seen in the screen and provided us with a 
cohort of targets that could serve as starting points for multiple research projects 
in future. Other multiple targets that affected cancer cell sensitivity to either 
cisplatin or paclitaxel only, if taken through validation steps could zero in on some 
interesting and effective hits for further research. In short, our screening project 
provides a huge source of data that could be used for interesting research in 
bladder and other cancer cell types. In addition our experiments  on RSK4 have  
shed light on some previously unknown but interesting facts  and this is explained 
in detail in the following chapters. 
As explained earlier, we used sensitivity index as a measure of chemotherapeutic 
sensitivity or resistance to cancer cell death in response to siRNA mediated 
knockdown of various kinases. However, we did not explore the effect of the 
above hits on the IC50 of cisplatin or paclitaxel in various cancer cell lines. This 
experiment is intended to be carried out in near future.  
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Chapter 4 
 
RSK4 knockdown 
sensitises cancer 
cells to both 
Cisplatin and 
Paclitaxel 
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   Introduction 
One of the strongest hits that consistently sensitised bladder cancer cells to 
chemotherapy (cisplatin as well as paclitaxel) in our screening and validation 
experiments presented in the last chapter was RPS6KA6 also known as RSK4. 
Interestingly, RSK4 was of special interest to our lab as one of our previous 
research projects had shown that silencing of this kinase markedly reduced lung 
cancer cell migration [208] and reproduced figure 35 below.  
Figure 35: Distribution of the mean migration speed ratio obtained following the 
downregulation of the 779 targets of the Dharmacon kinome library. RPS6KA1 or RSK1= 
p90 ribosomal protein S6 kinase 1; RPS6KA3 or RSK2= p90 ribosomal protein S6 kinase 3; 
RPS6KA6 or RSK4= p90 ribosomal protein S6 kinase 6; ERBB2= v-erb-b2 avian 
erythroblastic leukemia viral oncogene homolog 2; Src= v-src sarcoma viral oncogene; NT 
= Non targeting control. [208] 
Ribosomal protein S6 kinase polypeptide 6 (RPS6KA6), also known as RSK4, is a 
member of the RSK serine/threonine protein kinase family. The level of RSK4 in 
various tissues and cell lines has been shown to be very low, the highest levels 
being in the brain, gastrointestinal and the kidney tissue 
[http://www.proteinatlas.org/ENSG00000072133/tissue]. Some studies have 
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shown that RSK4 is constitutively activated on serum starvation in many cell types 
[209].  While some studies suggest that RSK4 functions as a tumour suppressor 
[210], others state the opposite [211]. Little research has been undertaken into 
RSK4 and therefore there is a lack of information on the specific function of this 
protein in contrast to  other RSK family members. Hence, in the present chapter, 
we decided to focus our efforts on elucidating the role of this protein in bladder 
cancer while also expanding our data into lung cancer.  
 
4.1     RSK4 sensitises cancer cells to cisplatin and paclitaxel 
In our previous experiments, RSK4 significantly sensitised three different bladder 
cancer cell lines to cisplatin and paclitaxel, although to a variable extent.  
 
Figure 36: Sensitisation of T24 cells upon knockdown using individual oligonucleotides 
targeting RSK4. Degree of sensitisation of T24 cells to (A) Cisplatin (5 μM) & (C) Paclitaxel 
(160 nM), based on the value of sensitivity index, upon knockdown of RSK4 with four 
different siRNA oligonucleotides targeting RSK4. The horizontal red line depicts the value 
at which the sensitivity index achieves significance. Following transfection of T24 cells 
with RSK4 or non-targeting siRNAs, the cell death in response to (B) Cisplatin (5 μM)& (D) 
Paclitaxel (160 nM) was measured and normalised to that seen for the non-targeting 
oligonucleotides condition. The bars are average of at least three replicates. Statistical 
test : Students T- Test. * = p< 0.05; ** = p< 0.01; *** = p< 0.001, n.s = not significant. 
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For cisplatin, three of the four oligonucleotides sensitised T24 cells above the set 
significant value whereas the fourth one sensitised them to a lesser degree (See 
Figure 36). For paclitaxel, two of the four oligonucleotides reached the significant 
value for sensitisation, one sensitised the cells to a lesser degree and one had very 
little effect (Figure 36).  
In the validation experiments four siRNAs from an alternative provider were 
pooled to target RSK4 . We found that down regulation of RSK4 not only 
reproduced the above findings in T24 cell lines but also yielded similar results in 
two additional bladder cancer cell lines (Figure 37). Thus abrogating the RSK4 
protein in three different bladder cancer cell lines was found to sensitise bladder 
cancer cells to both cisplatin and paclitaxel. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 37: Increased sensitivity of three different bladder cancer cell lines to Cisplatin & 
Paclitaxel upon down-regulation of RSK4 by an siRNA pool comprising four different 
RSK4 siRNA oligonucleotides. A sensitivity index value of 0.1 or above was considered 
significant. The bars are average of at least three replicates. Statistical test : Students T- 
Test. * = p< 0.05; ** = p< 0.01; *** = p< 0.001, n.s = not significant. 
 
Furthermore, when we carried out similar experiments in the A549 human lung 
adenocarcinoma cell line where RSK4 had been identified as a modulator of cell migration, 
we observed similar chemosensitising effects. In conclusion, the siRNA screen of the 
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kinome library identified a robust target which sensitised cancer cells to cisplatin and 
paclitaxel across different cancer types.  
 
4.2   RSK4 knockdown decreases XIAP 
As downregulation of RSK4 led to increased sensitivity of various cancer cell lines 
to the chemotherapeutic agents tested, we looked at whether RSK4 modulated the 
expression levels of various apoptotic proteins. Interestingly, we found that in all 
cell lines tested, siRNA-mediated knockdown of RSK4 led to a decrease in the level 
of the X-linked inhibitor of apoptosis protein (XIAP) (Figure 38).  
 
 
Figure 38: Downregulation of RSK4 leads to decrease in the protein levels of XIAP. On 
RSK4 knockdown, XIAP protein levels are seen to decrease and this might very well 
explain the increased sensitivity of the cancer cell lines to the chemotherapeutic agents. 
As no specific RSK4 antibody was available, the above graph does not include a western 
blot probed for RSK4 knockdown. However, the RSK4 mRNA downregulation was 
confirmed by qPCR. UT= Untransfected; siNT= Non- targeting siRNA control & siRSK4= 
RSK4 siRNA transfected. 
We then looked at the mRNA levels for XIAP and found that RSK4 downregulation led to a 
20-30% decrease in the levels of mRNA for XIAP across all cell lines tested (Figure 39). The 
decrease in the levels of an anti-apoptotic protein such as XIAP could explain the increased 
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chemo sensitivity of the bladder and lung cancer cells upon RSK4 silencing. The exact 
mechanism of how this takes place is not clear yet and needs further work.  
 
Figure 39: Effect of RSK4 knockdown on the mRNA levels of XIAP. The figure above 
depicts the change in the mRNA levels of XIAP as assessed by qPCR upon knockdown of 
RSK4 by transfection with RSK4 siRNAs in (A) T24 cell line  (B)A549 cell line,  (C) J82 cell 
line & (D) TCC-SUP cell line. siNT= Non- targeting siRNA control & siRSK4= RSK4 siRNA 
transfected. The bars are average of at least three replicates. Statistical test : Students T- 
Test. * = p< 0.05; ** = p< 0.01; *** = p< 0.001, n.s = not significant. 
 
4.3    RSK4 knockdown leads to increase in RSK1 levels 
We also observed that siRNA-mediated RSK4 silencing led to an increase in mRNA 
levels of RSK1. This increment in the levels of RSK1 was more than 25% in all four 
cell lines tested (Figure 40). In A549 cell line, the results were the same but not 
significant as there was slight variation in the degree of increase over multiple 
repeats. However on all repeats the levels of RSK1 increased. This increase in RSK1 
in response to RSK4 silencing had previously been observed at the protein level in 
work carried out on several lung cancer cell lines, including A549, in our lab and 
our current observations further this by revealing this regulation to be at least in 
part at the transcriptional level [208].  
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Figure 40: Effect of RSK4 knockdown on the mRNA levels of RSK1. The figure above 
depicts the change in the mRNA levels of RSK1 as assessed by qPCR upon knockdown of 
RSK4 by transfection with RSK4 siRNAs in (A) T24 cell line  (B) A549 cell line,  (C) J82 cell 
line & (D) TCC-SUP cell line. siNT= Non- targeting siRNA control & siRSK4= RSK4 siRNA 
transfected. The bars are average of at least three replicates. Statistical test : Students T- 
Test. * = p< 0.05; ** = p< 0.01; *** = p< 0.001, n.s = not significant. 
We wanted to investigate the underlying mechanism that brings about a change in 
the level of RSK1 on RSK4 knockdown. As previously described RSK1 plays an 
important role in cancer cell metastasis by interacting with actin regulators VASP 
and Mena [208]. Hence this regulation could possibly be brought about by a 
transcriptional factor involved with cancer cell invasion.   
SP1 (Specificity Protein 1) is a human transcription factor belonging to Sp/KLF 
family which is 785 amino acid long with a molecular weight of 81kDA. It can 
activate or repress transcription by directly binding to DNA and has been shown to 
regulate invasion and metastasis inversely [275]. SP1 expression correlates with 
better differentiation and maintenance of epithelial morphology.  The state of SP1 
phosphorylation affects its transcriptional activity and this can both positively or 
negatively influence DNA binding and transcriptional activity depending on the 
kinase phosphorylating it.  
 123 
We hypothesised that RSK4 activation phosphorylates SP1 and this 
phosphorylation is inhibitory and thus SP1 binding to RSK1 gene decreases its 
transcriptional activity. Conversely, knockdown of RSK4 prevents the 
phosphorylation event regulating SP1 mediated transcription of RSK1 as a result of 
which its levels increase. We carried out double siRNA knockdown with 
combinations of non targeting, RSK4, RSK1 and SP1 siRNA in T24 cells to study this 
role but initial results did not suggest a role (Figure 41). 
 
 
 
 
 
 
 
Figure 41: mRNA levels of RSK4 and RSK1 were assessed by qPCR in response to double 
knockdown of different combinations of siRNAs. The bars are average of at least three 
replicates. Statistical test : Students T- Test. * = p< 0.05; ** = p< 0.01; *** = p< 0.001, n.s 
= not significant. 
4.4   RSK1 knockdown increases resistance to chemotherapy 
The above finding that RSK4 downregulation causes an increase in mRNA levels of 
RSK1 led us to hypothesise that knockdown of RSK1 should either have little effect 
or an effect opposite to that of RSK4 knockdown on cancer cell sensitivity to 
chemotherapy. Indeed, our results show that cancer cells transfected with RSK1 
siRNA were more resistant to cell death when treated with cisplatin or paclitaxel 
(Figure 42), with a sensitivity index for almost all pooled RSK1 siRNA conditions and 
most if not all individual oligonucleotides of less than -0.1 However, these indices 
did not reach our arbitrarily set value of -0.15 for significance. The only exclusion 
was TCC-SUP cell line where the values for resistance to paclitaxel achieved  
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Figure 42:  Decrease in sensitivity of cancer cells to chemotherapy (cisplatin & paclitaxel) 
upon knockdown with pooled siRNA and individual oligonucleotides of RSK4. Decrease in 
sensitivity  of T24, A549, J82 and TCC-SUP  cells respectively to (A, B, C and D): Cisplatin, 
& (E, F, G and H): Paclitaxel, based on the value of sensitivity index, upon knockdown of 
either a pool of four RSK1 siRNA oligonucleotides or individual RSK1 siRNA 
oligonucleotides. NT= Non-targeting siRNA, RSK1_pool = pool of four RSK1 siRNA 
oligonucleotides, RSK1_1= RSK1 siRNA oligonucleotide 1, RSK1_2= RSK1 siRNA 
oligonucleotide 2, RSK1_3= RSK1 siRNA oligonucleotide 3, RSK1_4= RSK1 siRNA 
oligonucleotide 4. The bars are average of at least three replicates.  
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significance. These results suggest the possibility that the effects seen upon RSK4 
modulation may be indirect and mediated by RSK1. 
 
4.5   RSK4 knockdown leads to a decrease in RSK2 levels 
On further experiments we found that there was a decrease in  mRNA levels of 
RSK2 (RPS6KA3) on siRNA mediated knockdown of RSK4. This reduction was 
significant across different bladder cancer cell lines and was also observed in A549 
lung cancer cell line (Figure 43). 
 
Figure 43: Effect of RSK4 knockdown on the mRNA levels of RSK2. The figure above 
depicts the change in the mRNA levels of XIAP on knockdown of RSK4 by transfection 
with RSK4 siRNA in (A) T24 cell line  (B) A549 cell line,  (C) J82 cell line & (D) TCC-SUP cell 
line. siNT= Non- targeting siRNA control & siRSK4= RSK4 siRNA transfected. The bars are 
average of at least three replicates. Statistical test : Students T- Test. * = p< 0.05; ** = p< 
0.01; *** = p< 0.001, n.s = not significant. 
 
4.6   RSK4 knockdown inhibits migration and invasion 
We studied the effect of RSK4 knockdown on cell migration using time-lapse 
imaging of the same cell lines in complete medium, manual tracking of the cells 
and analysis with MATLAB© software. We found that the mean speed and 
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distance of migration were significantly reduced in T24 cells following knockdown 
of RSK4 as compared to the non-targeting control (Figure 44).  
 
 
Figure 44: Effects of RSK1, RSK2, RSK4 and SP1 downregulation on cell migration speed 
and distance (+, increase; -, decrease) in T24 cell line.   A representative of 2 independent 
experiments performed in triplicate is shown. (A) Box and whisker plot showing the 
effect of knockdown on mean migration speed in T24 cells (B) Representative cell 
trajectory plots in an acquired field of view (n=42). T24 cells were transfected with either 
Rsk1, 2, 4, SP1 or non-targeting (NT) siRNA pools made of 4 oligonucleotide sequences. 
ANOVA analysis performed with non-targeting (NT) as reference: *; p<0.05, **; p<0.005, 
***; p<0.001. The box represents data stretching between the fist and third quartiles and 
the whiskers represent the highest & lowest observations. The dot represents the median 
speed. 
We made similar observations in A549, EKVX and HOP62 lung cancer cell lines and 
these findings are depicted in the Figures 45& 46. 
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Figure 45: Effects of RSK1, RSK2, RSK4 and SP1 downregulation on cell migration speed 
and distance (+, increase; -, decrease) in A549 cell line.   A representative of 2 
independent experiments performed in triplicate is shown. (A) Box and whisker plot 
showing the effect of knockdown on mean migration speed in A549 cells (B) 
Representative cell trajectory plots in an acquired field of view (n=42). A549 cells were 
transfected with either Rsk1, 2, 4, SP1 or non-targeting (NT) siRNA pools made of 4 
oligonucleotide sequences. ANOVA analysis performed with non-targeting (NT) as 
reference: *; p<0.05, **; p<0.005, ***; p<0.001. The box represents data stretching 
between the fist and third quartiles and the whiskers represent the highest & 
lowest observations. The dot represents the median speed. 
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Figure 46: Effects of RSK4 downregulation on cell migration speed and distance (+, 
increase; -, decrease) in EKVX & HOP62 cell lines.   A representative of 2 independent 
experiments performed in triplicate is shown. On the left side are the Box and whisker 
plot showing the effect of knockdown on mean migration speed in T24 cells and on the 
right are representative cell trajectory plots in an acquired field of view (n=42). Cells 
were transfected with either RSK4 or non-targeting (NT) siRNA pools made of 4 
oligonucleotide sequences. ANOVA analysis performed with non-targeting (NT) as 
reference: *; p<0.05, **; p<0.005, ***; p<0.001. The box represents data stretching 
between the fist and third quartiles and the whiskers represent the highest & 
lowest observations. The dot represents the median speed. 
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We also carried out cell invasion assays to study the effect of RSK4 downregulation 
on the three bladder cancer cell lines T24, J82 and TCC-SUP. After transfection with 
either non-targeting control siRNA or RSK4 siRNA, the cells covered with a collagen 
matrix were left to invade upward against a gradient of epidermal growth factor 
(EGF). Following fixation and nuclear staining, cell invasion was monitored by 
confocal microscopy and the degree of invasion calculated as a function of the 
proportion of cells that entered the collagen matrix and their distance from the  
 
 
Figure 47: Downregulation of RSK4 inhibits T24, J82 and TCCSUP bladder cancer cell 
invasiveness. Cells were transfected with RSK4 siRNA (siRSK4) or non-targeting control 
siRNA (siNT) and covered with a collagen I matrix in a 96 well-plate format. Chemotaxis 
was provided by EGF added to the top end of the collagen matrix and 24 h later, the 
wells were fixed with formaldehyde and stained with sytox green. Confocal microscopy 
imaging was performed and the extent of invasion determined as described in the text. 
Bar graphs represent average of triplicates and error bars are SEM. Students T-test:  * = 
p< 0.05; ** = p< 0.01; *** = p< 0.001, n.s = not significant. All data shown are 
representative of experiments performed at least in triplicates. 
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bottom of the well. Data were normalised to background invasion of non-targeting 
control siRNA transfected cells. We found that compared to control transfected 
cells invasion was significantly reduced when RSK4 was downregulated in three 
different bladder cancer cell lines (Figure 47). 
 
4.7    Discussion 
In this study a screening experiment using siRNA transfection identified RSK4 as a 
target, the inhibition of which induces sensitisation to cisplatin and paclitaxel in 
three different bladder cancer cell lines. This sensitisation is likely as a result of 
decrease in the levels of anti-apoptotic protein XIAP which normally provides a 
growth advantage to tumour cells.  Other studies have pointed out a similar role in 
other cancers but the mechanistic details have been lacking so far.  The ability of 
XIAP to inhibit caspases can render tumour cells resistant to chemotherapy [255]. 
XIAP overexpression has been reported in a variety of cancers and it is thought to 
be an adverse prognostic factor responsible for chemoresistance [256]. The 
cytotoxic activity of various cystostatic agents like has been shown to be enhanced 
when XIAP is inhibited [257]. However, recent data shows that in certain radically 
resected tumours like non small cell lung cancer and prostate cancer, high XIAP 
expression was associated with longer overall survival of patients compared to 
those with lower XIAP expression [258] [283].   
Compared to normal urothelium which shows minimal XIAP expression, XIAP was 
upregulated in almost three-quarters of the examined transitional cell cancer 
specimens [259]. In T24 cell line, overexpression of XIAP led to statistically 
significant survival of cancer cells suggesting a critical role of XIAP in maintaining 
viability and drug resistance in transitional cell carcinoma.  
In our study we found that RSK4 plays an important role in the migration of 
bladder and lung cancer cell lines. Downregulation of RSK4 inhibited cell motility 
across different cell lines. In bladder cancer cell lines, invasiveness was significantly 
reduced in response to RSK4 knockdown.  
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In response to knockdown of RSK4 we found that whereas the mRNA levels of 
RSK2 decreased, those of RSK1 increased significantly. Interestingly previous 
reports point out that whereas RSK2 expression increases migration and invasion, 
RSK1 expression has an opposite effect. RSK1 knockdown enhanced cell motility 
and invasion in A549 cell line [208].  
We have created RSK4 over-expression and RSK4 knockdown (shRNA) stable cell 
lines and it will be interesting to study their response to chemotherapeutic agents 
and the changes induced at a molecular level. Unfortunately our attempts at 
generating kinase active and kinase dead mutants using site directed mutagenesis 
were not successful.   
This effect of RSK4 knockdown on migration and invasion has also been previously 
reported in lung cancer cells [208]. Using cells with sustained knockdown (shRNA 
stables) would serve a better tool to study effect of RSK4 downregulation on 
metastasis in an animal model. These cells have been developed and we aim to 
carry out further experiments in future.  
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    Introduction 
In cancer cells, pathways that provide a growth advantage are preferentially expressed 
and those that do the opposite are suppressed.  Expression patterns of a  particular 
gene in a cancer cell type can provide a rough idea about their regulatory role. For 
example if a gene is overexpressed in cancer, it is most likely a tumour promoter and if 
it is underexpressed, its role is likely to be tumour suppressive.  
Expression patterns of RSK4 have been studied in various cancers. While some suggest 
that RSK4 is an oncogene due to high expression in certain cancers, others believe that 
it is a tumour suppressor due to lower expression in other cancer types. This could 
very well be due to differences in the role of RSK4 in different  cancer types. Hence we 
set out to  explore the degree of expression of RSK4 in bladder and lung cancer . We 
also compared the difference in expression in these two smoking related cancers. Also 
in lung cancer we studied the difference in expression in different lung cancer 
subtypes.  Further details and results are presented in the sections below. 
5.1 Immunohistochemistry of Bladder Cancer TMA 
In order to establish the clinical relevance of our findings, as a first step we set out 
to study the expression of RSK4 in a tissue microarray (TMA) containing matched 
primary transitional cell cancers and adjacent normal bladder tissue. This work was 
carried out with the co-operation of our collaborators at the Histopathology 
Department at the Hammersmith Hospital. For each antibody, external positive 
controls were used according to the manufacturer’s datasheets. Negative controls 
included omitting the primary antibody, competition with the antibody-raising 
peptides and staining of paraffin-embedded T24 cells treated with a non-targeting 
control or the relevant siRNAs (RSK4). A semi quantitative immunohistochemical 
score (IHS) was used as previously described [198] assessing both the percentage 
of positive cells and the intensity of staining. For the intensity, a score of 0 to 3, 
corresponding to negative, weak, moderate and strong positivity was recorded. 
The range of possible scores, thus, was between 0 to 300. Each core was scored  
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individually and two observers blinded to all the clinical data attached with the 
TMA scored all the cases and the results were compared. 
 
5.2 Optimisation of RSK4 antibody for 
Immunohistochemistry (IHC) 
The optimisation of the RSK4 antibody for immunohistochemical analysis was 
performed previously in our lab and we used the same protocol for bladder cancer 
IHC. The protocol was generated using formalin fixed paraffin embedded pellets of 
A549 cells transfected with non-targeting control or RSK4 siRNA. This helped 
confirm the specificity of RSK4 antibody. Figure 48 shows representative staining of 
A549 cell pellets treated with non-targeting control or RSK4 siRNA.  
 
 
Figure 48: Optimisation of RSK4 antibody for immunohistochemistry done in A549 cells. 
The figure shows A549 cells treated with either non targeting siRNA (left panel) or RSK4 
siRNA prior to being parafin-embeded and then stained with RSK4 antibody prior to HRP 
detection together with Diamino-benzidine (DAB) secondary staining & haematoxylin 
counter-stain, Brown;   
5.3  The Bladder Cancer TMA 
The TMA was obtained from Biomax US Inc. and contained bladder cancer cores 
with matched normal adjacent tissue. The clinical information associated with the 
TMA included pathological grade and TNM grade & stage. 37 cores of the bladder  
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TMA were transitional cell cancers, 2 squamous cell carcinomas, 1 adenocarcinoma 
and 40 adjacent normal tissue cores. 
5.4   IHC Results 
In transitional cell carcinomas of bladder, 72.5% cores stained positively for RSK4 
whereas 55% of cores of normal adjacent tissue did. Only 15% of normal adjacent 
tissue cores stained moderately or strongly for RSK4 as compared to roughly 40% 
of transitional cell carcinomas of bladder (Figure 49). The average values for 
positivity and overall score for transitional cell cancer and normal adjacent tissue 
were similar but the intensity of staining was much higher (1.5 times) in cores of 
transitional cell cancer (Figure 50) and the difference was statistically significant  
(p=0.01, t-test).   
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Figure 49: The bar chart shows the results of immunohistochemical staining (IHC) of a Tissue 
Microarray (TMA) containing 40 cores of each malignant bladder cancer (37 TCCs, 2 
squamous cell cancers and 1 mucinous adenocarcinoma) and normal adjacent tissue (NAT). 
The TMA was obtained from US Biomax and prepared as described earlier in materials and 
methods. The percentage of patients showing an immunohistochemical score of Negative = 
0; Weak = 1-100; Moderate = 101-200 and Strong = >200 is displayed. 
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Figure 50: The bar chart compares the average values for the intensity of staining, percent 
positivity and immunohistochemical score (IHS) of both normal adjacent tissue (NAT) and 
transitional cell carcinoma (TCC) when normalised to the values of NAT. The 
immunohistochemical staining was performed on a commercially available TMA obtained 
from US Biomax. 
 
When we stratified the transitional cell carcinoma cores on the basis of the clinical 
stage, 50% of stage III tumours had strong expression of RSK4 while this intensity of 
staining was not present in Stage I or II samples. Indeed, only moderate expression 
of RSK4 was found in 33% of stage I and II tumours (Figure 51). Similarly when the 
cores were stratified on the basis of pathological grade, 50% of grade 3 tumours had 
moderate to strong staining while 30% of grade 2 tumours and 57% of grade 1 
tumours had only moderate staining for RSK4 (Figure 52). 
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Figure 51: The bar chart shows the percentage of cases with the indicated 
immunohistochemical score (IHS) when the transitional cell carcinoma (TCC) cores are 
stratified on the basis of the clinical stage of the patient. 
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Figure 52:  The bar chart shows the distribution the percentage of cases with the indicated 
immunohistochemical score (IHS) when the transitional cell carcinoma (TCC) cores are 
stratified on the basis of histological grade in the US Biomax TMA. 
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5.5 RSK4 expression in Lung cancer TMA 
We also carried out an analysis of the IHC staining of a lung cancer TMA available to 
our lab. We used the same antibody as for the bladder cancer TMA. 55% of squamous  
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Figure 53: Percentage of cases with RSK4 staining positivity  in the three subtypes of 
lung cancers represented in our lung cancer TMA.  
 
cell lung cancer, 68% of adenocarcinoma lung and 28% small cell lung cancer 
cores showed RSK4 expression (Figure 53). This contrasts with the negative 
staining for this protein previously found in normal lung tissues [208]. 
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Figure 54: Average immunostaining score for RSK4 in the three subtypes of lung 
cancers represented in our lung cancer TMA.  
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The average IHC score varied between the three lung cancer types and was 28%, 
57% and 20% for squamous cell, adenocarcinoma and small cell lung cancer 
subtypes respectively (Figure 54). Intensity differences are depicted in Figure 55. 
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Figure 55: Intensity of RSK4 staining score in the three subtypes of lung cancers 
represented in our lung cancer TMA.. The percentage of cores showing an 
immunohistochemical score of Negative = 0; Weak = 1-100; Moderate = 101-200 and 
Strong = >200 is displayed. 
 
 5.6  Discussion 
RSK4 is ubiquitously expressed in all tissue types but northern blot analyses have 
shown that RSK4 expression is abundant in fetal and adult brain and kidney but 
lower in all other tissue types [251].  
In a bladder cancer TMA we found that more bladder cancer cores with moderate 
to strong expression compared to normal urothelium with a significantly higher 
intensity of RSK4 staining in tumour cores. In a lung cancer TMA available to our 
lab we found positive RSK4 expression in 55% of squamous cell lung cancer, 68% of 
adenocarcinoma lung and 28% small cell lung cancer cores.   
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Recent scientific studies have compared normal adjacent tissue with cancer in 
other cancers and suggested a role of RSK4 in cancer progression. RSK4 was 
expressed in normal mammary ducts but the expression was lower in benign 
mammary tissues. In ductal carcinoma and invasive ductal carcinoma RSK4 seemed 
to reappear at a higher level [211]. RSK4 was also found to be frequently 
hypermethylated in primary endometrial cancer tissue and in endometrial cancer 
cell lines when compared to the normal endometrial tissue. RSK4 methylation was 
also inversely related to the severity of the tumour grade i.e. higher grade tumours 
had lower level of methylation [252].  
A very recent study has shown that RSK4 is a prognostic factor for renal cell 
carcinoma [243]. Immunohistochemical expression patterns of RSK4 in renal cell 
carcinoma when compared to normal tissue, showed a significantly positive 
correlation of RSK4 expression to high pT stage, high Fuhrman grade, lymph node 
involvement and distant metastasis. Higher expression was thought to predict a 
poor outcome [243]. RSK4 was overexpressed in RCCs (P=0.003), compared with 
normal tissues, and the expression varied in different RCC subtypes (P=0.021), 
especially in two subtypes of papillary RCCs (P=0.001). RSK4 expression was 
positively correlated with high pT stage (P<0.001), high Fuhrman grade (P<0.001), 
lymph node involvement (P<0.001), and presence of distant metastasis (P=0.039), 
and could predict poor outcome in RCC patients. Molecular studies showed that 
overexpression of RSK4 could promote cell cycle progression and enhance the 
invasive and metastatic capability of RCC cell lines and vice versa. 
After this initial immunohistochemical analysis of the commercially available TMA, 
the aim is to study the expression levels in bladder cancer tissue samples of 
patients available in the tissue bank of the Imperial College AHSC. At the time of 
the writing of this thesis, the ethical approval for collection and use of cystectomy 
tissue has been granted and more than 50 patient specimens have been collected 
for processing into a TMA in order to carry out further immunohistochemical  
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studies which will include expression of RSK4, RSK1 and XIAP. More specifically, 
attention will be given to expression levels at sites of invasion versus primary 
lesions and surrounding normal tissue to assess whether expression changes of our 
chemoresistance modulators correlate with disease progression. Available clinical 
data will be used to address possible correlation between expression levels in the 
primary tumour and clinical outcome (e.g. survival, presence of metastatic lesion). 
This work will be carried out with the co-operation of our collaborators, Dr 
Nyethane Ngo & Dr Francesco Mauri at the Histopathology Department at the 
Imperial College Healthcare NHS Trust.  
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Chapter 6 
 
 
 
 
 
 
 
Role of RSK4 
in metastasis 
In Vivo 
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  Introduction 
One of the main reasons for mortality associated with most cancers is the spread of 
cancer cells to adjacent organs and distant sites. Greater understanding of the 
molecular mechanisms and role of kinases can provide us with additional options to 
prevent this spread and hence improve overall survival rates.  
When we explored the role if RSK4 in vitro we found that true to our hypothesis 
downregulation of RSK4 reduced the speed of migration and invasion in various cancer 
cell   lines. Hence we set out to test the effect of RSK4 downregulation on metastasis in 
an in vivo setting. We used a zebrafish and mouse model to study this and the 
following sections present the results in detail.   
6.1   Zebrafish Experiments 
In order to demonstrate that dissemination of cancer cells in vivo is reduced on 
RSK4 knockdown, we established a cancer metastasis zebrafish model. In this 
metastatic model, A549 cells stably expressing a histone 2B-GFP fusion protein 
were established so as to allow convenient visualisation of the cells by 
fluorescence microscopy. Flow cytometric cell sorting was used in order to select 
cells expressing high levels of GFP and thus obtain a more homogenous cell 
population. 30 cells were injected into the cell mass of 4 hours post-fertilisation 
(hpi) zebrafish embryos.  
Whole fish imaging demonstrated that the injected A549 cells formed a primary 
tumour mass in the head region of all injected fish at 24 hpi. After that single cells 
were seen to be separating from the primary tumour to invade down the body of 
the fish (Fig 56). Using this model, we hypothesised that down-regulation of RSK4 
might prevent the dissemination of A549 cells away from this cranial mass.  
 
 144 
 
Figure 56: Effects of downregulating RSK4 on lung cancer cell invasion in zebrafish. A549 
cells expressing H2B-GFP were injected in zebrafish embryos 24 hours post fertilisation 
(hpf). 48 h later these the injected zebrafish were imaged using fluorescence microscopy. 
(A and B) A representative picture of the distribution of A549 cells transfected with (A) 
non-targeting control  or (B) RSK4 siRNAs. (C) Bar chart showing the percentage of cases 
with cancer cells metastasizing into the body of the fish when A549 cells transfected with 
either non-targeting (Sc) or RSK4 siRNAs were injected into the yolk sac. N=60 fish per 
condition. The location of observed invading cells is also indicated as per picture in (A). 
Indeed, our hypothesis held true and A549 cells down-regulated for RSK4 
remained at the injection site even at 48 hpi. The difference between the two 
conditions was quantified by scoring for the presence or absence of tumour cells 
within 3 defined regions of the fish body; Head, Middle and Tail (n=120 fish per 
condition). Thus, Rsk4 knockdown significantly impairs the ability of A549 cells to 
invade and disseminate in vivo.  
 6.2   Mouse Experiments 
We intended to study the role of RSK4 in metastasis in an animal model. We used a 
mouse model for the purpose. In this model SCID (severe combined 
immunodeficiency) mice (Charles River) were injected with luciferase expressing 
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lung cancer A549 cells (A549-Luc-C8) and the growth and spread of these cells was 
monitored by the luciferase assay as described later. Our hypothesis was that 
compared to mice injected with A549-Luc-C8 cells transfected with non-targeting 
siRNA, those injected with A549-Luc-C8 cells transfected with RSK4 siRNA would 
show less tumour load and less metastatic deposits. 
The experiment was carried out on a total of eighteen 42-48 days male SCID mice 
from Charles River. The mice were housed in microisolator cages in pathogen free 
conditions and had free availability of rodent chow and water. All the experiments 
were carried out in a designated lab with vast experience of carrying out animal 
experiments.  
A549-Luc-C8 cells were transfected wither with control siRNA or RSK4 siRNA as 
described earlier in materials and methods. 5x10⁶ cells in 100μL PBS with 10%EDTA 
were injected intravenously, using a 26 gauge needle via tail vein, into each 
experimental mouse on day 0 [212]. The mice were anaesthetised with isoflurane 
prior to the injection and/or BLI in adherence with a strict safety protocol. Ventral 
and dorsal bioluminescent imaging (BLI) was then carried out on a weekly basis for 
8 weeks as described below. 
6.2.1   Results 
The take up rates of A549-Luc-C8 cells in the lungs was 100% with all the mice 
exhibiting bioluminescence after injection. Unfortunately, however, 5/9 mice in 
the group injected with A549-Luc-C8 cells transfected with non-targeting siRNA 
and 7/9 mice in the group injected with A549-Luc-C8 cells transfected with RSK4 
siRNA died. We ascribed the reason for this to be the very high cell number that 
was injected per mouse (5X10⁶ cells/100 μL PBS). However because of paucity of 
time we continued to monitor the surviving mice over an 8 week period, thus 
generating preliminary results which could be expanded upon in future. So the 
results below are from four mice injected with control siRNA transfected and two 
mice with RSK4 siRNA transfected A549-Luc-C8 cells.  
All the surviving mice developed metastatic lesions in different parts of the body 
(Figure 57). The most commonly colonized tissues, as detected by whole body BLI), 
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following A549-luc cells i.e. injection were the lungs and bones - mandible, knee 
joints and spine (Figure 59). Upon dissection, additional metastatic sites were seen 
macroscopically and these included stomach, gastrointestinal tract and liver 
(Figure 58). Although BLI quantification was difficult to achieve, one of the two 
RSK4 siRNA injected mice seemed to have significantly less metastatic lesions and 
BLI signal. Even though CT imaging was performed, it was not sensitive enough to 
discriminate and identify metastatic lesions in the soft tissue.  
Overall, our  preliminary results were not confirmatory of the prior in vitro and 
zebrafish experiments.   However, this may in part be due to toxicity issues and 
repeat experiments are planned. 
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Figure 57: Sequential whole animal images of mice injected intravenously with A549-Luc-
C8 cells transfected either with non-targeting or (#529, #530, #531 & #532) or RSK4 siRNAs 
(#524 and #521). Bioluminescent Imaging (ventral and dorsal) of the injected mice was 
carried out on a weekly basis for 8 weeks. Bioluminescence expressed as photons/sec/cm². 
Colour scale : Minimum 2.3 x 10³ (dark blue)  & Maximum 2.14 x 10⁴ (dark red). 
 
. 
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Figure 58: Representative BLI showing the location of metastatic lesions in (A) whole mice 
and (B) ex vivo following dissection. The mice were injected intravenously with A549-Luc-
C8 cells transfected either with non-targeting (#529, #530, #531 & #532) or RSK4 siRNAs 
(#524 and #521). Bioluminescence expressed as photons/sec/cm². Colour scale : Minimum 
2.3 x 10³ (dark blue)  & Maximum 2.14 x 10⁴ (dark red). 
A. 
B. 
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Figure 59: CT imaging (surface rendering) assessment of bone metastatic lesions 
(mandible, spine and knee joints) in mice injected intravenously with either A549-Luc-C8 
cells transfected with non-targeting (#529, #530, #531 & #532) or RSK4 siRNAs (#524 and 
#521). The left panels represent the corresponding BLI data for these mice. 
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6.3    Discussion 
In our experiments in zebrafish, we clearly demonstrated that abrogation of RSK4 
diminished the migratory and invasive capacity of A549 lung cancer cells. Our 
initial mouse experiment did not so clearly support this finding although mice 
injected with A549-Luc-C8 cells with RSK4 knockdown did not show as extensive 
metastatic tumours as seen in control transfected A549-Luc-C8 cells in the first 3-4 
weeks.  
It is well known that siRNA transfection leads to  transient downregulation only 
and this could very well be the reason why inhibition of migration and invasion did 
not last the period of the study. Our aim is to carry out further experiments using 
cell lines with sustained knockdown of RSK4 (shRNA stable cell lines) and this will 
hopefully shed further light on the role of RSK4 in migration and invasion. 
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Chapter 7 
 
Metabolic 
effects of RSK4 
in T24 & A549 
cell lines 
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  Introduction 
As part of this project we carried out experiments in order to study the metabolic 
changes that correlate with RSK4 expression in cancer cells using 1H NMR 
spectroscopy.  We studied T24 and A549 cancer cell lines (bladder and lung 
respectively) so as to determine whether RSK4 controlled the same metabolic profile 
in varied carcinomas with a similar etiological factor of smoking. These experiments 
were carried out under the guidance and in collaboration of Dr Hector Keun 
(Biomolecular Medicine, Imperial College London)  
7.1    NMR Data Acquisition and Analysis 
The ¹H spectra are acquired at 300 K on a Bruker spectrometer (600MHz ¹H 
frequency). The ¹H spectra for the media samples is acquired using a total 
repetition time (TR) of 256 s and a 90° flip, the TR used for the cell extracts was 512 
s. The data is analysed using Bruker's TopSpin™ software package for NMR data 
analysis. Metabolites are assigned to their corresponding peaks with Chenomix 
NMR suite 7.5 software. The metabolite peak areas for each media or cell extract 
spectrum are compared against each other using MATLAB software.   
Absolute sample concentrations are determined using the area under the curve for 
selected metabolite peaks normalised to 4,4-Dimethyl-4-silapentane-1-ammonium 
trifluoroacetate (DSA) or Trimethylsilyl propionate (TSP) concentration and 
adjusted for the proton number associated with the peak of interest. Metabolite 
consumption and production rates were calculated by obtaining the picomolar 
difference for metabolites at a specific time point and dividing by the number of 
remaining viable cells in the culture.  
7.2   Results 
7.2.1   Analysis of media samples from control and siRSK4 treated A549 
and T24 cells 
A549 and T24 cells were transfected with RSK4 or non-targeting control siRNAs and 
culture media as well as cellular material collected at two separate time-points (24 
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and 48h post-transfection) to assess changes in cellular metabolism occurring upon 
RSK4 silencing. RT-PCR was used to confirm downregulation of RSK4 compared to  
 
Figure 60:  The  1H-NMR spectrum of A549 cell media at 48 hours post transfection with 
either (A) non-targeting (control) or (B) RSK4 siRNAs. (C) close up of the glucose doublet 
peak at 5.2 ppm and (D) close up of lactate doublet at 1.32 ppm. Peaks identity: 
1:Glutamate, 2: Glutamine, 3: Histidine, 4: Isolecucine, 5: Leucine, 6: Phenylalanine, 7: 
Tyrosine, 8: Valine, 9: Acetate, 10: Formate, 11: Glucose, 12: lactate, 13: Pyruvate, 14: 
DSA. The results are average of three repeats.  
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the control prior to metabonomic analysis. The 1H NMR spectra of cell media 
comprised of multiple peaks corresponding to metabolites, a total of 14 of which  
were identified across the two cell lines (A549 and T24). The peak intensity 
corresponds directly proportional to the number of nuclei contributing to the 
signal under experimental conditions and indicates the abundance of that 
metabolite. On visual inspection of the 1H NMR spectra, there was a difference in 
glucose peak intensity for the control A549 cell media at 48hrs as compared to that 
of the RSK4 knockdown (0.212 units vs. 0.088 units respectively) at the same time 
point (Figure 60).  
An expanded section of the spectra corresponding to a doublet of glucose (C-2) at 
5.2 ppm. This indicates that more glucose was present in the media from the 
control cells than the knockdown cells at this time point. A difference in metabolite 
intensity is also seen for lactate. Its doublet at 1.32 ppm (C-3) has a peak intensity 
of ≈ 2.87 units for the control and ≈ 4.598 units for the RSK4 knockdown. This 
implies that less lactate was present in the media for control cells compared to 
that of the RSK4 knockdown cells (Figure 60).  
This observation wasn’t as clear cut in the T24 cell media and there was only an 
insignificant difference between glucose peak intensities at 5.2 ppm (C-2), between 
the control (0.177 units) and the RSK4 knockdown (0.157 units). This was also true 
for the lactate doublet at 1.32 ppm (C-3), being 4.078 units for the control and 4.22 
units for the RSK4 knockdown condition (Figure 61).  
However, data based solely on the peak intensities of metabolites alone at a single 
time point can be misleading as the spectrum may not account for the number of 
cells contributing to the metabolite pooling in the media. Hence the rates of 
metabolite change in the media at 24hrs and 48hrs were calculated for each 
molecule identified from the spectra (please, refer to the methods section).  
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Figure 61:  The  1H-NMR spectrum of T24 cell media at 48 hours post transfection with 
either (A) non-targeting (control) or (B) RSK4 siRNAs. (C) close up of the glucose doublet 
peak at 5.2 ppm and (D) close up of lactate doublet at 1.32 ppm. Peaks identity: 1: 
Glutamate, 2: Glutamine, 3: Histidine, 4: Isolecucine, 5: Leucine, 6: Phenylalanine, 7: 
Tyrosine, 8: Valine,  9: Acetate, 10: Formate, 11: Glucose, 12: Lactate, 13: Pyruvate, 14: 
DSA. The results are average of three repeats. 
7.2.2   Changes in metabolite consumption/production over a 48h period 
In order to obtain more information about the changes in metabolite 
concentrations spectrum data were converted into rates of concentration change. 
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Whereas positive values indicate an increased concentration of metabolites in the 
media since the time of transfection (at 0 h), a negative value indicates that a 
decreased concentration of metabolites is present in the media since the time of 
transfection. In other words, a positive value indicates production and secretion of 
the metabolite into the media and a negative value indicates consumption of the 
metabolite from the media by the cells.   
 
 
 
 
 
 
 
 
 
 
 
 
                 
 
 
 
 
                   
 
 
 
 
                   Table 15: Changes in the concentration of identified metabolites in the medium of A549 
cells transfected with either non-targeting or RSK4 siRNAs over a 48 hour period. The 
results are average of three repeats.  
 
 
A549 
Cells 
 
Change in metabolite concentration (picomoles) in the medium per 
cell per hour [Ä pM  cell-1 hr-1] 
 
 Non-targeting Control cells RSK4 knockdown cells 
Metabolites 
 
1 day after 
transfection 
2 days after 
transfection 
1 day after 
transfection 
2 days after 
transfection 
Glutamate* 0.457 0.269 0.618 0.444 
Glutamine -18.9 -9.41 -22.6 -10.5 
Histidine -0.148 0.192 1.33 0.113 
Isoleucine -3.69 -1.22 -4.27 -0.768 
Leucine -0.133 -0.0819 -0.110 -0.0649 
Phenylalanine 0.228 0.0212 1.54 0.171 
Tyrosine 3.88 1.24 6.01 0.418 
Valine 0.376 -1.25 11.8 2.90 
Acetate 21.0 15.1 24.2 21.9 
Formate 0.515 0.270 0.643 0.453 
Glucose* -6.21 -4.58 -6.04 -8.01 
Lactate* 27.0 20.1 38.8 38.1 
Pyruvate -7.40 -0.328 -10.8 -1.37 
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Most of the metabolites were consumed over the 48 hour period in both the cell 
lines. Rates of consumption/production of a significant proportion of the 
metabolites (for example isoleucine and acetate) decreased over the 48hr period  
 
 
 
 
 
 
 
 
 
 
 
     
 
 
 
 
 
 
       
   Table 16: Changes in the concentration of identified metabolites in the medium of T24 
cells transfected with either non-targeting or RSK4 siRNAs over a 48 hour period. The 
results are average of three repeats.  
for both transfection conditions and this was common for both cell lines, shown in 
Table 15 & 16. This may very well be due to cellular metabolic processes utilizing 
 
T24 Cells 
Change in metabolite concentration (picomoles) in the medium per 
cell per hour [Ä pM  cell-1 hr-1 ] 
 Non-targeting Control cells RSK4 knockdown cells 
Metabolites 
 
1 day after 
transfection 
2 days after 
transfection 
1 day after 
transfection 
2 days after 
transfection 
Alanine 4.26 4.44 12.3 7.25 
Glutamate* 0.172 0.103 0.340 0.190 
Glutamine* -17.0 -8.71 -27.1 -11.1 
Histidine 1.22 0.0117 1.08 0.0530 
Isoleucine -1.99 -0.826 -1.57 -0.984 
Leucine -0.153 -0.0629 -0.0952 -0.0698 
Phenylalanine 1.42 0.177 4.80 -0.0245 
Tyrosine 0.718 -0.228 0.275 0.232 
Valine -0.0974 -0.666 14.0 0.904 
Acetate 1.94 0.139 2.36 0.471 
Formate 2.08 0.533 1.20 0.613 
Glucose* -3.20 -2.00 -4.16 -2.96 
Lactate* 60.3 34.0 77.1 48.1 
Pyruvate* -10.7 -3.98 -16.6 -5.93 
 160 
the finite source of metabolites in the initial media and getting exhausted by the 
increasing number of cells. 
   Despite this, statistical analysis showed that the rate of metabolism for glucose, 
lactate, pyruvate, glutamate and glutamine was significantly different between the 
two transfection conditions.  
 
 
Figure 62: Change in glucose (A and B), pyruvate (C and D) and glutamine (E and F) 
concentration at 24 (black bars) and 48 hour (grey bars) post transfection of T24 or A549 
cells with Non targeting control (siNT) or RSK4 (siRSK4) siRNAs. Results are the mean of 
at least three repeats + SE. Statistical test: Student t-test. Significance is calculated using 
siNT as control (*; p < 0.05). 
Metabonomic analysis in T24 cells shows a statistically significant difference in 
production/consumption of glucose, lactate, pyruvate, glutamine and glutamate 
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(Figure 62). On the other hand, A549 cells exhibit a significant change between the 
conditions for only glutamate, glucose and lactate (Figure 63). From the graphs it is 
clear that A549 cells naturally tend to have a greater demand for glucose and 
production of glutamate than the T24 cells. However, T24 cells seem to naturally 
produce more lactate and consume more pyruvate. Such differences are expected 
as the metabolic demands of different tissue types vary considerably. 
 
Figure 63: Change in lactate (A and B), glutamate (C and D) and acetate (E and F) 
concentration at 24 (black bars) and 48 hour (grey bars) post transfection of T24 or A549 
cells with Non targeting control (siNT) or RSK4 (siRSK4) siRNAs. Results are the mean of 
at least three repeats + SE. Statistical test: Student t-test. Significance is calculated using 
siNT as control (*; p < 0.05). 
As a result of down regulation of RSK4 in the two cell lines, there appears to be 
some difference in the way glucose and lactate are metabolised. RSK4 silenced 
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cells exhibit their highest rate of glucose consumption at day 1 (-4.16 pM cell-1 hr-1) 
and this reduces by day 2 to -2.96 pM cell-1 hr-1.  On the contrary, in the A549 cell 
line this rate is highest at day 2 (-8.011 pM cell-1 hr-1). The decrease in the rate of 
glucose consumption over the 48hr period under the control conditions occurs for 
both cell lines, suggesting that RSK4’s effect on glucose uptake is slightly greater on 
the A549 cells.  
Upon RSK4 silencing, the production of lactate was highest at 24h (77.1 pM cell-1 
hr-1) and this reduced to 48.1 pM cell-1 hr-1 at 48hrs.  The rate of lactate production 
was 38.8 pM cell-1 hr-1 at 24hrs and 38.1 pM cell-1 hr-1 at 48h in A549 cell line. 
These two rate values show a minimal difference compared to that seen in the T24 
cell.   
 
 
Figure 64: Metabolic changes that occur with the Warburg effect. The bold arrows 
indicate the most prevalent metabolic process which are glucose uptake and lactate 
production. The dotted arrow shows the least prevalent metabolic process which is 
pyruvate oxidation (decarboxylation), resulting in reduced oxidative phosphorylation. 
Figure adapted from [269]. 
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However, there is a decrease in the rate of lactate production over the 48h period 
under the control conditions in both cell lines, which suggests that RSK4’s effect on 
lactate production is slightly greater in A549 cells.  
In short, our data suggest that RSK4 silencing causes both the cell lines to increase 
their aerobic glycolysis (Warburg effect). This utilises glucose metabolism to yield 
energy and a higher proportion of lactate (lactic acid) as a by-product (Figure 64). 
7.2.3   Metabolite concentrations within A549 cell extracts after 48 hrs 
To obtain more insight into metabolite utilisation, 1H NMR analysis was performed 
on A549 cell extracts at the 48 h time-point following siRNA transfection. The 
spectra were inspected for the chemoresistance markers Phosphocholine and 
glycerophosphocholine (GPC) in addition to the 14 metabolites mentioned in 
Tables 15 & 16 earlier. 8 of these metabolites were identified along with GPC. Also 
the general peak intensity was significantly lower in this spectrum compared to the 
media’s. This was expected as the media in which the cells were incubated in was 
originally supplemented with high amounts of metabolites. The metabolite 
concentrations were obtained by processing the spectra and these were 
normalised by the cell counts for each condition and plotted into a graph (Figure 
65).  
We found a significant increase in the amounts of glutamate in the RSK4 silenced 
cells compared to the control (0.167μM vs. 0.0983μM, respectively, p<0.05). This 
observation is in line with the findings from the analysis of media samples 
described above. This could result from high glutamate production in the RSK4-
silenced cells. Similar inference can be made out of the results for lactate which 
has a significantly higher concentration in the RSK4 downregulated as compared to 
the non-targeting control cells (13.0μM vs. 9.70μM respectively. As mentioned 
previously, the rate of production of this metabolite at 48h was significantly higher 
than the control’s. Alanine, which was identified in the cell extract 1H NMR 
spectrum but not in the media spectrum also showed a significantly higher 
concentration in the RSK4-silenced cells compared to the control, at 1.99μM and  
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1.06μM, respectively. The results for other metabolites found in the cell extract 
showing no significant change between conditions are concordant with the data of 
metabolite consumption/secretion rates as these also showed no significant 
change for these molecules between the transfection conditions. 
 
 
Figure 65. Metabolite concentrations obtained from A549 cell extracts at 48 hrs. Black 
and grey bars represent data from cells transfected with non-targeting control and RSK4 
siRNA, respectively. Results are the mean of three repeats + SE. Statistical test: Student t-
test. Significance is calculated using siNT as control (*; p < 0.05). 
7.3     Discussion 
While normal differentiated cells rely on oxidative phosphorylation via the TCA 
cycle for generation of most of its energy demands, cancer cells utilise relatively 
inefficient 'aerobic glycolysis' for ATP production. A by-product of this preferential 
pathway of cancer cells is lactate. No study so far has directly compared the 
differences in rate of production of lactate in normal and cancer cells. It is 
estimated that in normal cells lactate production is minimal and any increase is 
pathological usually occurring in anaerobic conditions. In contrast, as much as 90% 
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of glucose in glioblastoma cell line SF188 is converted to lactate [285]. Using 
genetically encoded Forster resonance Energy Transfer (FRET) nanosensors, a 
recent study showed that the basal lactate production is 3-5 times higher in T98G 
glioma cells than astrocytes [286]. Our experiments did not compare metabolite 
variations between normal and cancer cells but studied the metabolic changes in 
response to knockdown of RSK4 in two smoking associated cancers (lung and 
bladder). 
 In the A549 cell line, analysis of siRSK4 spectra at 48 h showed a reduction in 
glucose and increase in lactate peak intensity as compared to the control. The rate 
of metabolism was different in the two conditions and while glucose consumption 
was higher, lactate production remained constant in the cells silenced with siRSK4 .  
Glutamate was the only other metabolite which showed a significant increase in 
the rate of production for siRSK4 condition.  
In T24 cells, similar observation of increased rates of glucose utilisation, increased 
lactate and glutamate production was also seen, although not to the same extent. 
These changes in cancer cells with RSK4 knockdown was similar to those 
hypothesised to occur in cancer cells undergoing aerobic glycolysis (Warburg 
effect). A549 cell extracts of siRSK4 cells had abundant lactate compared to 
control. Glutamate and alanine which have been linked to the aerobic glycolysis 
shift have a significantly higher concentration in the siRSK4 condition. In T24 cells, 
increased pyruvate and glutamine consumption was seen in the siRSK4 condition 
and thus goes along the Warburg effect. The results point to a metabolic role of 
RSK4 in bladder cancer and lung cancer as a suppressor of aerobic glycolysis.  
With the Warburg shift, a concomitant increase in glutamine metabolism is seen. 
Glutamine is initially converted to glutamate which is the converted lactate along 
with ammonia and alanine (Figure 64). This could be the reason for increased 
glutamate production in siRSK4 condition but a similar increase in glutamine 
production was not seen, suggesting that a different metabolic process as a source 
of glutamate [269]. 
Differences in the metabolic processes in T24 bladder cancer cell and A549 lung 
cancer cell lines can explain slight difference in the degree of Warburg effect seen. 
This is evidenced by a comparison of the control transfected cells which show a 
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higher rate of glucose consumption and glutamate production for A549 cells and 
increased lactate production for T24 cells. More fats as an energy source resulting 
in higher utilisation of fatty acid oxidation to yield ATP explains why glucose uptake 
is lower in T24 cells compared to A549 cells [270].  
In summary we found a number of metabolic changes that were similar in bladder 
and lung cancer cell lines although to a different extent when silenced for RSK4. 
These changes were consistent with Warburg effect but further research is needed 
to elaborate these findings and elucidate their clinical implications. 
 
 
 
 
 
 
 
 167 
Chapter 8 
 
 
 
 
Discussion 
 
 
 
 
 
 
 
 
 
 168 
Introduction 
A major shortcoming of the current chemotherapy for bladder and lung cancer is 
the frequently observed development of chemotherapeutic drug resistance. 
Equally frustrating for the clinician is the toxicity associated with administration of 
these therapeutic agents. Therefore, an agent that can reverse chemotherapeutic 
drug resistance can go a long way in improving patient outcomes. Such a 
sensitising agent may also reduce the therapeutic dose of chemotherapeutic drugs 
required and hence the associated toxicity. Consequently, a lot of research is being        
carried out to identify such agents and our project is an example in case.  
We employed small interference RNAs to systematically screen the kinome and 
identify kinases involved in chemotherapeutic drug resistance in bladder, and 
possibly other, cancers (lung). In this screen we identified 88 hits affecting 
sensitivity to cisplatin and 85 hits for paclitaxel. Most of the hits were sensitising  
 Table 17: Kinase families represented in our screen hit list; hits that sensitise the 
T24 cells to both cisplatin and paclitaxel are shown in green; hits that increase 
resistance to both cisplatin and paclitaxel in red. * Hits with more than 10% 
toxicity (but less than 22%). 
and did not necessarily have major toxicity on their own. There were around 25 
common hits for cisplatin and paclitaxel (Table 17) and obviously these were of 
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particular interest as these highlighted proteins with the potential to modulate 
drug resistance in general.  
8.1    Relevance of the Screen 
Of these hits, while some (BMPR1B, GIT2, MAP4K4, PIP5K1C, PRKCB1) have been 
investigated for a role in cancer, very little is known about the part they play in 
determining drug sensitivity. Recent reports indicate that selective BMP type 1 
receptor antagonists like DMH2 (Dorsomorphin) caused growth inhibition, reduced 
clonogenic growth and induced cell death in lung cancer cell lines [214].  
There is some evidence that MAPK10, SNF1LK2 and UMP-CMPK have a role in 
chemotherapeutic drug sensitivity/resistance. The activity of MAPK10 also known 
JNK3 is thought to negatively correlate with multidrug resistance in hepatocellular 
carcinoma cell line SMMC-7221 [215].  Also, recent research provides clues that 
SNF1LK2 (SIK2) is required for AKT phosphorylation and growth of ovarian cancer 
cells and its knockdown sensitises ovarian cancer cells to paclitaxel both in vitro as 
well as in vivo [216]. Mitogen-activated protein 4 kinase 4 (MAP4K4) also called 
hepatocyte progenitor kinase-like/germinal center kinase-like kinase has a role in 
cancer development and progression. It is overexpressed in many types of human 
cancer [217] and MAP4K4 overexpression serves as an independent prognostic in 
hepatocellular carcinoma [218] and pancreatic ductal adenocarcinoma [219]. A 
small-interfering RNA-mediated knockdown of MAP4K4 inhibits tumour cell 
migration and invasion in various cancers such as ovarian, breast, prostate, 
malignant melanoma, and hepatocellular carcinoma [220].  
In endometrial cancer cell lines, RPS6KC1 was found to be a potential cancer driver 
oncogene [221] and in previous studies RPS6KC1 mutations were found in ovarian, 
breast and lung cancer [222] [223]. UMPK expression levels were found to be low 
in colorectal tumour samples of patient s with acquired 5-fluorouracil (5-FU) 
resistance [224]. UMPK expression was identified to be a predictive marker for 
xenograft model sensitivity to 5-FU [225] and low doses of 5-azadeoxycytidine 
(DAC), an inhibitor of DNA hypermethylation restored sensitivity of 5-FU-resistant 
tumours by increasing UMPK levels [226]. GIT2, an ArfGAP scaffold protein, is a 
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component of Gβ λ mediated directional sensing machinery [227] and participates 
in focal adhesion dynamics, cytoskeletal organisation, cell migration and invasion 
[228]. 
Our screening and validation experiments in several bladder cancer cell lines 
identified multiple candidates that could be targeted to sensitise bladder cancer to 
the chemotherapeutic drugs tested (cisplatin & paclitaxel). Most of the hits are 
relevant to cancer and thus provide an opportunity for multiple follow-on projects 
in future. As mentioned earlier, amongst the hits generated, we decided to pursue 
work on RPS6KA6 (RSK4) as this kinase was also identified in a parallel invasion 
screen performed in lung cancer cell lines in our lab.  
8.2   RSK family of Kinases   
The p90 Ribosomal S6 Kinases also known as RSKs are a family of intracellular 
serine/threonine kinases that are substrates of ERK and play a key role in various 
cellular processes such as cell proliferation, survival, migration and invasion [61]. It 
is estimated that approximately 30% of all human cancers have mutations within 
the MEK/ERK pathway [229] and RSK members being downstream of ERK are 
thought to play a vital role in tumour biology. This role needs further elucidation if 
one is to develop therapeutic strategies targeting these kinases. RSKs modulate 
cellular transformation, tumorigenesis and metastasis and changes in the 
expression of RSK isoforms have been reported in several malignancies including 
breast, prostate and lung cancer.  
Four RSK members with a very high degree of homology (75–80% amino-acid 
identity) have been identified. These include RSK1 (RPS6KA1), RSK2 (RPS6KA3), 
RSK3 (RPS6KA2) and the most recently identified RSK4 (RPS6KA6). While these 
members share many characteristics, they also differ in some respects and the 
following sections will highlight the differences relevant to this thesis.  
 
8.2.1 Structure of RSK4 
As mentioned earlier, the four isoforms have 75-80% sequence homology. They 
are classified as MAPK-activated protein kinases and phosphorylate 
serine/threonine residues on their substrates. The four isoforms show structural 
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similarity and consist of two independent kinase domains connected by a linker 
region and flanked by N- and C- terminal tails [230]. The N-terminal kinase domain 
(NTKD) is responsible for the phosphorylation of downstream substrate whereas 
the C-terminal kinase domain (CTKD) receives an upstream activating signal from 
extracellular signal-regulated kinase (ERK1/2) that regulates the activity of the 
NTKD[62]. The ERK1/2 docking site at the NTKD is known as the D-domain and the 
RSK-ERK interaction occurs through the Leu-Arg-Gln-Arg-Arg motif in this domain 
[231]. The CTKD is closely related to the kinase domains found in the 
calcium/calmodulin dependent protein kinase (CAMK) family. In contrast, the 
amino-terminal kinase domain (NTKD) is homologous to that of AGC kinases. The 
linker region is approximately 100 amino acids long and contains important 
regulatory domains like the hydrophobic motif and the turn motif which play an 
important role in the activation of the NTKD. 
 
 
Figure 66: Structure of RSKs - The p90 ribosomal S6 kinase proteins 1-4 share a structural 
similarity and have two functional kinase domains, the NTKD & the CTKD connected by a 
linker region. Six functionally important sites which are highly conserved in RSK members 
lead to activation of RSKs and subsequent substrate phosphorylation, following binding 
of ERK1/2 at the ERK docking motif (D domain). In this figure the amino acid numbering 
corresponds to human RSK4. Figure adapted from [230].  
Amino acid alignment of all the RSK family members shows conservation of the 
phosphorylation sites at serine 232 and threonine 581 residues located in the NTKD  
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and CTKD respectively. Two more phosphorylation sites are found in the linker 
region at Ser 372 and Ser 389 (Figure 66). These sites transmit activation signals 
from the CTKD to the NTKD, in a way that will be explained in detail later. 
8.2.2   Mechanism of Activation of RSKs 
The mechanism of activation of RSKs is made complex by the fact that it involves 
sequential phosphorylation of multiple serine and threonine regulatory sites 
located on the CTKD, linker region and NTKD of the protein. Six different 
phosphorylation sites have been mapped in RSK1/2 and these sites are conserved 
in RSK3 and RSK4 as well. Extracellular signals and growth factors activating the 
Ras/MAPK pathway culminate in the activation of ERK1/2. ERK1/2 subsequently 
phosphorylates RSKs and bring about their activation [232]. In the following 
paragraphs, in order to simplify the explanation, the amino acid numbering refers 
to RSK4.  
ERK1/2 binds to RSK4 at the ERK docking site of the CTKD and once bound it leads 
to activating phosphorylation of the activation loop site of the CTKD (Thr581) as 
well as phosphorylation of Thr368 & Ser372 in the linker region. Once 
phosphorylated,  Ser372 promotes the catalytic activity of NTKD. At the same time, 
the phosphorylated Thr368 causes the CTKD to autophosphorylate Ser389 in the 
linker region which in RSK4 leads to phosphorylation of Ser232 in the activation 
loop of NTKD. This is in contrast to rest of the RSKs where autophosphorylation of 
S389 leads to the formation of a docking site for pyruvate dehydrogenase 
lipoamide kinase isozyme 1 (PDK1) which then phosphorylates serine residue in the 
activation loop of the NTKD (Figure 67) [233]. Activated NTKD then leads to 
downstream effects of RSKs which are mainly in the form of substrate 
phosphorylation.  
RSK4, compared to RSK1-3, seems to be much less dependent on Ras/MAPK 
pathway and from previous studies one is led to believe that the basal activity of 
ERK or another kinase may be high enough to cause sufficient phosphorylation and 
activation of RSK4. Alternatively, these results may suggest that RSK4 has a low rate 
of dephosphorylation or an ability to autophosphorylate [209].  
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Figure 67: Mechanism of activation of RSKs: The figure illustrates the sequential steps 
that lead to the activation of RSKs leading to their downstream effects. The mechanism is 
explained in the text in detail and the amino acid numbers of the phosphorylation sites 
refer to those of RSK4 and vary for other RSK family members. 
8.2.3   RSK Expression & Localisation 
Apart from RSK4, the expression of RSKs is ubiquitous as they have been detected 
in all human tissues tested [234]. On the other hand RSK4 is in low abundance in 
both embryonic as well as adult tissue.  RSK1 transcripts are more abundant in the 
lung, kidney, pancreas, bone marrow and T-cells while RSK2 mRNAs are 
predominantly found in T cells, lymph nodes skeletal muscle and prostate. RSK3 
transcripts are mainly expressed in the lung, skeletal muscle brain, spinal cord and 
retina. The mRNA expression of RSK4 is much lower than that of the other three 
isoforms and its levels vary far less between tissues. Compared to other tissues, 
RSK4 expression is higher in brain, cerebellum, kidney, heart and skeletal muscle. 
 174 
However, Sun et al. have recently demonstrated the existence of novel RSK4 splice 
variants as well as of various RSK4 protein variants of molecular weights ranging 
from 33 to 135kDa from a single cDNA [235], thus complicating our understanding 
of previously assumed RSK4 expression patterns.  
All RSKs are mainly cytoplasmic but on growth factor stimulation of the MEK/ERK 
they have been shown to translocate to the nucleus. For example, RSK1 on growth 
factor stimulation transiently translocates to the plasma membrane and 
subsequently localises to the nucleus [236]. Similarly, mitogen stimulation triggers 
RSK2 localisation to the nucleus but, upon oxidative stress, RSK2 localizes to stress 
granules to promote cell survival [237]. RSK4 contrary to other isoforms seems to 
not significantly accumulate in the nucleus following mitogenic stimulation. 
However, this needs to be studied further as the functional roles of RSKs are still 
not clear and very little is known about their mechanistic details.   
8.2.4   Regulation of Cellular processes by RSKs 
RSKs have been shown to regulate cellular proliferation, both directly as well as 
indirectly. Indirect proliferation is brought about by modulating the expression of 
transcription regulators like JUN [238] or by post translational modification of 
transcription factors regulating the cell cycle machinery e.g. c-FOS [239]. In some 
instances, RSKs may in conjunction with ERK, help fine tune the activity of some of 
the transcription factors [240]. RSKs have also been reported to phosphorylate 
cAMP response elements binding protein (CREB) and in fibroblasts derived from 
patients with Coffin-Lowry syndrome, EGF induced phosphorylation of CREB and 
transcription of c-FOS is impaired. By preventing Cyclin D1 expression, the cell cycle 
is arrested in G1 in MCF-7 breast cancer cell line treated with a pan RSK inhibitor, 
thus hinting towards a role in cell cycle progression [241]. 
Several reports suggest that RSK4 behaves as a tumour suppressor whose 
expression is down-regulated in human tumours [242] while others suggest 
contrary[211].  However, in the lung, our own data suggest that while undetectable 
in normal epithelium, RSK4 is overexpressed in over 50% of primary malignant 
lesions [208], suggesting that RSK4 may provide tumour cells with a growth 
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advantage. This has further been corroborated in a recent study of expression of 
RSK4 in renal cell cancers [243].  
RSKs may control mRNA translation by controlling the phosphorylation of 
regulatory associated protein of the mTOR (RAPTOR), a constituent of the mTOR 
complex [244]. In addition phosphorylation of tuberous sclerosis complex 2 (TSC2) 
by RSK releases its inhibitory effect on the RAS homolog enriched in brain (RHEB) to 
promote mTORC1 mediated translation [245]. RSK and ERK can phosphorylate LKB1 
and impair its interaction with and activation of AMPK which is an inhibitor of 
mTOR signalling, thus resulting in uncontrolled cell proliferation [246].   
Phosphorylation of CREB by RSK1 and RSK2 also promotes cell survival in neurons 
by transcriptional increase of pro-survival genes such as the B-cell lymphoma 
protein-2 (BCL2) family members like BCL2, BCL-XL and MCL1 [247].  RSK1 & RSK2 
also phosphorylate and thus prevent heterodimerisation of pro-apoptotic protein 
BAD. RSK1 & 2 can also phosphorylate distinct residues on death associated protein 
kinase 1 (DAPK1) and prevent DAPK1 mediated cell death [248]. 
RSKs are thought to be involved in cell migration, invasion and metastasis. RSK2 has 
been reported to be pro-metastatic [249] and overexpression of RSK1 was shown 
to increase cell motility in two melanoma cell lines [250]. In contrast, using RNA 
interference against individual RSK isoforms, our lab found that silencing RSK1 
increased, while downregulating RSK2 and 4 decreased lung cancer cell motility. 
Furthermore, RSK1 silencing promoted cell invasion in vitro and metastasis in vivo. 
Conversely, overexpression of wild-type RSK1 inhibited lung cancer cell migration 
[208].  
 
8.3   RSK4 in Cancer 
Even though there is quite a bit of published literature about RSK family of kinases, 
there are a lot of discrepancies and lacunae that need to filled. This is especially true 
for RSK4 which has not been studies much and so far there have been no studies into 
the role of RSK4 in bladder cancer. Our project is a small effort in that direction and 
certainly further research needs to be carried out to make our understanding of the 
role of RSK4 and the mechanisms of its functioning in health and disease.  
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Whereas some research papers hint towards a 'tumour suppressor' role of RSK4 in 
certain cancers, others including our project suggest the opposite. In a large siRNA 
screen RSK4 was identified as one of the five modulators of p53 induced growth 
arrest and this was brought about via p21 [281]. RSK4 was found to regulate stress 
and replication induced senescence and RSK4 inhibition induces senescence 
resistance [282]. Findings from the same study proving that RSK4 mRNA is 
downregulated in colonic and renal carcinomas further confirmed a tumour 
suppressor role of RSK4.  
However c-DNA microarray analysis of mammary tumours in transgenic mice 
showed that the gene expression of RSK4 was two-fold or higher compared to 
lactating mammary gland [278]. Further mRNA expression studies in breast cancer 
samples indicated a higher expression of RSK4 and 47% (9/19) samples showed 
higher expression of RSK4 compared to adjacent breast tissue. Interestingly 
immunostaining of these samples for RSK4 showed high expression in normal breast 
ductal epithelium, weak or no expression in benign papillomas and strong expression 
in invasive ductal carcinomas [211]. RSK4 expression was both cytoplasmic as well as 
nuclear. They suggested that RSK4 may have a role in the initial stage of 
tumorigenesis and that its downregulation can lead to cell proliferation.  
In contrast, a recent study on 49 breast cancer patient' specimens found significantly 
lower (p=0.002) RSK4 mRNA in most breast cancer tissues compared with paired 
non-cancerous tissues. This corresponded to  significantly higher (p=0.009) RSK4 
methylation in breast cancers and RSK4 promoter hypermethylation could explain its 
role in tumorigenesis [279]. RSK4 was also found to be frequently hypermethylated 
in primary endometrial cancer tissue and in endometrial cancer cell lines when 
compared to the normal endometrial tissue. RSK4 methylation was also inversely 
related to the severity of the tumour grade i.e. higher grade tumours had lower level 
of methylation [252]. 
In breast cancer cell lines RSK4 was shown to limit invasive, oncogeneic and 
metastatic potential. When RSK4 was overexpressed in these cell lines, cellular 
proliferation decreased cells accumulated in Gₒ - G₁ phase. Exogenous expression of 
 177 
RSK4 also resulted in decreased colony formation in soft agar and suppressed 
invasive & migratory ability of breast cancer cell lines [280].   
In line with our findings in bladder and lung cancer, a recent research study pointed 
out that RSK4 was overexpressed in renal cell carcinoma (RCC) and there was a 
positive correlation of RSK4 expression to high pT stage, high Furhman grade, lymph 
node involvement and distant metastasis. Higher expression was thought to predict 
a poor outcome [243]. RSK4 was thus thought to predict a poor outcome in RCC 
patients. Molecular studies showed that overexpression of RSK4 could promote cell 
cycle progression and enhance the invasive and metastatic capability of RCC cell lines 
and vice versa. 
In this study a screening experiment using siRNA transfection identified RSK4 as a 
target, the inhibition of which induces sensitisation to cisplatin and paclitaxel in 
three different bladder cancer cell lines. Similar findings were identified in a kinome 
expression change study. RSK4 was one of three common genes found to be 
upregulated in both Sunitinib resistant kidney carcinoma and melanoma cell lines. 
Specific downregulation of RSK4 using siRNA transfection sensitised kidney cancer 
and melanoma cells to Sunitinib -  a receptor tyrosine kinase. The sensitisation effect 
was strikingly higher  in Sunitinib resistant cell lines, thus suggesting an expression 
based response and a potential for RSK4 targeting strategies to overcome drug 
resistance [253]. 
RSK4 overexpression has also been reported to mediate resistance to inhibitors of 
phosphoinositol 3 kinase (PI3K) inhibitors in breast cancer. RSK4 overexpression 
promotes proliferation upon PI3K inhibition both in vitro and in vivo through 
apoptotic response attenuation and upregulation of protein translation. In RSK4 
overexpression cell lines and patient derived xenograft models with elevated RSK 
activity, addition of RSK specific inhibitors can overcome this resistance and hence a 
combined  use of PI3K & RSK inhibitors has been suggested as a possible therapy in 
breast cancer patients with high RSK4 activity [254]. 
Although we may not have elucidated an exact mechanism by which RSK4 regulates 
the response of cancer cells to chemotherapeutic agents, we found that the 
sensitisation was likely as a result of decrease in the levels of anti-apoptotic protein 
 178 
XIAP which normally provides a growth advantage to tumour cells.  Other studies 
that have indicated a similar role in other cancers have lacked in mechanistic details 
so far.  XIAP directly inhibits processing of caspase 3 in response to caspase 8 
activation and this can render tumour cells resistant to chemotherapy [255] and its 
overexpression in a variety of cancers and is thought to be an adverse prognostic 
factor responsible for chemoresistance [256]. The cytotoxic activity of various 
cystostatic agents like cisplatin & etoposide has been shown to be enhanced when 
XIAP is inhibited [257].  
In acute myelogenous leukemia and renal cell carcinoma, the levels of XIAP protein  
levels correlate with disease severity and prognosis. As compared to normal 
urothelium which shows minimal XIAP expression, XIAP was upregulated in almost  
three-quarters of the examined transitional cell cancer specimens [259]. Similarly in   
T24 cell line, overexpression of XIAP led to statistically significant survival  advantage 
suggesting a critical role of XIAP in maintaining viability and drug resistance in  
transitional cell carcinoma. However, recent data shows that in certain radically  
resected tumours like non small cell lung cancer and prostate cancer, XIAP 
overexpression is associated with favourable clinical outcome [258].   
Our results indicated that RSK4 downregulation also led to a decrease in the mRNA 
levels of RSK2. RSK2 itself has been linked to tumorigenesis in many cancers [260]. It 
contributes to survival in multiple myeloma cells in response to FGFR3 [261] and 
RSK2 levels decrease when ovarian cancer cells are treated with platinum based 
chemotherapeutic agents. RSK2 depletion also enhances sensitivity to platinum 
based cytotoxic agent in cisplatin sensitive as well as resistant ovarian cancer cell 
lines [262]. RSK2 inhibition also suppresses growth of tumour initiating cells in breast 
cancer by decreasing CD44 expression. It also delays initiation of development of 
triple negative breast cancer and thus is thought to be a potential druggable target in 
breast cancer [263].  
In our study the RSK4 knockdown inhibited cellular migration speeds across different 
bladder and lung cancer cell lines. This added another dimension to its importance in 
cancer and cancer therapeutics. Furthermore invasiveness was significantly reduced 
in response to RSK4 knockdown in bladder cancer cell lines. Our in vivo experiments 
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in zebra fish supplemented the above results as we clearly demonstrated that 
abrogation of RSK4 diminished the migratory and invasive capacity of A549 lung 
cancer cells. This effect of RSK4 knockdown on migration and invasion has also been 
previously reported in lung cancer cells [208].  
We encountered problems with the animal (read mouse) experiments but they still 
supported the above observation. Due to the transient nature of downregulation 
using siRNA technique, the mice injected with A549-Luc-C8 cells with RSK4 
knockdown did not show as extensive metastatic tumours as control transfected 
A549-Luc-C8 cells in the first 3-4 weeks. However this inhibition of migration and 
invasion did not last the period of the study and at the end of 8 weeks there was no 
significant difference between the two groups when the parameters for migration 
and invasion were quantified. Using cells with sustained knockdown (shRNA stables) 
would serve a better tool to study effect of RSK4 downregulation on metastasis in an 
animal model. We have developed these stable cell lines and we aim to carry out 
further experiments in future.  
In response to knockdown of RSK4 we found that whereas the mRNA levels of RSK2 
decreased, those of RSK1 increased significantly. Interestingly previous reports point 
out that whereas RSK2 expression increases migration and invasion, RSK1 expression 
has an opposite effect. RSK1 knockdown enhanced cell motility and invasion in A549 
cell line [208]. In another study, although RSK2 inhibition inhibited cell motility, it did 
not have a significant effect on invasiveness. RSK2 has been thought to be the main 
factor linking Macrophage Stimulating protein (MSP)-activated RON signalling to 
cellular EMT leading to increased migration and subsequent invasion [264]. RSK2 
knockdown sensitises cancer cells to anoikis and the ribosomal S6 kinase 2-cAMP 
response element-binding protein (RSK2-CREB)  which provides anoikis protection 
[265] and promotes tumour metastasis  and in highly invasive cancer cell lines, 
inhibition of RSK2 disrupts filopodia formation leading to an diminished invasive and 
metastatic potential in vitro and in vivo [266]. RSK2 is an important effector that 
brings about insulin-like growth factor II mRNA-binding protein 1 (IMP-1) mediated 
regulation of migration and invasion in cancer cells [267]. RSK2 also impairs cell 
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adhesion and enhances cell motility by suppressing integrin activation, disrupting 
focal adhesions and promoting filamin phosphorylation [268]. 
Metabonomic analysis of A549 lung cancer and T24 bladder cancer cell lines showed 
changes in line with the Warburg effect. Spectral analysis in A549 cell line at 48 h 
after RSK4 knockdown showed a reduction in glucose and increase in lactate peak 
intensity as compared to the control. While glucose consumption was higher, lactate 
production remained constant in the siRSK4 condition.  Glutamate was the only 
other metabolite which showed a significant increase in the rate of production for 
siRSK4 condition. Similar observation of increased rates of glucose utilisation, 
increased lactate and glutamate production was also seen in T24 cell line, although 
not to the same extent.  
Analysis of the A549 cell extracts of siRSK4 cells revealed abundant lactate compared 
to control. Glutamate and alanine which have been linked to the aerobic glycolysis 
shift also had a significantly higher concentration in the siRSK4 condition. In T24 
cells, increased pyruvate and glutamine consumption was seen in the siRSK4 
condition and thus goes along the Warburg effect. These results point to a metabolic 
role of RSK4 in bladder cancer and lung cancer as a suppressor of aerobic glycolysis.  
With the Warburg shift, a concomitant increase in glutamine metabolism is seen. 
Glutamine is initially converted to glutamate which is the converted lactate along 
with ammonia and alanine (Figure 64). This could be the reason for increased 
glutamate production in siRSK4 condition. A similar increase in glutamine production 
was not seen, suggesting involvement of a different metabolic process as a source of 
glutamate [269]. A difference in the metabolic processes in T24 bladder cancer cell 
and A549 lung cancer cell lines can explain slight difference in the degree of Warburg 
effect seen. This is evidenced by a comparison of the control transfected cells which 
show a higher rate of glucose consumption and glutamate production for A549 cells 
and increased lactate production for T24 cells. More fats as an energy source 
resulting in higher utilisation of fatty acid oxidation to yield ATP explains why glucose 
uptake is lower in T24 cells compared to A549 cells [270].  
Chemoresistance in cancer cells occurs concomitantly with aerobic glycolysis and 
hence the results above were different from what was expected. Warburg effect 
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promotes mitochondrial uncoupling which decreases oxidative phosphorylation and 
thus impedes pyruvate oxidation, increases glycolysis and promotes lactate 
production. The discrepancy could possibly be because our experiments were done 
in cells which were non - chemoresistant. The results might actually be different if 
the experiment is carried out in drug resistant cell lines.  
Recent research has suggested a role of Phosphatidylcholine in promoting resistance 
to platinum based chemotherapeutic agents.  Glycerophosphocholine (GPC) is a 
precursor while phosphocholine is an intermediate in the synthesis of 
phosphatidylcholine [271]. When we analysed A549 cell extracts, phosphocholine 
was absent and GPC was not significantly different in the two conditions. 
There is hardly any data elucidating the role of RSK4 in the regulation of cellular 
metabolism. Hence our data being the first of its kind needs to be substantiated by 
further studies in future in different cell lines.  
A role of RSK4 in diabetes mellitus is being explored and it will be interesting to see 
the results of this study [271].  It is believed that RSK4 could modulate synthesis of 
glucose by RSK4 mediated senescence of Endothelial progenitor cells (EPCs). 
Hyperglycemia is the commonest cause of EPC senescence and targeting RSK4 may 
offer new therapeutic options in future. Even insulin resistance may be related to 
EPC senescence and future research will throw more light at this hypothesis.  
Emergence of RSKs as an anticancer targets has led to a major push for research into 
discovery of small molecule RSK inhibitors (Figure 69). As structural and functional 
features of serine threonine kinases are conserved a number of well-known, 
nonspecific protein kinase inhibitors such as Ro31-8220, GF109203X, indirubin-3-
oxime, and SB216763 have potent activity against RSK. However many RSK specific 
inhibitors e.g.  SL0101, BI-D1870, and FMK have been identified and studied  [273]. 
SL0101, a naturally obtained kaempferol glycoside,  is an ATP competitive inhibitor  
that binds at the RSK NTKD ATP binding site [274].  SL0101 has remarkable in vivo 
potency and specificity and does not interfere with upstream kinases that activate 
RSK. Dihydropteridinone BI-D1870 is a potent inhibitor of all four RSK isoforms 
synthesised and assayed as a racemate. Its RSK specificity is 500 fold higher than 
other AGC kinases. The pyrrolopyrimidine fmk is another potent RSK specific 
inhibitor  
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containing a reactive electrophile in its fluoromethylketone motif with affinity for 
the CTKD ATP binding site [273].  
 
 
Figure 68: Crystal structure of various RSK inhibitors[273] 
RSKs have a high degree of homology especially in their kinase domains and hence so 
far no highly specific inhibitor of the RSK isoforms has been generated. The problem 
with a non specific RSK inhibitor is that different RSK isoforms have different and even 
opposing actions. Currently there are no known inhibitors specific for RSK4 and this is 
complicated by the fact that the crystal structure of RSK4 is yet unknown. RSK4 isoform 
specific inhibitors would go a long way study the effect of RSK4 inhibition of different 
cancer cell lines.  
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8.4   Conclusions & Future work 
Our screen of the kinome library identified multiple kinases that affect bladder cancer 
cells response to cisplatin and paclitaxel. Further filtration generated a subset of 
potential targets which need to be further looked into and are potential future research 
projects.  
From our work on RSK4 it is clear that, in the cancer cell lines we carried our 
experiments on, RSK4 not only has a role in response of cancer cells to cisplatin and 
paclitaxel but also modulates migration and invasion. An inhibitor of RSK4 would thus 
potentially sensitise cancer cells to different chemotherapeutic agents and at the same 
time decrease the capacity of primary tumours to metastasise. This could translate into 
better chemotherapeutic drug tolerability, potential lowering of therapeutic doses, 
reversal of drug resistance and improved patient experience and outcomes. As RSK4 
inhibition increases RSK1 levels at the same time as decreasing RSK2 levels, a specific 
RSK4 inhibitor would definitely achieve two favourable situations at molecular levels. 
As discussed earlier, previous research has shown that higher levels of RSK2 promotes 
cytotoxic drug resistance and cancer cell migration whereas high levels of RSK1 inhibit 
cell migration. 
RSK4 probably has a regulatory role and  brings about above effects by altering the 
levels of other RSKs like RSK1 & RSK2 as well as XIAP by a yet unknown mechanism. We 
hypothesise that RSK4 brings about the above either directly or indirectly as a result of 
phosphorylation of a transcription factor which can either have an inhibitory or 
excitatory effect on the target gene. The exact downstream pathway needs to be 
extrapolated and a clear understanding of this regulatory mechanism will aid further 
clarification of its role in cancer.  
The reduction of XIAP on downregulation of RSK4 in our experiments could have been 
an off target effect of RSK4 siRNA.  We intend to address this concern by studying the 
effect of  RSK4 specific inhibitors on XIAP levels. Also the RSK4 siRNA pool will be 
deconvoluted in order to ensure that all four oligonucleotides of RSK4 have a similar 
effect on XIAP levels. A study of expression of RSK4 and XIAP on bladder tissue samples 
available to us will shed further light on the correlation between RSK4 and XIAP. Co-
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immunoprecipitation studies will be helpful in this regard. Further studies are needed 
to find the mechanism of this interaction and a limited screen of the transcription 
factors might provide an answer. 
More experiments to determine the causality between decreased XIAP levels on RSK4 
inhibition and sensitisation of bladder and lung cancer cells to chemotherapy are 
required. We intend to study this by comparing the effect of RSK4 knockdown on 
chemosensitivity in wild type and XIAP null cancer cell lines which will be created in the 
lab[284]. In vivo experiments using wild type and XIAP knockout mice will help establish 
this role.  
Future research work will help clarify whether the effects of RSK4 on chemosensitivity, 
migration, invasion and other cellular processes are solely due to its ability to alter the 
levels of other target genes or whether some of these effects are partly brought about 
directly. 
As discussed earlier, RSK4’s role in cancer seems to be very cell specific but RSK4 
inhibition in bladder and lung cancer has a promising therapeutic  potential. Further 
work is much needed to study its role in other cancers and establish a deeper 
understanding of its regulatory mechanism of various cellular processes. Steps to 
pursue research into development of specific inhibitors against it and elucidate its 
crystal structure are necessary.  Research is also needed to study its role in other 
cellular metabolic processes which may provide some new insights into cancer and 
other metabolic diseases like diabetes mellitus.  
In a nutshell, RSK4 is a promising target that has a potential to translate from the 
bench to the clinic but there are many aspects that still need further work. This 
research project has provided some of the groundwork for this additional research, 
which is now in progress.  
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Appendix 1: The above tables lists all the siRNAs in the Qiagen kinome library (Human Kinase 
siRNA Set Version 2.0 ). The accession number and a brief description is provided against each 
gene symbol. The library came in a deconvulated form and each siRNA set comprised of four 
oligonucleotides in seperate 96 well plates. 
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Appendix 1: Results of FACS analysis showing changes in cell cycle profile on RSK4 and 
RSK1 knockdown in (A) A549 cell line and (B) T24 cell line. 
 
